cluster_labels,Nom du médicament,Substance active,Diseases,A.1 Member State Concerned,A.2 EudraCT number,A.3 Full title of the trial,A.4.1 Sponsor's protocol code number,A.7 Trial is part of a Paediatric Investigation Plan,B.1.1 Name of Sponsor,B.1.3.4	Country,B.3.1 and B.3.2	Status of the sponsor,D.1.2 and D.1.3 IMP Role,D.2.1 IMP to be used in the trial has a marketing authorisation,D.2.1.1.2 Name of the Marketing Authorisation holder,D.2.1.2 Country which granted the Marketing Authorisation,D.2.5 The IMP has been designated in this indication as an orphan drug in the Community,D.3.1 Product name,D.3.11.1 Active substance of chemical origin,D.3.11.10 Medicinal product containing genetically modified organisms,D.3.11.11 Herbal medicinal product,D.3.11.12 Homeopathic medicinal product,D.3.11.13 Another type of medicinal product,D.3.11.2 Active substance of biological/ biotechnological origin,D.3.11.3 Advanced Therapy IMP,D.3.11.3.1 Somatic cell therapy medicinal product,D.3.11.3.2 Gene therapy medical product,D.3.11.3.3 Tissue Engineered Product,D.3.11.3.4 Combination ATIMP,D.3.11.3.5 Committee on Advanced therapieshas issued a classification for this product,"D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy",D.3.11.5 Radiopharmaceutical medicinal product,D.3.11.6 Immunological medicinal product,D.3.11.7 Plasma derived medicinal product,D.3.11.8 Extractive medicinal product,D.3.11.9 Recombinant medicinal product,D.3.4 Pharmaceutical form,D.3.4.1 Specific paediatric formulation,D.IMP,E.1.1 Medical conditionbeing investigated,E.1.3 Condition being studied is a rare disease,E.2.1 Main objective of the trial,E.2.2 Secondary objectives of the trial,E.2.3 Trial contains a sub-study,E.3 Principal inclusion criteria,E.4 Principal exclusion criteria,E.5.1 Primary end point,E.6.1 Diagnosis,E.6.10 Pharmacogenetic,E.6.11 Pharmacogenomic,E.6.12 Pharmacoeconomic,E.6.13 Others,E.6.2 Prophylaxis,E.6.3 Therapy,E.6.4 Safety,E.6.5 Efficacy,E.6.6 Pharmacokinetic,E.6.7 Pharmacodynamic,E.6.8 Bioequivalence,E.6.9 Dose response,E.7.1 Human pharmacology,E.7.1.1 First administration to humans,E.7.1.2 Bioequivalence study,E.7.1.3 Other,E.7.2 Therapeutic exploratory,E.7.3 Therapeutic confirmatory,E.7.4 Therapeutic use,E.8.1 Controlled,E.8.1.1 Randomised,E.8.1.2 Open,E.8.1.3 Single blind,E.8.1.4 Double blind,E.8.1.5 Parallel group,E.8.1.6 Cross over,E.8.1.7 Other,E.8.2.1 Other medicinal product,E.8.2.2 Placebo,E.8.2.3 Other,E.8.3 The trial involves single site in the Member State concerned,E.8.4 The trial involves multiple sites in the Member State concerned,E.8.5 The trial involves multiple Member States,E.8.6.1 Trial being conducted both within and outside the EEA,E.8.6.2 Trial being conducted completely outside of the EEA,E.8.7 Trial has a data monitoring committee,F.1.1 Trial has subjects under 18,F.1.1.1 In Utero,F.1.1.2 Preterm newborn infants,F.1.1.3 Newborns,F.1.1.4 Infants and toddlers,F.1.1.5 Children,F.1.1.6 Adolescents,F.1.2 Adults,F.1.3 Elderly,F.2.1 Female,F.2.2 Male,F.3.1 Healthy volunteers,F.3.2 Patients,F.3.3 Specific vulnerable populations,F.3.3.2 Women of child-bearing potential using contraception,F.3.3.3 Pregnant women,F.3.3.4 Nursing women,F.3.3.5 Emergency situation,F.3.3.6 Subjects incapable of giving consent personally,F.3.3.7 Others,F.4.1 In the member state,N. Competent Authority Decision,N. Date of Competent Authority Decision,N. Date of Ethics Committee Opinion,N. Ethics Committee Opinion,N. Ethics Committee Opinion of the trial application,P. End of Trial Status,combined_key
3,Pegasys,peginterferon alfa-2a,"['compensée signes réplication', 'inflammation', 'aghbe positif chez enfants non cirrhotiques adolescents', 'prise cas cas voir rubrique 4 4']",UK - MHRA,2006-000977-31,"['PHASE IIIB, RANDOMIZED, OPEN LABEL STUDY OF PEGYLATED INTERFERON ALFA-2A IN COMBINATION WITH LAMIVUDINE OR ENTECAVIR COMPARED WITH UNTREATED CONTROL PATIENTS IN CHILDREN WITH HBEAG POSITIVE CHRONIC HEPATITIS B IN THE IMMUNE TOLERANT PHASE']",['NV25361'],['Yes'],['F. Hoffmann-La Roche Ltd'],['Switzerland'],['Commercial'],"['Test', 'Test', 'Test', 'Test', 'Test']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['Roche Registration Ltd', 'ViiV Healthcare UK Ltd.', 'TEVA Pharma B.V', 'BRISTOL-MYERS SQUIBB PHARMA EEIG', 'BRISTOL-MYERS SQUIBB PHARMA EEIG']","['European Union', 'European Union', 'European Union', 'European Union', 'European Union']","['No', 'No', 'No', 'No', 'No']",Pegasys,"['No', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['Yes', 'No', 'No', 'No', 'No']","['Yes', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['Yes', 'No', 'No', 'No', 'No']","['Injection', 'Oral solution', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet']","['No', 'No', 'No', 'No', 'No']","['1', '2', '3', '4', '5']",['Chronic Hepatitis B Virus infection'],['No'],"To evaluate the efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by loss of HBsAg 24 weeks post-end of treatment/end of untreated observation.","['•To evaluate efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by seroconversion to anti-HBs, seroconversion to anti-HBe, loss of HBeAg, and HBV DNA levels, at 24 weeks post-end of treatment/end of untreated observation.']",['No'],['• Male and female patients 3 to less than 18 years of age at baseline (12< 18 years of age at baseline in Russia and India)'],"['Patients who have had any previous anti-HBV treatment, or who are co-infected with hepatitis A virus (HAV), HCV, hepatitis D virus (HDV) or HIV, or who have decompensated liver disease will beexcluded.']",['Loss of HBsAg at 24 weeks post-end of treatment (follow-up Week 24)/end of untreated observation (Week 80).'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['10'],['Authorised'],['2006-04-27'],['2006-05-05'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To evaluate the efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by loss of HBsAg 24 weeks post-end of treatment/end of untreated observation.-2006-000977-31-UK - MHRA-peginterferon alfa-2a"
3,Pegasys,peginterferon alfa-2a,"['compensée signes réplication', 'inflammation', 'aghbe positif chez enfants non cirrhotiques adolescents', 'prise cas cas voir rubrique 4 4']",Belgium - FPS Health-DGM,2006-000977-31,"['PHASE IIIB, RANDOMIZED, OPEN LABEL STUDY OF PEGYLATED INTERFERON ALFA-2A IN COMBINATION WITH LAMIVUDINE OR ENTECAVIR COMPARED WITH UNTREATED CONTROL PATIENTS IN CHILDREN WITH HBEAG POSITIVE CHRONIC HEPATITIS B IN THE IMMUNE TOLERANT PHASE']",['NV25361'],['Yes'],['F. Hoffmann-La Roche Ltd'],['Switzerland'],['Commercial'],"['Test', 'Test', 'Test', 'Test', 'Test']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['Roche Registration Ltd', 'ViiV Healthcare UK Ltd.', 'TEVA Pharma B.V', 'BRISTOL-MYERS SQUIBB PHARMA EEIG', 'BRISTOL-MYERS SQUIBB PHARMA EEIG']","['European Union', 'European Union', 'European Union', 'European Union', 'European Union']","['No', 'No', 'No', 'No', 'No']",Pegasys,"['No', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['Yes', 'No', 'No', 'No', 'No']","['Yes', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['Yes', 'No', 'No', 'No', 'No']","['Injection', 'Oral solution', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet']","['No', 'No', 'No', 'No', 'No']","['1', '2', '3', '4', '5']",['Chronic Hepatitis B Virus infection'],['No'],"To evaluate the efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by loss of HBsAg 24 weeks post-end of treatment/end of untreated observation.","['•To evaluate efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by seroconversion to anti-HBs, seroconversion to anti-HBe, loss of HBeAg, and HBV DNA levels, at 24 weeks post-end of treatment/end of untreated observation.']",['No'],['• Male and female patients 3 to less than 18 years of age at baseline (12< 18 years of age at baseline in Russia and India)'],"['Patients who have had any previous anti-HBV treatment, or who are co-infected with hepatitis A virus (HAV), HCV, hepatitis D virus (HDV) or HIV, or who have decompensated liver disease will beexcluded.']",['Loss of HBsAg at 24 weeks post-end of treatment (follow-up Week 24)/end of untreated observation (Week 80).'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],,['Authorised'],['2015-10-29'],['2015-11-02'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To evaluate the efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by loss of HBsAg 24 weeks post-end of treatment/end of untreated observation.-2006-000977-31-Belgium - FPS Health-DGM-peginterferon alfa-2a"
3,Pegasys,peginterferon alfa-2a,"['compensée signes réplication', 'inflammation', 'aghbe positif chez enfants non cirrhotiques adolescents', 'prise cas cas voir rubrique 4 4']",Italy - Italian Medicines Agency,2006-000977-31,"['PHASE IIIB, RANDOMIZED, OPEN LABEL STUDY OF PEGYLATED INTERFERON ALFA-2A IN COMBINATION WITH LAMIVUDINE OR']",['NV25361'],['Yes'],['F. HOFFMANN - LA ROCHE LTD.'],['Switzerland'],['Commercial'],"['Test', 'Test', 'Test']","['Yes', 'Yes', 'Yes']","['Roche Registration Ltd', 'ViiV Healthcare UK Ltd.', 'TEVA Pharma B.V']","['United Kingdom', 'United Kingdom', 'United Kingdom']","['No', 'No', 'No']",Pegasys,"['No', 'Yes', 'Yes']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Yes', 'No', 'No']","['Yes', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Yes', 'No', 'No']","['Solution for injection', 'Oral solution', 'Film-coated tablet']","['Yes', 'No', 'No']","['1', '2', '3']",['Chronic Hepatitis B Virus infection in children.'],['No'],"To evaluate the efficacy of Pegasys¿ + lamivudine compared with an untreated control in children with CHB, as measured by loss of HBsAg 24 weeks post-end of treatment/end of untreated observation.","['¿To evaluate efficacy of Pegasys¿ + lamivudine compared with an untreated control in children with CHB, as measured by seroconversion to anti-HBs, seroconversion to anti-HBe, loss of HBeAg, and HBV DNA levels, at 24 weeks post-end of treatment/end of untreated observation']",['No'],['• Male and female patients 3 to less than 18 years of age at baseline (12– 17 years of age at baseline in Russia)'],"['Patients who have had any previous anti-HBV treatment, or who are co-infected with hepatitis A virus (HAV), HCV, hepatitis D virus (HDV) or HIV, or who have decompensated liver disease will be excluded.']",['The primary efficacy endpoint is defined as loss of HBsAg at 24 weeks post-end of treatment (follow-up Week 24)/end of untreated observation (Week 80).'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['4'],['Authorised'],['2015-08-10'],,['Reason(s) for unfavourable opinion:'],,['Completed'],"To evaluate the efficacy of Pegasys¿ + lamivudine compared with an untreated control in children with CHB, as measured by loss of HBsAg 24 weeks post-end of treatment/end of untreated observation.-2006-000977-31-Italy - Italian Medicines Agency-peginterferon alfa-2a"
3,Pegasys,peginterferon alfa-2a,"['compensée signes réplication', 'inflammation', 'aghbe positif chez enfants non cirrhotiques adolescents', 'prise cas cas voir rubrique 4 4']",Germany - BfArM,2006-000977-31,"['PHASE IIIB, RANDOMIZED, OPEN-LABEL STUDY OF PEGYLATED INTERFERON ALFA-2A IN COMBINATION WITH LAMIVUDINE OR ENTECAVIR COMPARED WITH UNTREATED CONTROL PATIENTS IN CHILDREN WITH HBEAG-POSITIVE CHRONIC HEPATITIS B IN THE IMMUNE-TOLERANT PHASE']",['NV25361'],['No'],['F. Hoffmann-La Roche Ltd'],['Switzerland'],['Commercial'],"['Test', 'Test', 'Test', 'Test', 'Test']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['Roche Registration GmbH', 'ViiV Healthcare UK Ltd.', 'TEVA Pharma B.V', 'BRISTOL-MYERS SQUIBB PHARMA EEIG', 'BRISTOL-MYERS SQUIBB PHARMA EEIG']","['European Union', 'European Union', 'European Union', 'European Union', 'European Union']","['No', 'No', 'No', 'No', 'No']",Pegasys,"['No', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['Yes', 'No', 'No', 'No', 'No']","['Yes', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['Yes', 'No', 'No', 'No', 'No']","['Injection', 'Oral solution', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet']","['No', 'No', 'No', 'No', 'No']","['1', '2', '3', '4', '5']",['Chronic Hepatitis B Virus infection'],['No'],"To evaluate the efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by loss of HBsAg 24 weeks post-end of treatment/end of untreated observation.","['•To evaluate efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by seroconversion to anti-HBs, seroconversion to anti-HBe, loss of HBeAg, and HBV DNA levels, at 24 weeks post-end of']",['No'],['• Male and female patients 3 to less than 18 years of age at baseline (12 to < 18 years of age at baseline in Russia and India)'],"['Patients who have had any previous anti-HBV treatment, or']",['Loss of HBsAg at 24 weeks post-end of treatment (follow-up Week 24)/end of untreated observation (Week 80).'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['10'],['Authorised'],['2014-10-06'],['2015-01-19'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To evaluate the efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by loss of HBsAg 24 weeks post-end of treatment/end of untreated observation.-2006-000977-31-Germany - BfArM-peginterferon alfa-2a"
2,Karvezide,"irbesartan, hydrochlorothiazide","['hypertension', 'hypertension']",Belgium - FPS Health-DGM,2004-000020-32,['The Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as First Line'],['CV131-176'],['Information not present in EudraCT'],['Bristol Myers Squibb International Corporation'],['Belgium'],['Commercial'],"['Test', 'Test']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Bristol Myers Squibb Pharma EEIG, 141-149 Staines Road, Hounslow, TW3 3JA, UK', 'Bristol Myers Squibb Pharma EEIG, 141-149 Staines Road, Hounslow, TW3 3JA, UK']","['Belgium', 'Belgium']","['No', 'No']",Karvezide,"['Yes', 'Yes']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Tablet', 'Tablet']","['Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2']",['Severe Hypertension'],['No'],"The primary objective of this study is to compare the proportion of subjects whose seated diastolic blood pressure (SeDBP) is controlled (SeDBP < 90mmHg) at Week 5 when initiating irbesartan 150mg/HCTZ 12.5mg combination therapy as first-line treatment (titrated to irbesartan 300mg/HCTZ 25mg), as compared to initiating irbesartan 150mg monotherapy and titrating to irbesartan 300mg.","['To characterize the safety/tolerability in the two treatment groups over the sevenweek study period, examining in particular the frequency of treatment']",['Information not present in EudraCT'],['* Subjects must have uncontrolled hypertension defined as:'],['* SeSBP ≥ 220mmHg or SeDBP ≥ 130mmHg and/or evidence of malignant or'],['The primary efficacy outcome measurements is the proportion of subjects with seated diastolic blood pressure less than 90 mmHg at the end of Week 5.'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['36'],['Authorised'],['2005-02-16'],['2004-12-21'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"The primary objective of this study is to compare the proportion of subjects whose seated diastolic blood pressure (SeDBP) is controlled (SeDBP < 90mmHg) at Week 5 when initiating irbesartan 150mg/HCTZ 12.5mg combination therapy as first-line treatment (titrated to irbesartan 300mg/HCTZ 25mg), as compared to initiating irbesartan 150mg monotherapy and titrating to irbesartan 300mg.-2004-000020-32-Belgium - FPS Health-DGM-irbesartan, hydrochlorothiazide"
1,Norvir,ritonavir,['infections'],Spain - AEMPS,2008-001611-38,['Estudio piloto prospectivo de la farmacocinética y farmacodinamia de la interaciión entre tipranavir/ritonavir y raltegravir en pacientes infectados por el VIH-1'],['PK12-RAL/TPV'],['Information not present in EudraCT'],['Jose M Gatell - Hospital Clinic de Barcelona'],['Spain'],['Non-Commercial'],"['Test', 'Test', 'Test']","['Yes', 'Yes', 'Yes']","['Merck Sharp & Dohme Ltd.', 'Boehringer Ingelheim International GmbH', 'Abbot Laboratories Ltd']","['Spain', 'Spain']","['No', 'No', 'No']",Norvir,"['Yes', 'Yes', 'Yes']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Film-coated tablet', 'Capsule, soft', 'Capsule, soft']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3']",['Pacientes con infección crónica por VIH-1'],['No'],Evaluar la interacción farmacocinética entre raltegravir y la combinación de tipranavir/ritonavir en pacientes VIH que reciben ambos fármacos en una pauta de rescate.,['Evaluación de la respuesta virológica e inmunológica a las 24 semanas'],['No'],['Pacientes con infección por VIH'],"['Embarazo, lactancia o previsión de embarazo durante el periodo de estudio']","['Comparación de los niveles plasmáticos de raltegravir administrado sin TPV/r ( basal : día 5) y tras su administración conjunta con TPV/r (tras alcanzado el equilibrio estacionario (steady state) de éste a partir de las dos semanas de su coadministración, aproximadamente en el día 20)']",['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['Yes'],['Yes'],['No'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['10'],['Authorised'],['2008-06-27'],['2008-05-23'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Ongoing'],Evaluar la interacción farmacocinética entre raltegravir y la combinación de tipranavir/ritonavir en pacientes VIH que reciben ambos fármacos en una pauta de rescate.-2008-001611-38-Spain - AEMPS-ritonavir
1,Ziagen,abacavir,"['infections', 'traitement infection virus immunodéficience humaine vih chez adultes adolescents enfants démonstration bénéfice ziagen repose principalement résultats études réalisées régime biquotidien chez patients naïfs traitement', 'combiné avant commencer traitement']",Italy - Italian Medicines Agency,2016-002413-22,"['Open label, Randomized (1:1), clinical trial to evaluate switching from dual regimens based on Dolutegravir plus a reverse transcriptase inhibitor to  elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in virologically suppressed, HIV-1 infected patients.']",['Be-OnE1/08-03-2016'],['No'],['OSPEDALE SAN RAFFAELE'],['Italy'],['Non-Commercial'],"['Test', 'Test', 'Comparator', 'Comparator', 'Comparator', 'Comparator', 'Comparator', 'Comparator', 'Comparator', 'Comparator']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['Gilead Sciences Int. Ltd', 'VIIV HEALTHCARE UK LTD', 'GILEAD SCIENCE INTERNATIONAL LIMITED', 'MYLAN S.P.A.', 'GILEAD SCIENCE INTERNATIONAL LIMITED', 'GLAXO GROUP LIMITED', 'JANSSEN-CILAG INTERNATIONAL N.V.', 'JANSSEN-CILAG INTERNATIONAL N.V.', 'BRISTOL-MYERS SQUIBB PHARMA EEIG', 'BOEHRINGER INGELHEIM INTERNATIONAL GMBH']","['Ireland', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']",Ziagen,"['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'No', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'No', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Film-coated tablet', 'Film-coated tablet', 'Capsule, hard', 'Film-coated tablet', 'Film-coated tablet', 'Film-coated tablet', 'Tablet', 'Tablet', 'Tablet', 'Prolonged-release tablet']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['1', '2', '3', '4', '5', '6', '7', '8', '9', '10']",['HIV infection'],['No'],To investigate Residual Viremia  through 48 weeks in virologically suppressed patients randomized to continue treatment with Dolutegravir plus a single RTI or to switch to E/C/F/TAF.,['Secondary Objectives'],['No'],['1.\tAge >18  years'],['1.\tActive AIDS-defining condition (except Kaposi’s sarcoma non requiring systemic chemotherapy)'],['Proportion of subjects without Residual Viremia  through 48 weeks of follow-up.'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['100'],['Authorised'],['2016-10-31'],['2016-07-14'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Prematurely Ended'],To investigate Residual Viremia  through 48 weeks in virologically suppressed patients randomized to continue treatment with Dolutegravir plus a single RTI or to switch to E/C/F/TAF.-2016-002413-22-Italy - Italian Medicines Agency-abacavir
3,Victoza,liraglutide,['complément régime'],Austria - BASG,2011-006300-12,['Pilot study of the incretin effect on the immunological phenotype in healthy subjects and subjects with type 1 diabetes: Step 4 of the Austrian Diabetes Prevention Programme (ADPP-004).'],['ADPP-004'],['No'],"['Medizinische Universität Graz, Kl. Abteilung für Endokrinologie und Stoffwechsel']",['Austria'],['Non-Commercial'],"['Test', 'Test']","['Yes', 'Yes']","['Novo Nordisk, Dänemark', 'BMS USA']","['European Union', 'European Union']","['No', 'No']",Victoza,"['Yes', 'Yes']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['Solution for injection in pre-filled pen', 'Tablet']","['No', 'No']","['1', '2']",['healthy volunteers'],['No'],"Zu evaluieren, welchen Effekt zwei unterschiedliche Inkretin-basierte Therapien (GLP-1 Analog Liraglutide und DPP-4 Hemmer Saxagliptin) über 4 Wochen auf die prozentuelle Anzahl und Funktion der im Blut zirkulierenden regulatorischen T-Zellen (Tregs) bei gesunden Probanden und PatientInnen mit Typ 1 Diabetes hat.","['Zu evaluieren, welchen Effekt Inkretin-basierte Therapien (GLP-1 Analog Liraglutide und DPP-4 Hemmer Saxagliptin) über 4 Wochen auf die Frequenz und Aktivität anderer wichtiger zirkulierender Immunzellen (Immunphenotyping).']",['No'],"['Gesunde ProbandInnen bzw. PatientInnen mit  Typ 1 Diabetes, behandelt mit Insulin seit mindestens 1 Jahr, Informed Consent, Alter: 18-64 Jahre.']","['Schwangerschaft, Therapie mit GLP-1 Analoga (Liraglutide, Exenatide), Therapie mit DPP-4-Inhibitoren (Sitagliptin, Vildagliptin, Saxagliptin), chronische Grunderkrankungen, die ein medikamentöse Dauertherapie mehr als 4 Wochen pro Jahr nach sich zieht (außer Typ 1 Diabetes).']",['Treg Anstieg im Blut unter Liraglutid- und Saxagliptingabe'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['32'],['Authorised'],['2012-02-23'],['2012-01-16'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Prematurely Ended'],"Zu evaluieren, welchen Effekt zwei unterschiedliche Inkretin-basierte Therapien (GLP-1 Analog Liraglutide und DPP-4 Hemmer Saxagliptin) über 4 Wochen auf die prozentuelle Anzahl und Funktion der im Blut zirkulierenden regulatorischen T-Zellen (Tregs) bei gesunden Probanden und PatientInnen mit Typ 1 Diabetes hat.-2011-006300-12-Austria - BASG-liraglutide"
3,Victoza,liraglutide,['complément régime'],Germany - BfArM,2011-003818-16,"['A randomized, open-label, cross-over study to evaluate patient preferences for Eucreas® versus Victoza® as add-on to Metformin in Type 2 Diabetes mellitus patients who did not have adequate glycaemic control with metformin']",['CLMF237ADE03'],['No'],['Novartis Pharma GmbH'],['Germany'],['Commercial'],"['Test', 'Comparator', 'Comparator']","['Yes', 'Yes', 'No']","['Novartis Europharm Limited', 'Novo Nordisk A/S', 'Stadapharm GmbH']","['European Union', 'European Union', 'Germany']","['No', 'No', 'No']",Victoza,"['Yes', 'No', 'Yes']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'Yes', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'Yes', 'No']","['Film-coated tablet', 'Solution for injection in pre-filled pen', 'Film-coated tablet']","['No', 'No', 'No']","['1', '2', '3']",['type 2 diabetes mellitus'],['No'],The primary objective of this trial is to demonstrate that a higher proportion of subjects with T2DM and inadequate glycemic control have a preference for an oral treatment with the SPC of vildagliptin/metformin compared to an injectable treatment with liraglutide as add-on to metformin after experiencing both treatments.,['•\tTo evaluate the subjective reason of preference for an oral or and injectable treatment after experiencing both treatments.'],['No'],['1. Age: > 18 and < 80 years at Visit 1.'],['1.\tFPG ≥270mg/dL (15.0 mmol/L) at Visit 1.'],['The primary outcome variable is the patient´s preference for one treatment.'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['60'],['Authorised'],['2011-12-21'],['2011-11-21'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],The primary objective of this trial is to demonstrate that a higher proportion of subjects with T2DM and inadequate glycemic control have a preference for an oral treatment with the SPC of vildagliptin/metformin compared to an injectable treatment with liraglutide as add-on to metformin after experiencing both treatments.-2011-003818-16-Germany - BfArM-liraglutide
3,Mircera,Methoxy polyethylene glycol-epoetin beta,['après taux hémoglobine'],Italy - Italian Medicines Agency,2007-007758-70,"['An open-label multi-center, multiple dose study to determine the optimum starting dose of intravenous MIRCERA for maintenance treatment of anemia in pediatric patients with chronic kidney disease on hemodialysis']",['NH19707'],['No'],['ROCHE'],['Italy'],['Commercial'],"['Test', 'Test', 'Test', 'Test', 'Test', 'Test']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['Roche Registration Limited', 'Roche Registration Limited', 'Roche Registration Limited', 'Roche Registration Limited', 'Roche Registration Limited', 'Roche Registration Limited']","['United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom']","['No', 'No', 'No', 'No', 'No', 'No']",Mircera,"['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['Solution for injection', 'Solution for injection', 'Solution for injection', 'Solution for injection', 'Solution for injection', 'Solution for injection']","['No', 'No', 'No', 'No', 'No', 'No']","['1', '2', '3', '4', '5', '6']",['Chronic renal anemia'],['No'],"- To determine the starting dose of MIRCERA in pediatric patients with CKD on hemodialysis when switching from  stable maintenance treatment with epoetin alfa, epoetin beta or darbepoetin alfa  - To demonstrate changes in Hb over time in response to different iv doses of MIRCERA",['- To study the pharmacokinetics (PK) of MIRCERA in  pediatric patients  - To explore MIRCERA exposure response relationship  - To assess the safety and tolerability of multiple doses of  MIRCERA in pediatric patients  - To document long-term safety and efficacy of MIRCERA administration in pediatric patients with anemia associated with CKD'],['No'],"['1. Written informed consent  2. Pediatric patients 5 -17 years old with clinically stable chronic renal anemia  3. Hemodialysis treatment for at least 8 weeks  4. Body weight &#8805; 10 kg  5. Adequate hemodialysis: URR of > 65% or Kt/V >1.2 for  patients on thrice weekly HD. Patients with fewer or with  more HD sessions per week should have a weekly Kt/V &#8805; 3.6  6. Baseline pre-dialysis Hb concentration 10.0 - 12.0 g/dL  determined from the mean of weekly Hb values measured  between weeks -2 to -1  7. Intravenous maintenance epoetin alfa, epoetin beta, or  darbepoetin alfa with same dosing interval for at least 8  weeks before screening  8. Stable maintenance epoetin alfa, epoetin beta, or darbepoetin  alfa treatment with no weekly dose change &#8805; 25% (increase  or decrease) during the 2-weeks of screening. Patients who  had been previously treated by the sc route could only  participate if they have been receiving their ESA by the iv  route for at least 8 weeks before screening.  9. Adequate iron status defined as serum ferritin &#8805; 100 ng/mL or  TSAT &#8805; 20% (or percentage of hypochromic red cells <  10%); mean of two values measured during screening']","['1. Overt gastrointestinal bleeding within 8 weeks before screening or during the screening period  2. RBC transfusions within 8 weeks before screening or during the screening period  3. Hemoglobinopathies (e.g., omozygous sickle-cell disease, thalassemia of all types)  4. Hemolysis  5. Active malignant disease  6. Chronic, uncontrolled or symptomatic inflammatory disease  (e.g. systemic lupus erythematosus)  7. Uncontrolled hypertension as assessed by the investigator  8. Epileptic seizures within 3 months prior to screening and during the screening period  9. Administration of any investigational drug within 4 weeks  prior to screening and planned during the study  10. Severe hyperparathyroidism (Intact PTH &#8805; 1000 pg/ml or  whole PTH &#8805; 500 pg/ml) or biopsy-proven bone marrow fibrosis  11. Known hypersensitivity to recombinant human erythropoietin, polyethylene glycol, or to any constituent of the study drug formulation  12. Pure red cell aplasia (PRCA) or history of PRCA  13. High likelihood of early withdrawal or interruption of the  study (e.g. planned living donor kidney transplant within 16  weeks after randomization)  14. Planned elective surgery during the entire study period (except hemodialysis access surgery)']",['- Change in hemoglobin concentration between the baseline  and evaluation periods (weeks 17-20)'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['No'],['6'],['Authorised'],['2008-11-11'],['2008-07-01'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"- To determine the starting dose of MIRCERA in pediatric patients with CKD on hemodialysis when switching from  stable maintenance treatment with epoetin alfa, epoetin beta or darbepoetin alfa  - To demonstrate changes in Hb over time in response to different iv doses of MIRCERA-2007-007758-70-Italy - Italian Medicines Agency-Methoxy polyethylene glycol-epoetin beta"
3,Bonviva,ibandronic acid,"['fractures', 'fractures']",Sweden - MPA,2009-014414-98,['The impact of local bisphosphonate treatment on prosthetic fixation'],['58185'],['Information not present in EudraCT'],['Department of Orthopaedic Surgery University Hospital Linköping'],['Sweden'],['Non-Commercial'],['Test'],['Yes'],,['Sweden'],['No'],Bonviva,['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Spot-on solution'],['Information not present in EudraCT'],['1'],['Osteoarthritis of the hip joint treated with total hip replacement'],['No'],To Investigate if local treatment of the bonebed with bisphosphonate solution prior to fixation of the acetabular component of a cemented hip prosthesis decreases the risk for future loosening of the prosthesis.,,['Information not present in EudraCT'],['Patients 50-65 years of age with primary osteoarthritis of the hip that are planned  for total hip arthroplasty.'],"['Osteoporosis. Treatment with coticosteroids. Treatment with drugs that influence bone metabolism e.g.bisphosphonates, cytostatic drugs, anticonvulsive drugs.']",['Local treatment of the acetabular bone bed with bisphosphonate drugs results in less resorption of the periprosthetic bone and consequently in a more stabile fixation.'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Information not present in EudraCT'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['60'],['Authorised'],['2009-10-29'],['2009-10-14'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],To Investigate if local treatment of the bonebed with bisphosphonate solution prior to fixation of the acetabular component of a cemented hip prosthesis decreases the risk for future loosening of the prosthesis.-2009-014414-98-Sweden - MPA-ibandronic acid
3,Ruconest,Recombinant human C1-inhibitor,['déficit inhibiteur'],Germany - PEI,2011-000987-92,"['Open-label, phase II, single arm study to evaluate the safety, immunogenicity, pharmacokinetics and efficacy of recombinant human C1 inhibitor for the treatment of acute attacks in pediatric patients with hereditary angioedema, from 2 up to and including 13 years of age']",['C11209'],['Yes'],['Pharming Technologies B.V.'],['Netherlands'],['Commercial'],['Test'],['Yes'],['Pharming Group N.V'],['European Union'],['No'],Ruconest,['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Powder for solution for injection'],['No'],['1'],['Attacks associated with hereditary angioedema (HAE) in pediatric population 2-13 years of age.'],['Yes'],"To assess the clinical safety, immunogenicity and tolerability of Ruconest in the treatment of acute angioedema attacks in 2-13 year old HAE patients.",['To assess the pharmacokinetics (PK) and pharmacodynamics (PD) of Ruconest in the treatment of acute angioedema attacks in 2-13 year old HAE patients.'],['No'],['Screening'],['Screening'],['Assessment of safety and tolerability.'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['No'],['6'],['Authorised'],['2011-09-26'],['2011-08-02'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To assess the clinical safety, immunogenicity and tolerability of Ruconest in the treatment of acute angioedema attacks in 2-13 year old HAE patients.-2011-000987-92-Germany - PEI-Recombinant human C1-inhibitor"
3,Ruconest,Recombinant human C1-inhibitor,['déficit inhibiteur'],Italy - Italian Medicines Agency,2011-000987-92,"['Open-label, phase II, single arm study to evaluate the safety, immunogenicity, pharmacokinetics and efficacy of recombinant human C1 inhibitor for the treatment of acute attacks in pediatric patients with hereditary angioedema, from 2 up to and including 13 years of age']",['C11209'],['Yes'],['PHARMING TECHNOLOGIES B.V.'],['Netherlands'],['Commercial'],['Test'],['Yes'],['Pharming Technologies'],['Germany'],['No'],Ruconest,['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Powder for solution for injection'],['No'],['1'],['Hereditary angioedema (HAE). Hereditary angioedema is characterized by angioedema localized and recurrent caused by by uncontrolled activation of the Complement systems due to congenital deficiency of Functional C1 inhibitor (C1INH). Reports in Medical the literature suggests that C1INH replacement therapy with human plasma-derived represents a safe and  effective acute attacks of HA'],['Yes'],"to assess the clinical safety, immunogenicity and tolerability of Ruconest in the treatment of acute angioedema attacks in 2-13 year old HAE patients",['- to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of Ruconest in the treatment of acute angioedema attacks in 2-13 year old HAE patients    to assess the efficacy of Ruconest in the treatment of acute angioedema attacks in 2-13 year old HAE patientsu'],['No'],['Screening  • From 2 up to and including 13 years of age  • Clinical and laboratory confirmed diagnosis of HAE (baseline C1INH activity <50% of normal)  • Signed written informed consent (parental permission) signed by the legal guardian(s)     Treatment  • Clinical symptoms of an acute HAE attack  • Onset of eligible symptoms within 5 hours from the moment at which medical evaluation to determine eligibility has occurred  • IS score for at least one anatomical location at the time of initial evaluation of at least 3 (moderate severity or greater) without signs of spontaneous regression  • 24h or more have passed since the patient’s last study treatment'],['Screening'],"['The primary objective is Safety Tolllerability and immunogenicity.  Safety and tolerability by standard criteria (vital signs, ECG, adverse events, routine laboratory safety parameters and immunogenicity (anti-host related impurities (HRI) and anti C1INH antibodies)']",['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['No'],['5'],['Authorised'],['2011-12-27'],['2011-11-09'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"to assess the clinical safety, immunogenicity and tolerability of Ruconest in the treatment of acute angioedema attacks in 2-13 year old HAE patients-2011-000987-92-Italy - Italian Medicines Agency-Recombinant human C1-inhibitor"
3,Ruconest,Recombinant human C1-inhibitor,['déficit inhibiteur'],Czech Republic - SUKL,2011-000987-92,"['Open-label, phase II, single arm study to evaluate the safety, immunogenicity, pharmacokinetics and efficacy of recombinant human C1 inhibitor for the treatment of acute attacks in pediatric patients with hereditary angioedema, from 2 up to and including 13 years of age']",['C11209'],['Yes'],['Pharming Technologies B.V.'],['Netherlands'],['Commercial'],['Test'],['Yes'],['Pharming Group N.V'],['Netherlands'],['No'],Ruconest,['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Powder for solution for injection'],['No'],['1'],['Attacks associated with hereditary angioedema (HAE) in pediatric population 2-13 years of age.'],['Yes'],"To assess the clinical safety, immunogenicity and tolerability of Ruconest in the treatment of acute angioedema attacks in 2-13 year old HAE patients.",['To assess the pharmacokinetics (PK) and pharmacodynamics (PD) of Ruconest in the treatment of acute angioedema attacks in 2-13 year old HAE patients.'],['No'],['Screening'],['Screening'],['Assessment of safety and tolerability.'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['No'],['6'],['Authorised'],['2014-08-29'],['2014-10-02'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To assess the clinical safety, immunogenicity and tolerability of Ruconest in the treatment of acute angioedema attacks in 2-13 year old HAE patients.-2011-000987-92-Czech Republic - SUKL-Recombinant human C1-inhibitor"
3,Ruconest,Recombinant human C1-inhibitor,['déficit inhibiteur'],Slovakia - SIDC (Slovak),2011-000987-92,"['Open-label, phase II, single arm study to evaluate the safety, immunogenicity, pharmacokinetics and efficacy of recombinant human C1 inhibitor for the treatment of acute attacks in pediatric patients with hereditary angioedema, from 2 up to and including 13 years of age']",['C11209'],['Yes'],['Pharming Technologies B.V.'],['Netherlands'],['Commercial'],['Test'],['Yes'],['Pharming Group N.V'],['Netherlands'],['No'],Ruconest,['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Powder for solution for injection'],['No'],['1'],['Attacks associated with hereditary angioedema (HAE) in pediatric population 2-13 years of age.'],['Yes'],"To assess the clinical safety, immunogenicity and tolerability of Ruconest in the treatment of acute angioedema attacks in 2-13 year old HAE patients.",['To assess the pharmacokinetics (PK) and pharmacodynamics (PD) of Ruconest in the treatment of acute angioedema attacks in 2-13 year old HAE patients.'],['No'],['Screening'],['Screening'],['Assessment of safety and tolerability.'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['No'],['6'],['Authorised'],['2014-09-24'],['2014-09-24'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To assess the clinical safety, immunogenicity and tolerability of Ruconest in the treatment of acute angioedema attacks in 2-13 year old HAE patients.-2011-000987-92-Slovakia - SIDC (Slovak)-Recombinant human C1-inhibitor"
3,Ruconest,Recombinant human C1-inhibitor,['déficit inhibiteur'],Hungary - National Institute of Pharmacy,2011-000987-92,"['Open-label, phase II, single arm study to evaluate the safety, immunogenicity, pharmacokinetics and efficacy of recombinant human C1 inhibitor for the treatment of acute attacks in pediatric patients with hereditary angioedema, from 2 up to and including 13 years of age']",['C11209'],['Yes'],['Pharming Technologies B.V.'],['Netherlands'],['Commercial'],['Test'],['Yes'],['Pharming Group N.V'],['European Union'],['No'],Ruconest,['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Powder for solution for injection'],['No'],['1'],['Attacks associated with hereditary angioedema (HAE) in pediatric population 2-13 years of age.'],['Yes'],"To assess the clinical safety, immunogenicity and tolerability of Ruconest in the treatment of acute angioedema attacks in 2-13 year old HAE patients.",['To assess the pharmacokinetics (PK) and pharmacodynamics (PD) of Ruconest in the treatment of acute angioedema attacks in 2-13 year old HAE patients.'],['No'],['Screening'],['Screening'],['Assessment of safety and tolerability.'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['No'],['2'],['Authorised'],['2015-09-14'],['2015-09-07'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To assess the clinical safety, immunogenicity and tolerability of Ruconest in the treatment of acute angioedema attacks in 2-13 year old HAE patients.-2011-000987-92-Hungary - National Institute of Pharmacy-Recombinant human C1-inhibitor"
0,Janumet,"sitagliptin, metformin hydrochloride",['complément régime alimentaire exercices physiques améliorer contrôle glycémique chez patients insuffisamment contrôlés dose maximale tolérée'],Germany - BfArM,2011-000518-21,['Cross-over study to assess the difference in fasting plasma glucose (FPG) between vildagliptin (Galvus®/Eucreas®) and sitagliptin (Januvia®/Janumet®) after two weeks (FPG-VISIT)'],['CLMF237ADE02'],['No'],['Novartis Pharma GmbH'],['Germany'],['Commercial'],"['Test', 'Comparator']","['Yes', 'Yes']","['Novartis Europharm Limited', 'Merck Sharp & Dohme, Inc.']","['European Union', 'European Union']","['No', 'No']",Janumet,"['Yes', 'Yes']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['Film-coated tablet', 'Film-coated tablet']","['No', 'No']","['1', '2']",['Diabetes mellitus type 2'],['No'],To assess the difference in FPG between vildagliptin and sitagliptin after two weeks in patients with type 2 diabetes mellitus pre-treated with metformin.,['To assess the difference in FPG between vildagliptin and sitagliptin after a missed dose of either drug in patients with type 2 diabetes mellitus on concomitant treatment with metformin.'],['No'],['1.\tType 2 diabetic patients stabilized on metformin monotherapy (stable dose for at least 4 weeks prior to Screening) ≥ 1000 mg/day and ≤ 2000 mg/day.'],['1.\tFPG ≥ 270mg/dL (15mmol/L) at Visit 1 and Visit 102.'],['The primary objective of the study is to demonstrate that the FPG after 14 days of treatment with Vildagliptin is superior to the FPG after 14 days of treatment with.'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['100'],['Authorised'],['2011-04-29'],['2011-06-20'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To assess the difference in FPG between vildagliptin and sitagliptin after two weeks in patients with type 2 diabetes mellitus pre-treated with metformin.-2011-000518-21-Germany - BfArM-sitagliptin, metformin hydrochloride"
0,Retacrit,epoetin zeta,['rapporté événements thromboemboliques traitement doit être administré'],Sweden - MPA,2011-001673-70,['EPO to protect renal function after cardiac surgery. EPRICS. A phase II double blind randomized controlled study.'],,['No'],['Skånes Universitetssjukhus'],['Sweden'],['Non-Commercial'],['Test'],['Yes'],['Hospira UK Limited'],['United Kingdom'],['No'],Retacrit,['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Injection'],['No'],['1'],['Renal function after cardiac surgery'],['No'],To study the efficacy of erythropoietin zeta with brand name Retracrit® given preoperatively in Coronary Artery Bypass Grafting (CABG) patients to attenuate further decrease in renal dysfunction after open heart surgery and it’s safety. Different biological markers for kidney function will be measured postoperatively.,['Secondary objectives will be regarding to the study drugs potential effect on brain and heart. These will be evaluated by specific biomarkers.'],['No'],['Patients planed for Coronary Artery Bypass Grafting (CABG).'],"['Exclusion criteria: Uncontrolled hypertension, pregnancy or fertile woman (less than 50 years old), Epo treatment within 4 weeks, eGFR-CyC<15 or dialysis, known malignancy and Off-pump surgery']",['Primary endpoint: Plasma CyC change from day -1 to day 3.'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['70'],['Authorised'],['2011-07-27'],['2011-08-09'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],To study the efficacy of erythropoietin zeta with brand name Retracrit® given preoperatively in Coronary Artery Bypass Grafting (CABG) patients to attenuate further decrease in renal dysfunction after open heart surgery and it’s safety. Different biological markers for kidney function will be measured postoperatively.-2011-001673-70-Sweden - MPA-epoetin zeta
3,Sifrol,pramipexole dihydrochloride monohydrate,"['parkinson idiopathique seul sans lévodopa association lévodopa est-à-dire cours évolution maladie jusqu stades avancés lorsque effet lévodopa', 'sifrol indiqué', 'traitement symptomatique syndrome jambes sans repos idiopathique modéré sévère']",UK - MHRA,2005-003788-22,"['A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson’s disease patients with stable motor function and depressive symptoms.']",['248.596'],['Information not present in EudraCT'],['Boehringer Ingelheim Limited'],['United Kingdom'],['Commercial'],"['Test', 'Test', 'Test', 'Test']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Boehringer Ingelheim International GmbH', 'Boehringer Ingelheim International GmbH', 'Boehringer Ingelheim International GmbH', 'Boehringer Ingelheim International GmbH']","['United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom']","['No', 'No', 'No', 'No']",Sifrol,"['Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Tablet', 'Tablet', 'Tablet', 'Tablet']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3', '4']","['A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson’s disease patients with stable motor function and depressive symptoms']",['No'],"To investigate the efficacy of pramipexole, compared with placebo in treating Parkinson’s  disease patients with stable motor function and depressive symptoms.  The efficacy of pramipexole vs. placebo will be based on the Beck Depression Inventory (BDI) total score.","['To assess further depression response (% patients with 50% reduction from baseline in total BDI score, GDS total score, and UPDRS part I), motor function (standard version UPDRS part II & III), complications of therapy (UPDRS part IV), anhedonia (SHAPS), quality of life (PDQ-39 and EQ-5D), Clinical Global Improvement (CGI-I) and pain (VAS)']",['Information not present in EudraCT'],['1. 15-item Geriatric Depression Scale (GDS)  ≥ 5'],"['1. Previous history of allergic response, lack of efficacy or complications with pramipexole or its excipients.']","['The primary endpoint for this study is clinical response after 12 weeks of treatment, defined as a change in total score of baseline symptoms as measured by the BDI total score.']",['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['40'],['Authorised'],['2005-12-12'],['2006-01-06'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To investigate the efficacy of pramipexole, compared with placebo in treating Parkinson’s  disease patients with stable motor function and depressive symptoms.  The efficacy of pramipexole vs. placebo will be based on the Beck Depression Inventory (BDI) total score.-2005-003788-22-UK - MHRA-pramipexole dihydrochloride monohydrate"
3,Sifrol,pramipexole dihydrochloride monohydrate,"['parkinson idiopathique seul sans lévodopa association lévodopa est-à-dire cours évolution maladie jusqu stades avancés lorsque effet lévodopa', 'sifrol indiqué', 'traitement symptomatique syndrome jambes sans repos idiopathique modéré sévère']",Germany - BfArM,2005-003788-22,"['A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson’s disease patients with stable motor function and depressive symptoms.']",['248.596'],['Information not present in EudraCT'],['Boehringer Ingelheim Pharma GmbH & Co. KG'],['Germany'],['Commercial'],"['Test', 'Test', 'Test', 'Test']","['Yes', 'Yes', 'Yes', 'Yes']","['Boehringer Ingelheim International GmbH', 'Boehringer Ingelheim International GmbH', 'Boehringer Ingelheim International GmbH', 'Boehringer Ingelheim International GmbH']","['European Union', 'European Union', 'European Union', 'European Union']","['No', 'No', 'No', 'No']",Sifrol,"['Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Tablet', 'Tablet', 'Tablet', 'Tablet']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3', '4']","['A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson’s disease patients with stable motor function and depressive symptoms']",['No'],"To investigate the efficacy of pramipexole, compared with placebo in treating Parkinson’s  disease patients with stable motor function and depressive symptoms.  The efficacy of pramipexole vs. placebo will be based on the Beck Depression Inventory (BDI) total score.","['To assess further depression response (% patients with 50% reduction from baseline in total BDI score, GDS total score, and UPDRS part I), motor function (standard version UPDRS part II & III), complications of therapy (UPDRS part IV), anhedonia (SHAPS), quality of life (PDQ-39 and EQ-5D), Clinical Global Improvement (CGI-I) and pain (VAS)']",['Information not present in EudraCT'],['1. 15-item Geriatric Depression Scale (GDS)  ≥ 5'],"['1. Previous history of allergic response, lack of efficacy or complications with pramipexole or its excipients.']","['The primary endpoint for this study is clinical response after 12 weeks of treatment, defined as a change in total score of baseline symptoms as measured by the BDI total score.']",['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['40'],['Authorised'],['2005-12-05'],['2006-02-01'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To investigate the efficacy of pramipexole, compared with placebo in treating Parkinson’s  disease patients with stable motor function and depressive symptoms.  The efficacy of pramipexole vs. placebo will be based on the Beck Depression Inventory (BDI) total score.-2005-003788-22-Germany - BfArM-pramipexole dihydrochloride monohydrate"
3,Sifrol,pramipexole dihydrochloride monohydrate,"['parkinson idiopathique seul sans lévodopa association lévodopa est-à-dire cours évolution maladie jusqu stades avancés lorsque effet lévodopa', 'sifrol indiqué', 'traitement symptomatique syndrome jambes sans repos idiopathique modéré sévère']",Finland - Fimea,2005-003788-22,"['A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson’s disease patients with stable motor function and depressive symptoms.']",['248.596'],['Information not present in EudraCT'],['Boehringer Ingelheim Finland Ky'],['Finland'],"['Commercial', 'Non-Commercial']","['Test', 'Test', 'Test', 'Test']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Boehringer Ingelheim International GmbH', 'Boehringer Ingelheim International GmbH', 'Boehringer Ingelheim International GmbH', 'Boehringer Ingelheim International GmbH']","['Finland', 'Finland', 'Finland', 'Finland']","['No', 'No', 'No', 'No']",Sifrol,"['Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Tablet', 'Tablet', 'Tablet', 'Tablet']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3', '4']","['A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson’s disease patients with stable motor function and depressive symptoms']",['No'],"To investigate the efficacy of pramipexole, compared with placebo in treating Parkinson’s  disease patients with stable motor function and depressive symptoms.  The efficacy of pramipexole vs. placebo will be based on the Beck Depression Inventory (BDI) total score.","['To assess further depression response (% patients with 50% reduction from baseline in total BDI score, GDS total score, and UPDRS part I), motor function (standard version UPDRS part II & III), complications of therapy (UPDRS part IV), anhedonia (SHAPS), quality of life (PDQ-39 and EQ-5D), Clinical Global Improvement (CGI-I) and pain (VAS)']",['Information not present in EudraCT'],['1. 15-item Geriatric Depression Scale (GDS)  ≥ 5'],"['1. Previous history of allergic response, lack of efficacy or complications with pramipexole or its excipients.']","['The primary endpoint for this study is clinical response after 12 weeks of treatment, defined as a change in total score of baseline symptoms as measured by the BDI total score.']",['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['40'],['Authorised'],['2006-01-17'],['2006-01-10'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To investigate the efficacy of pramipexole, compared with placebo in treating Parkinson’s  disease patients with stable motor function and depressive symptoms.  The efficacy of pramipexole vs. placebo will be based on the Beck Depression Inventory (BDI) total score.-2005-003788-22-Finland - Fimea-pramipexole dihydrochloride monohydrate"
3,Sifrol,pramipexole dihydrochloride monohydrate,"['parkinson idiopathique seul sans lévodopa association lévodopa est-à-dire cours évolution maladie jusqu stades avancés lorsque effet lévodopa', 'sifrol indiqué', 'traitement symptomatique syndrome jambes sans repos idiopathique modéré sévère']",Sweden - MPA,2005-003788-22,"['A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson’s disease patients with stable motor function and depressive symptoms.']",['248.596'],['Information not present in EudraCT'],['Boehringer Ingelheim AB'],['Sweden'],['Commercial'],"['Test', 'Test', 'Test', 'Test']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Boehringer Ingelheim International GmbH', 'Boehringer Ingelheim International GmbH', 'Boehringer Ingelheim International GmbH', 'Boehringer Ingelheim International GmbH']","['Sweden', 'Sweden', 'Sweden', 'Sweden']","['No', 'No', 'No', 'No']",Sifrol,"['Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Tablet', 'Tablet', 'Tablet', 'Tablet']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3', '4']","['A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson’s disease patients with stable motor function and depressive symptoms']",['No'],"To investigate the efficacy of pramipexole, compared with placebo in treating Parkinson’s  disease patients with stable motor function and depressive symptoms.  The efficacy of pramipexole vs. placebo will be based on the Beck Depression Inventory (BDI) total score.","['To assess further depression response (% patients with 50% reduction from baseline in total BDI score, GDS total score, and UPDRS part I), motor function (standard version UPDRS part II & III), complications of therapy (UPDRS part IV), anhedonia (SHAPS), quality of life (PDQ-39 and EQ-5D), Clinical Global Improvement (CGI-I) and pain (VAS)']",['Information not present in EudraCT'],['1. 15-item Geriatric Depression Scale (GDS)  ≥ 5'],"['1. Previous history of allergic response, lack of efficacy or complications with pramipexole or its excipients.']","['The primary endpoint for this study is clinical response after 12 weeks of treatment, defined as a change in total score of baseline symptoms as measured by the BDI total score.']",['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['32'],['Authorised'],['2006-02-15'],['2006-03-03'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To investigate the efficacy of pramipexole, compared with placebo in treating Parkinson’s  disease patients with stable motor function and depressive symptoms.  The efficacy of pramipexole vs. placebo will be based on the Beck Depression Inventory (BDI) total score.-2005-003788-22-Sweden - MPA-pramipexole dihydrochloride monohydrate"
3,Sifrol,pramipexole dihydrochloride monohydrate,"['parkinson idiopathique seul sans lévodopa association lévodopa est-à-dire cours évolution maladie jusqu stades avancés lorsque effet lévodopa', 'sifrol indiqué', 'traitement symptomatique syndrome jambes sans repos idiopathique modéré sévère']",Austria - BASG,2005-003788-22,"['A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson’s disease patients with stable motor function and depressive symptoms.']",['248.596'],['Information not present in EudraCT'],['Boehringer Ingelheim Austria GmbH'],['Austria'],['Commercial'],"['Test', 'Test', 'Test', 'Test']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Boehringer Ingelheim International GmbH', 'Boehringer Ingelheim International GmbH', 'Boehringer Ingelheim International GmbH', 'Boehringer Ingelheim International GmbH']","['Austria', 'Austria', 'Austria', 'Austria']","['No', 'No', 'No', 'No']",Sifrol,"['Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Tablet', 'Tablet', 'Tablet', 'Tablet']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3', '4']","['A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson’s disease patients with stable motor function and depressive symptoms']",['No'],"To investigate the efficacy of pramipexole, compared with placebo in treating Parkinson’s  disease patients with stable motor function and depressive symptoms.  The efficacy of pramipexole vs. placebo will be based on the Beck Depression Inventory (BDI) total score.","['To assess further depression response (% patients with 50% reduction from baseline in total BDI score, GDS total score, and UPDRS part I), motor function (standard version UPDRS part II & III), complications of therapy (UPDRS part IV), anhedonia (SHAPS), quality of life (PDQ-39 and EQ-5D), Clinical Global Improvement (CGI-I) and pain (VAS)']",['Information not present in EudraCT'],['1. 15-item Geriatric Depression Scale (GDS)  ≥ 5'],"['1. Previous history of allergic response, lack of efficacy or complications with pramipexole or its excipients.']","['The primary endpoint for this study is clinical response after 12 weeks of treatment, defined as a change in total score of baseline symptoms as measured by the BDI total score.']",['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['20'],['Authorised'],['2006-02-22'],['2006-02-22'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To investigate the efficacy of pramipexole, compared with placebo in treating Parkinson’s  disease patients with stable motor function and depressive symptoms.  The efficacy of pramipexole vs. placebo will be based on the Beck Depression Inventory (BDI) total score.-2005-003788-22-Austria - BASG-pramipexole dihydrochloride monohydrate"
3,Mirapexin,pramipexole dihydrochloride monohydrate,"['parkinson idiopathique seul sans lévodopa association lévodopa est-à-dire cours évolution maladie jusqu stades avancés lorsque effet lévodopa', 'traitement symptomatique syndrome jambes sans repos idiopathique modéré sévère']",Hungary - National Institute of Pharmacy,2007-006271-37,['Dopamin agonista pramipexol hatása tinnitusra presbyacusisban'],['MIRA 1/2007'],['Information not present in EudraCT'],"['Medical and Health Science Center, University of Debrecen Dept. of Otolaryngology']",['Hungary'],['Non-Commercial'],['Test'],['Information not present in EudraCT'],['Boehringer Ingelheim'],['Hungary'],['No'],Mirapexin,['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Tablet'],['Information not present in EudraCT'],['1'],['Tinnitus and old age presbycusis.'],['No'],To study the putative efficacy of Mirapexin on tinnitus and presbycusis.,,['No'],"['Age over 50 years,']",['Conductive hearing loss'],['Hearing after 4 weeks and 12 weeks after one month treatment.'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['40'],['Authorised'],['2008-06-16'],['2008-02-06'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Ongoing'],To study the putative efficacy of Mirapexin on tinnitus and presbycusis.-2007-006271-37-Hungary - National Institute of Pharmacy-pramipexole dihydrochloride monohydrate
0,NutropinAq,somatropin,"['turner nanisme hypophyse traitement long terme enfants présentant retard', 'turner traitement enfants prépubères présentant retard croissance associé', 'croissance origine infantile adulte déficit hormone croissance doit']",Denmark - DHMA,2004-000356-17,"['PHASE IIIB, INTERNATIONAL, SINGLE GROUP, OPEN STUDY TO DEFINE AN OPTIMAL MONITORING OF IGF-I IN CHILDREN TREATED WITH NUTROPINAQ']",['2-79-58035-700'],['Information not present in EudraCT'],['Beaufour Ipsen Pharma'],['France'],['Commercial'],['Test'],['Information not present in EudraCT'],['Ipsen Ltd'],['Denmark'],['No'],NutropinAq,['No'],['No'],['No'],['No'],['No'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Solution for injection'],['Information not present in EudraCT'],['1'],"['Children presenting growth failure associated with Growth Hormone Deficiency (GHD), Tuner Syndrome (TS) or Chronic Renal Insufficiency (CRI).']",['No'],The number of capillary blood spot IGF-I measurements and the optimal timing of samples to assess the IGF-I status of NutropinAq treated patients,['The factors affecting the variability of capillary IGF-I measurements; i.e. to establish whether the variability of IGF-I levels is homogeneously distributed in the patient population and/or if individual factors affect the day to day variability of IGF-I levels.'],['Information not present in EudraCT'],['Children (boys and girls under 18) with growth failure associated with:'],['Children with hypersensitivity to somatropin or any of the excipients'],['The number of capillary blood spot IGF-I measurements and the optimal timing of samples to assess the IGF-I status of NutropinAq treated patients'],['No'],['Information not present in EudraCT'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['Yes'],['No'],['6'],['Authorised'],['2004-12-15'],['2005-04-19'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],The number of capillary blood spot IGF-I measurements and the optimal timing of samples to assess the IGF-I status of NutropinAq treated patients-2004-000356-17-Denmark - DHMA-somatropin
0,NutropinAq,somatropin,"['turner nanisme hypophyse traitement long terme enfants présentant retard', 'turner traitement enfants prépubères présentant retard croissance associé', 'croissance origine infantile adulte déficit hormone croissance doit']",Austria - BASG,2004-000356-17,"['Phase IIIB, international, single group, open study to define an optimal monitor-ing of IGF-I in children treated with NutropinAq™, using a novel capillary blood collection method']",['2-79-58035-700'],['Information not present in EudraCT'],['Beaufour Ipsen Pharma'],['France'],['Commercial'],['Test'],['Information not present in EudraCT'],"['Ipsen Ltd., UK']",['Austria'],['No'],NutropinAq,['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Solution for injection'],['Information not present in EudraCT'],['1'],"['Children presenting growth failure associated with Growth Hormone Deficiency (GHD), Tuner Syndrome (TS) or Chronic Renal Insufficiency (CRI).']",['No'],The number of capillary blood spot IGF-I measurements and the optimal timing of samples to assess the IGF-I status of NutropinAq treated patients.,['The factors affecting the variability of capillary IGF-I measurements; i.e. to establish whether the variability of IGF-I levels is homogeneously distributed in the patient population and/or if individual factors affect the day to day variability of IGF-I levels.'],['Information not present in EudraCT'],['Children (boys and girls under 18) with growth failure associated with:'],['Children with hypersensitivity to somatropin or any of the excipients'],['The number of capillary blood spot IGF-I measurements and the optimal timing of samples to assess the IGF-I status of NutropinAq treated patients'],['No'],['Information not present in EudraCT'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['Yes'],['No'],['5'],['Authorised'],['2005-03-12'],['2005-03-12'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],The number of capillary blood spot IGF-I measurements and the optimal timing of samples to assess the IGF-I status of NutropinAq treated patients.-2004-000356-17-Austria - BASG-somatropin
0,NutropinAq,somatropin,"['turner nanisme hypophyse traitement long terme enfants présentant retard', 'turner traitement enfants prépubères présentant retard croissance associé', 'croissance origine infantile adulte déficit hormone croissance doit']",Sweden - MPA,2004-000356-17,"['PHASE IIIB, INTERNATIONAL, SINGLE GROUP, OPEN STUDY TO DEFINE AN OPTIMAL MONITORING OF IGF-I IN CHILDREN TREATED WITH NUTROPINAQ']",['2-79-58035-700'],['Information not present in EudraCT'],['Ipsen Scandinavia'],['Denmark'],['Commercial'],['Test'],['Information not present in EudraCT'],['Ipsen Ltd'],['Sweden'],['No'],NutropinAq,['No'],['No'],['No'],['No'],['No'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Solution for injection'],['Information not present in EudraCT'],['1'],"['Children presenting growth failure associated with Growth Hormone Deficiency (GHD), Tuner Syndrome (TS) or Chronic Renal Insufficiency (CRI).']",['No'],The number of capillary blood spot IGF-I measurements and the optimal timing of samples to assess the IGF-I status of NutropinAq treated patients,['Secundary objectives'],['Information not present in EudraCT'],['Children (boys and girls under 18) with growth failure associated with:'],['Children with hypersensitivity to somatropin or any of the excipients'],['The number of capillary blood spot IGF-I measurements and the optimal timing of samples to assess the IGF-I status of NutropinAq treated patients'],['No'],['Information not present in EudraCT'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['6'],['Authorised'],['2005-08-29'],,['Reason(s) for unfavourable opinion:'],,['Completed'],The number of capillary blood spot IGF-I measurements and the optimal timing of samples to assess the IGF-I status of NutropinAq treated patients-2004-000356-17-Sweden - MPA-somatropin
0,NutropinAq,somatropin,"['turner nanisme hypophyse traitement long terme enfants présentant retard', 'turner traitement enfants prépubères présentant retard croissance associé', 'croissance origine infantile adulte déficit hormone croissance doit']",Finland - Fimea,2004-000356-17,"['PHASE IIIB, INTERNATIONAL, SINGLE GROUP, OPEN STUDY TO DEFINE AN OPTIMAL MONITORING OF IGF-I IN CHILDREN TREATED WITH NUTROPINAQ']",['2-79-58035-700'],['Information not present in EudraCT'],['Ipsen Scandinavia'],['Denmark'],['Commercial'],['Test'],['Information not present in EudraCT'],['Ipsen Ltd'],['Finland'],['No'],NutropinAq,['No'],['No'],['No'],['No'],['No'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Solution for injection'],['Information not present in EudraCT'],['1'],"['Children presenting growth failure associated with Growth Hormone Deficiency (GHD), Tuner Syndrome (TS) or Chronic Renal Insufficiency (CRI).']",['No'],The number of capillary blood spot IGF-I measurements and the optimal timing of samples to assess the IGF-I status of NutropinAq treated patients,['Secundary objectives'],['Information not present in EudraCT'],['Children (boys and girls under 18) with growth failure associated with:'],['Children with hypersensitivity to somatropin or any of the excipients'],['The number of capillary blood spot IGF-I measurements and the optimal timing of samples to assess the IGF-I status of NutropinAq treated patients'],['No'],['Information not present in EudraCT'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['15'],['Authorised'],['2006-04-25'],['2006-05-16'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],The number of capillary blood spot IGF-I measurements and the optimal timing of samples to assess the IGF-I status of NutropinAq treated patients-2004-000356-17-Finland - Fimea-somatropin
0,Iressa,gefitinib,"['adultes atteints cancer poumon', 'récepteur facteur croissance']",Austria - BASG,2004-005093-24,"['Multicentre, open label, extension study of treatment with gefitinib (IRESSA™) for patients completing other gefitinib clinical studies who may benefit from gefitinib treatment']",['D791AC00008'],['Information not present in EudraCT'],['AstraZeneca Österreich GmbH'],['Austria'],['Commercial'],['Test'],['Information not present in EudraCT'],,,['No'],Iressa,['Yes'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Tablet'],['Information not present in EudraCT'],['1'],['This trial is for patients with advanced non-small cell lung cancer who have completed a preceding gefitinib trial (ZD1839IL0709 or ZD1839IL0710) and in the opinion of the investigator may benefit from gefitinib treatment'],['Information not present in EudraCT'],"The primary objective of this study is to provide, or continue to provide, gefitinib treatment to patients who have recently participated in other gefitinib clinical studies.",['There are no secondary objectives of the study.'],['Information not present in EudraCT'],['1.Provision of informed consent'],['1.Known severe hypersensitivity to gefitinib or any of the excipients of this product'],['There are no endpoints for this study'],['No'],['Information not present in EudraCT'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['6'],['Authorised'],['2005-01-24'],['2005-01-24'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"The primary objective of this study is to provide, or continue to provide, gefitinib treatment to patients who have recently participated in other gefitinib clinical studies.-2004-005093-24-Austria - BASG-gefitinib"
0,Iressa,gefitinib,"['adultes atteints cancer poumon', 'récepteur facteur croissance']",Hungary - National Institute of Pharmacy,2004-005093-24,"['Multicentre, open label, extension study of treatment with gefitinib (IRESSA™) for patients completing other gefitinib clinical studies who may benefit from gefitinib treatment']",['D791AC00008'],['Information not present in EudraCT'],['AstraZeneca AB'],['Sweden'],['Commercial'],['Test'],['Information not present in EudraCT'],,,['No'],Iressa,['Yes'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Tablet'],['Information not present in EudraCT'],['1'],['This trial is for patients with advanced non-small cell lung cancer who have completed a preceding gefitinib trial (ZD1839IL0709 or ZD1839IL0710) and in the opinion of the investigator may benefit from gefitinib treatment'],['Information not present in EudraCT'],"The primary objective of this study is to provide, or continue to provide, gefitinib treatment to patients who have recently participated in other gefitinib clinical studies.",['There are no secondary objectives of the study.'],['Information not present in EudraCT'],['1.Provision of informed consent'],['1.Known severe hypersensitivity to gefitinib or any of the excipients of this product'],['There are no endpoints for this study'],['No'],['Information not present in EudraCT'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],,['Authorised'],['2004-12-20'],['2004-12-10'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Ongoing'],"The primary objective of this study is to provide, or continue to provide, gefitinib treatment to patients who have recently participated in other gefitinib clinical studies.-2004-005093-24-Hungary - National Institute of Pharmacy-gefitinib"
0,Iressa,gefitinib,"['adultes atteints cancer poumon', 'récepteur facteur croissance']",Latvia - SAM,2004-005093-24,"['Multicentre, open label, extension study of treatment with gefitinib (IRESSA) for patients completing other gefitinib clinical studies who may benefit from gefitinib treatment']",['D791AC00008'],['Information not present in EudraCT'],['AstraZeneca AB'],['Sweden'],['Commercial'],['Test'],['Information not present in EudraCT'],,,['No'],Iressa,['Yes'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],,['Information not present in EudraCT'],['1'],['This trial is for patients with advanced non-small cell lung cancer who have completed a preceding gefitinib trial (ZD1839IL0709 or ZD1839IL0710) and in the opinion of the investigator may benefit from gefitinib treatment'],['Information not present in EudraCT'],"The primary objective of this study is to provide, or continue to provide, gefitinib treatment to patients who have recently participated in other gefitinib clinical studies.",['There are no secondary objectives of the study.'],['Information not present in EudraCT'],['1.Provision of informed consent'],['1.Known severe hypersensitivity to gefitinib or any of the excipients of this product'],['There are no endpoints for this study'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['2'],['Authorised'],['2005-01-28'],['2004-12-10'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"The primary objective of this study is to provide, or continue to provide, gefitinib treatment to patients who have recently participated in other gefitinib clinical studies.-2004-005093-24-Latvia - SAM-gefitinib"
0,Fareston,toremifene,"['tumeurs sein traitement', 'recommandé chez patientes présentant tumeurs négatives']",Finland - Fimea,2009-016948-39,['Toremifeenihoidon vaikutus rintojen 3D-ultraäänilöydökseen'],['tore5'],['Information not present in EudraCT'],['Sinikka Oksa'],['Finland'],['Non-Commercial'],['Test'],['Yes'],['Orion Pharma'],['Finland'],['Information not present in EudraCT'],Fareston,['Yes'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Tablet'],['Information not present in EudraCT'],['1'],['Tutkittavat ovat terveitä naisia iältään 20-45vuotta.'],['No'],Tutkimuksen tarkoituksena on tarkastella rintarauhasessa tapahtuvia muutoksia kuukautiskierron lopulla toremifeenihoidon aikana verrattuna normaaliin kuukautiskiertoon 3D-ultraäänikuvausta apuna käyttäen. Pyrimme mm.osoittamaan rintarauhasten parenkyymitilavuudessa ja verenvirtauksessa mahdollisesti tapahtuvia muutoksia.,['Lääkkeen sivuvaikutukset'],['No'],['•\tikä 20- 45 vuotta'],['•\traskaus'],['Pyrimme mm.osoittamaan rintarauhasen parenkyymitilavuudessa ja verenvirtauksessa mahdollisesti tapahtuvia muutoksia hoitokierrolla verrattuna lääkkeettömään kuukautiskiertoon.'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['20'],['Authorised'],['2010-08-02'],['2009-12-02'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],Tutkimuksen tarkoituksena on tarkastella rintarauhasessa tapahtuvia muutoksia kuukautiskierron lopulla toremifeenihoidon aikana verrattuna normaaliin kuukautiskiertoon 3D-ultraäänikuvausta apuna käyttäen. Pyrimme mm.osoittamaan rintarauhasten parenkyymitilavuudessa ja verenvirtauksessa mahdollisesti tapahtuvia muutoksia.-2009-016948-39-Finland - Fimea-toremifene
0,Arixtra,fondaparinux sodium,"['thrombose veineuse embolie pulmonaire infarctus myocarde angine', 'telle fracture hanche', 'genou arthroplastie hanche prévention tev chez adultes subissant chirurgie abdominale jugés haut risque complications thromboemboliques tels', 'injectabletraitement angor', 'infarctus myocarde sans élévation segment st ua', 'lesquels prise', 'adultes atteints troubles veineux profonds aigus thrombose tvp traitement embolie pulmonaire aiguë ep sauf chez']",Germany - BfArM,2007-003746-15,['prospective randomized open study on the comparison of fondaparinux with the low-molecular-weight heparin enoxaparin in patients undergoing femoro-distal venous bypass operation'],['259-4-111IIT-ARX0257'],['Information not present in EudraCT'],['Ammerland-Klinik Westerstede'],['Germany'],['Non-Commercial'],"['Test', 'Comparator']","['Yes', 'Yes']","['GlaxoSmithKline', 'Sanofi-Aventis']","['European Union', 'Germany']","['No', 'No']",Arixtra,"['Yes', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'Yes']","['Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Anticoagulant and preservative solution for blood', 'Anticoagulant and preservative solution for blood']","['Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2']",['Patients with underlying peripheral occlusive vascular disease undergoing bypass surgery'],['No'],Comparison of Enoxaparin vs. Arixtra in pateints undergoing peripheral bypass surgery concerning patency-rates,['Comparison of Enoxaparin vs. Arixtra in patients undergoing peripheral bypass surgery concerning bleedig complications'],['No'],['periperal arterial occlusive disease fontaine IIb - IV'],['progressive renal insufficiency (Creatinine-Clearance < 50 ml/min)'],['Efficacy: postoperative bypass patency'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['60'],['Authorised'],['2008-03-27'],['2007-10-19'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Ongoing'],Comparison of Enoxaparin vs. Arixtra in pateints undergoing peripheral bypass surgery concerning patency-rates-2007-003746-15-Germany - BfArM-fondaparinux sodium
2,Karvea,irbesartan,"['hypertension', 'hypertension essentielle traitement insuffisance rénale chez', 'hypertension']",Belgium - FPS Health-DGM,2004-000020-32,['The Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as First Line'],['CV131-176'],['Information not present in EudraCT'],['Bristol Myers Squibb International Corporation'],['Belgium'],['Commercial'],"['Test', 'Test']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Bristol Myers Squibb Pharma EEIG, 141-149 Staines Road, Hounslow, TW3 3JA, UK', 'Bristol Myers Squibb Pharma EEIG, 141-149 Staines Road, Hounslow, TW3 3JA, UK']","['Belgium', 'Belgium']","['No', 'No']",Karvea,"['Yes', 'Yes']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Tablet', 'Tablet']","['Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2']",['Severe Hypertension'],['No'],"The primary objective of this study is to compare the proportion of subjects whose seated diastolic blood pressure (SeDBP) is controlled (SeDBP < 90mmHg) at Week 5 when initiating irbesartan 150mg/HCTZ 12.5mg combination therapy as first-line treatment (titrated to irbesartan 300mg/HCTZ 25mg), as compared to initiating irbesartan 150mg monotherapy and titrating to irbesartan 300mg.","['To characterize the safety/tolerability in the two treatment groups over the sevenweek study period, examining in particular the frequency of treatment']",['Information not present in EudraCT'],['* Subjects must have uncontrolled hypertension defined as:'],['* SeSBP ≥ 220mmHg or SeDBP ≥ 130mmHg and/or evidence of malignant or'],['The primary efficacy outcome measurements is the proportion of subjects with seated diastolic blood pressure less than 90 mmHg at the end of Week 5.'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['36'],['Authorised'],['2005-02-16'],['2004-12-21'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"The primary objective of this study is to compare the proportion of subjects whose seated diastolic blood pressure (SeDBP) is controlled (SeDBP < 90mmHg) at Week 5 when initiating irbesartan 150mg/HCTZ 12.5mg combination therapy as first-line treatment (titrated to irbesartan 300mg/HCTZ 25mg), as compared to initiating irbesartan 150mg monotherapy and titrating to irbesartan 300mg.-2004-000020-32-Belgium - FPS Health-DGM-irbesartan"
0,Nexavar,sorafenib,"['hépatocellulaire', 'indiqué traitement carcinome hépatocellulaire carcinome rénalnexavar indiqué traitement patients atteints carcinome rénal avancé échoué traitement antérieur base interféron alpha interleukine-2 considérés comme inadaptés tel traitement carcinome différencié']",Austria - BASG,2008-008852-18,['Profile of soluble and cellular biomarkers and of functional imaging during antiangiogenic therapies in cancer patients'],['PRAEMARKERAAT08'],['Information not present in EudraCT'],['Medizinische Universität Innsbruck Innere Medizin V'],['Austria'],['Non-Commercial'],,"['Yes', 'Yes', 'Yes']","['Pfizer Ltd', 'Bayer Health Care AG', 'Roche']","['United Kingdom', 'Germany']","['No', 'No', 'No']",Nexavar,"['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Yes', 'Yes', 'Yes']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'Yes']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Tablet', 'Tablet', 'Concentrate and solvent for solution for injection']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3']","['The present project is an academic clinical trial in which patient suffering from hepatocellular carcinoma, non-small cell lung cancer, renal cell cancer and colorectal cancer treated routinely with antiangiogenic agents. The study protocol intends to include ten patients per tumour entitity (n=40), treated either with Sorafenib (Nexavar), Bevacizumab (Avastin) or Sunitinib (Sutent), which are all approved antiangiogenic drugs in Austria in one of the cancer types defined above.']",['No'],"Biomarker evaluation under antiannagiogenic therapy with Nexavar, Sutent and Avastin. Eligible patients are suffering from hepatocellular carcinoma, non small cell lung cancer, renal cell cancer and colorectal cancer routinely treated with the abov mentioned antiangiogenic agents.",,['No'],"['Histological confirmed Tumor specimen RCC, HCC, CRC or NSCLC']",['Prior or concurrent antitumor therapy (<3 weeks)'],['Evaluation of biomarker analyses'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['40'],['Authorised'],['2009-06-10'],['2009-06-10'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"Biomarker evaluation under antiannagiogenic therapy with Nexavar, Sutent and Avastin. Eligible patients are suffering from hepatocellular carcinoma, non small cell lung cancer, renal cell cancer and colorectal cancer routinely treated with the abov mentioned antiangiogenic agents.-2008-008852-18-Austria - BASG-sorafenib"
0,Jevtana,cabazitaxel,['cancer prostate'],Netherlands - Competent Authority,2011-003346-40,"['A phase II study in mCRPC on the pharmacodynamic effects of budesonide on cabazitaxel (Jevtana®): A randomised, open-label multicenter study: CABARESC']",['CABARESC'],['No'],['Erasmus MC-Daniël den Hoed'],['Netherlands'],['Non-Commercial'],"['Test', 'Test']","['Yes', 'Yes']","['Sanofi-Aventis', 'Dr. Falk Pharma Benelux BV']","['Netherlands', 'Netherlands']","['No', 'No']",Jevtana,"['Yes', 'Yes']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['Concentrate and solvent for solution for infusion', 'Capsule, hard']","['No', 'No']","['1', '2']",['metastatic prostate cancer'],['No'],To study the effects of budesonide on the incidence of cabazitaxel induced diarrhea,['•\tTo study the effects of budesonide on other side effects of cabazitaxel (e.g. myelotoxicity)'],['No'],['•\tMetastatic castrate resistant prostate cancer (mCRPC) patients with documented disease progression'],['•\tImpossibility or unwillingness to take oral drugs;'],['The incidence of cabazitaxel induced diarrhea'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['250'],['Authorised'],['2011-08-02'],['2011-12-06'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],To study the effects of budesonide on the incidence of cabazitaxel induced diarrhea-2011-003346-40-Netherlands - Competent Authority-cabazitaxel
0,Multaq,dronedarone,['fibrillation'],UK - MHRA,2010-019442-87,['Dronedarone in pacemaker patients with paroxysmal atrial fibrillation'],['DROPPAF'],['Information not present in EudraCT'],['East Sussex NHS Trust'],['United Kingdom'],['Non-Commercial'],['Test'],['Yes'],['Sanofi Aventis'],['European Union'],['No'],Multaq,['Yes'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Tablet'],['Information not present in EudraCT'],['1'],['Paroxysmal atrial fibrillation'],['No'],"To accurately assess, by the use of long term beat to beat pacemaker Holter monitoring, the effect of of dronedarone upon atrial fibrillation (AF) burden.","['To accurately assess the number of irregular heart beat episodes, the frequency of the episodes and average duration of normal heart rhythm (i.e. the pattern of the irregular heart rhythm).']",['Information not present in EudraCT'],['INCLUSION CRITERIA'],['•\tCurrent or previous treatment with amiodarone.'],['Atrial fibrillation burden as measured by permanent pacemaker.'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['50'],['Authorised'],['2010-07-02'],['2010-04-30'],['Reason(s) for unfavourable opinion:'],['Favourable'],['GB - no longer in EU/EEA'],"To accurately assess, by the use of long term beat to beat pacemaker Holter monitoring, the effect of of dronedarone upon atrial fibrillation (AF) burden.-2010-019442-87-UK - MHRA-dronedarone"
3,Zydelig,Idelalisib,"['aucun autre traitement', 'adultes atteints lymphome folliculaire fl', 'réfractaire deux lignes traitement']",UK - MHRA,2012-003631-36,['CALiBRe: Assessment of the Mechanism of Action of idelalisib (CAL-101) in B-cell Receptor Pathway Inhibition in CLL'],['RG_12-124'],['No'],['University of Birmingham'],['United Kingdom'],['Non-Commercial'],['Test'],['Yes'],['Gilead Sciences International'],['United Kingdom'],['Yes'],Zydelig,['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Tablet'],['No'],['1'],['Chronic lymphocytic leukaemia'],['Yes'],To investigate the mechanism of action of idelalisib,['To assess the biological response to idelalisib'],['Yes'],['1. Chronic lymphocytic leukaemia requiring therapy'],['1. Previously untreated for CLL'],['•Proportion of patients achieving MRD-negative remission by IWCLL criteria (depletion of CLL below 0.01% in the peripheral blood and bone marrow)'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['40'],['Authorised'],['2015-02-10'],['2015-01-22'],['Reason(s) for unfavourable opinion:'],['Favourable'],['GB - no longer in EU/EEA'],To investigate the mechanism of action of idelalisib-2012-003631-36-UK - MHRA-Idelalisib
0,Temodal,temozolomide,['atteints gliome malin tel'],Sweden - MPA,2004-002925-39,['A Phase II study of Temozolomide (Temodal) Given Continously 100mg/m2 for 21 Days in 28 Day cycles in Patients with Metastatic Melanoma.'],['040826'],['Information not present in EudraCT'],"['Kliniken för onkologi, Karolinska Universitetssjukhuset, Solna']",['Sweden'],['Non-Commercial'],"['Test', 'Test', 'Test', 'Test', 'Test', 'Test']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Schering-Plough Europe', 'Schering-Plough Europe', 'Schering-Plough Europe', 'Schering-Plough Europe', 'Schering-Plough Europe', 'Schering-Plough Europe']","['Sweden', 'Sweden', 'Sweden', 'Sweden', 'Sweden', 'Sweden']","['No', 'No', 'No', 'No', 'No', 'No']",Temodal,"['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Capsule, hard', 'Capsule, hard', 'Capsule, hard', 'Capsule, hard', 'Capsule, hard', 'Capsule, hard']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3', '4', '5', '6']",['Metastatic melanoma'],['No'],To investigate the efficacy and safety of Temodal in a continuous dose regime in patients with metastatic melanoma and good performance status defined as WHO 0-2.,"['Time to progression, Overall survival, Safety, new brain metastasis, correlation of response to tumor gene and MGMT expression and SNPs, Temodal  effect on Regulatory T lymphocytes.']",['Information not present in EudraCT'],['Histologically proven melanoma'],"['Prior chemotherapy, biologic therapy or immunotherapy for metastatic disease']",['Tumor respons rate'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['35'],['Authorised'],['2005-02-02'],['2005-01-26'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Ongoing'],To investigate the efficacy and safety of Temodal in a continuous dose regime in patients with metastatic melanoma and good performance status defined as WHO 0-2.-2004-002925-39-Sweden - MPA-temozolomide
0,Temodal,temozolomide,['atteints gliome malin tel'],Austria - BASG,2011-004062-15,"['Prospective, open label, randomized phase II trial to assess a multimodal molecular targeted therapy in children, adolescent and young adults with relapsed or refractory high risk neuroblastoma']",['RIST-rNB-2011'],['No'],['University Hospital of Regensburg'],['Germany'],['Non-Commercial'],"['Test', 'Comparator', 'Test', 'Comparator', 'Test', 'Test', 'Test', 'Comparator', 'Comparator', 'Comparator', 'Test', 'Test', 'Test', 'Test', 'Test']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['Bristol-Myers-Squibb', 'Merck Sharp & Dohme Limited', 'Pfizer', 'Fresenius Kabi Oncology', 'Pfizer Ltd.', 'Bristol-Myers-Squibb', 'Bristol-Myers-Squibb', 'Merck Sharp & Dohme Limited', 'Merck Sharp & Dohme Limited', 'Merck Sharp & Dohme Limited', 'Pfizer Ltd.', 'Pfizer Ltd.', 'Pfizer Ltd.', 'Bristol-Myers-Squibb', 'Bristol-Myers-Squibb']","['European Union', 'European Union', 'European Union', 'Austria', 'European Union', 'European Union', 'European Union', 'European Union', 'European Union', 'European Union', 'European Union', 'European Union', 'European Union', 'European Union', 'European Union']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']",Temodal,"['Yes', 'Yes', 'No', 'Yes', 'No', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'No', 'No', 'No', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'Yes', 'No', 'Yes', 'No', 'No', 'No', 'No', 'No', 'Yes', 'Yes', 'Yes', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'Yes', 'No', 'Yes', 'No', 'No', 'No', 'No', 'No', 'Yes', 'Yes', 'Yes', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Film-coated tablet', 'Capsule, hard', 'Oral solution', 'Concentrate for solution for infusion', 'Tablet', 'Film-coated tablet', 'Film-coated tablet', 'Capsule, hard', 'Capsule, hard', 'Capsule, hard', 'Tablet', 'Tablet', 'Tablet', 'Film-coated tablet', 'Film-coated tablet']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '14', '15']",['Relapsed or refractory high risk neuroblastoma'],['Yes'],"The primary objective of this trial is the evaluation of progression-free survival of rNB in children, adolescents and young adults, comparing a multimodal treatment regimen consisting of temozolomide (T), irinotecan (I), rapamycin (R) and dasatinib (S) against Irinotecan (I)/Temozolomide (T) alone.",['Secondary objectives are'],['No'],['Patients with relapsed high-risk neuroblastoma (stage IV and all MYCN pos. stages) or progressive disease during primary treatment (=rNB)'],['Patients presenting with any of the following criteria will not be included in this clinical trial:'],"['The primary endpoint is progression-free survival (PFS), which is defined as the time interval between randomization and date of progression (first time at which progression can be declared) according to']",['Yes'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['11'],['Authorised'],['2014-03-20'],['2014-04-08'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"The primary objective of this trial is the evaluation of progression-free survival of rNB in children, adolescents and young adults, comparing a multimodal treatment regimen consisting of temozolomide (T), irinotecan (I), rapamycin (R) and dasatinib (S) against Irinotecan (I)/Temozolomide (T) alone.-2011-004062-15-Austria - BASG-temozolomide"
3,Vidaza,azacitidine,['gcsh atteints syndromes myélodysplasiques smd risque intermédiaire 2 haut risque selon international pronostic scoring system ipss leucémie myélomonocytaire chronique cmml 10 29 blastes médullaires sans trouble myéloprolifératif leucémie'],UK - MHRA,2005-003732-22,['Pilot study of 5 Azacitidine in the treatment of MDS/AML with high risk (chromosome 7 and/or complex cytogenetic abnormality)'],"['M7-1, Version 1, 03/08/05']",['Information not present in EudraCT'],['Kings College London'],['United Kingdom'],['Non-Commercial'],['Test'],['Information not present in EudraCT'],['US'],['United States'],['Yes'],Vidaza,['Yes'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Powder for injection*'],['Information not present in EudraCT'],['1'],['myelodysplastic syndromes/relapsed Acute myeloid leukaemia'],['Yes'],Assess complete/cytogenetic remission in patients with chromosome 7 abnormalities,['Assess duration of response'],['Information not present in EudraCT'],['Chromosome 7 or complex cytogenetic abnormality in MDS/AML'],['Allergy to drug'],['Complete remission'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['40'],['Authorised'],['2005-10-03'],['2005-09-30'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Prematurely Ended'],Assess complete/cytogenetic remission in patients with chromosome 7 abnormalities-2005-003732-22-UK - MHRA-azacitidine
3,Myozyme,alglucosidase alfa,['tardive preuves'],Netherlands - Competent Authority,2007-001375-11,['Effects and health economic aspects of enzyme therapy in children and adults with Pompe disease'],['not applicable'],['Information not present in EudraCT'],,,,['Test'],['Yes'],['Genzyme'],['Netherlands'],['No'],Myozyme,['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Intravenous infusion'],['Information not present in EudraCT'],['1'],"['Pompe disease (glycogen storage disease type II) is a genetic, lysosomal storage disorder with a frequency of 1 in 40.000 newborns. The disease is caused by deficiency of alpha-glucosidase, a lysosomal hydrolase involved in the degradation of glycogen.']",['Yes'],"The objective of the study is to gather more information about the long-term effect of enzyme therapy in patients with Pompe disease with a different severity of disease. The goal is also to set guideline for start and stop of treatment and to evaluate health economic aspects. Furthermore, it is important to find an optimal dosing regimen.",['not applicable'],['No'],"['1. Patients should have a proven diagnosis of Pompe disease, which means that the diagnosis is confirmed by deficiency of a-glucosidase activity in leukocytes or skeletal muscle, or by a documented mutation in the a-glucosidase gene.']",['Patients who are not likely to benefit from treatment'],['-\tSurvival'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['100'],['Authorised'],['2007-04-10'],['2007-05-16'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Ongoing'],"The objective of the study is to gather more information about the long-term effect of enzyme therapy in patients with Pompe disease with a different severity of disease. The goal is also to set guideline for start and stop of treatment and to evaluate health economic aspects. Furthermore, it is important to find an optimal dosing regimen.-2007-001375-11-Netherlands - Competent Authority-alglucosidase alfa"
1,Sustiva,efavirenz,"['infections', 'traitement contenant inhibiteur protéase ip bien résistance croisée éfavirenz ip documentée données actuellement insuffisantes efficacité utilisation ultérieure thérapie combinée base ip après', 'échec schémas thérapeutiques contenant sustiva']",Italy - Italian Medicines Agency,2016-002413-22,"['Open label, Randomized (1:1), clinical trial to evaluate switching from dual regimens based on Dolutegravir plus a reverse transcriptase inhibitor to  elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in virologically suppressed, HIV-1 infected patients.']",['Be-OnE1/08-03-2016'],['No'],['OSPEDALE SAN RAFFAELE'],['Italy'],['Non-Commercial'],"['Test', 'Test', 'Comparator', 'Comparator', 'Comparator', 'Comparator', 'Comparator', 'Comparator', 'Comparator', 'Comparator']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['Gilead Sciences Int. Ltd', 'VIIV HEALTHCARE UK LTD', 'GILEAD SCIENCE INTERNATIONAL LIMITED', 'MYLAN S.P.A.', 'GILEAD SCIENCE INTERNATIONAL LIMITED', 'GLAXO GROUP LIMITED', 'JANSSEN-CILAG INTERNATIONAL N.V.', 'JANSSEN-CILAG INTERNATIONAL N.V.', 'BRISTOL-MYERS SQUIBB PHARMA EEIG', 'BOEHRINGER INGELHEIM INTERNATIONAL GMBH']","['Ireland', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']",Sustiva,"['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'No', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'No', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Film-coated tablet', 'Film-coated tablet', 'Capsule, hard', 'Film-coated tablet', 'Film-coated tablet', 'Film-coated tablet', 'Tablet', 'Tablet', 'Tablet', 'Prolonged-release tablet']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['1', '2', '3', '4', '5', '6', '7', '8', '9', '10']",['HIV infection'],['No'],To investigate Residual Viremia  through 48 weeks in virologically suppressed patients randomized to continue treatment with Dolutegravir plus a single RTI or to switch to E/C/F/TAF.,['Secondary Objectives'],['No'],['1.\tAge >18  years'],['1.\tActive AIDS-defining condition (except Kaposi’s sarcoma non requiring systemic chemotherapy)'],['Proportion of subjects without Residual Viremia  through 48 weeks of follow-up.'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['100'],['Authorised'],['2016-10-31'],['2016-07-14'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Prematurely Ended'],To investigate Residual Viremia  through 48 weeks in virologically suppressed patients randomized to continue treatment with Dolutegravir plus a single RTI or to switch to E/C/F/TAF.-2016-002413-22-Italy - Italian Medicines Agency-efavirenz
0,Twinrix Adult,"hepatitis A virus (inactivated), hepatitis B surface antigen",['risque infection'],Denmark - DHMA,2006-005999-41,"['A phase III, randomized, open, controlled, multicenter primary vaccination study to demonstrate the non inferiority of the immunogenicity of GSK Biologicals’ meningococcal serogroup ACWY conjugate vaccine when given as one dose with Twinrix™ versus GSK Biologicals’ meningococcal serogroup ACWY conjugate vaccine alone and versus Twinrix™ alone in healthy subjects aged 11 through 17 years']",['109063'],['Information not present in EudraCT'],['GlaxoSmithKline Biologicals'],['Belgium'],['Commercial'],"['Test', 'Test', 'Test']","['No', 'Yes', 'Yes']","['GlaxoSmithKline Biologicals', 'GlaxoSmithKline Biologicals']",,"['No', 'No', 'No']",Twinrix Adult,"['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Yes', 'Yes', 'Yes']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['Yes', 'Yes', 'Yes']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Powder and solvent for solution for injection', 'Suspension for injection', 'Suspension for injection']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3']","['Primary immunization of healthy subjects aged 11 through 17 years against meningococcal serogroups A, C, W 135 and Y and/or hepatitis A and hepatitis B diseases']",['No'],"To demonstrate the non-inferiority of the MenACWY-TT conjugate vaccine co-administered with Twinrix as compared to the MenACWY-TT conjugate vaccine administered alone with respect to the serum bactericidal antibody geometric mean titres as measured using baby rabbit complement (rSBA GMTs) for N. meningitidis serogroups A, C, W-135 and Y.",['To compare the immunogenicity of the MenACWY TT conjugate vaccine co-administered with Twinrix compared to that of the MenACWY-TT vaccine alone; To evaluate the safety and reactogenicity of the MenACWY-TT conjugate vaccine co-administered with Twinrix to that of the MenACWY-TT vaccine alone; To compare the immunogenicity of the 3th dose of Twinrix in the MenACWY-TT+ Twinrix group to that of the Twinrix group; To evaluate the safety and reactogenicity of Twinrix in the MenACWY-TT+Twinrix group to that of the Twinrix group after each Twinrix dose.'],['No'],"['healthy males and females aged 11 through 17 years who have previously completed routine childhood vaccinations to the best of his/her/the parents’/guardians’ knowledge. If a subject is female of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for two months after completion of the vaccination series']","['The following criteria should be checked at the time of study entry. If any apply, the subject must not be included in the study:']","['At one month after vaccination with MenACWY-TT and the first dose of Twinrix (Post vacc I Study Month 1), in subjects in the MenACWY-TT + Twinrix group and the MenACWY-TT group:']",['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['Information not present in EudraCT'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],,['Authorised'],['2007-03-20'],['2007-03-29'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To demonstrate the non-inferiority of the MenACWY-TT conjugate vaccine co-administered with Twinrix as compared to the MenACWY-TT conjugate vaccine administered alone with respect to the serum bactericidal antibody geometric mean titres as measured using baby rabbit complement (rSBA GMTs) for N. meningitidis serogroups A, C, W-135 and Y.-2006-005999-41-Denmark - DHMA-hepatitis A virus (inactivated), hepatitis B surface antigen"
1,Synflorix,"Pneumococcal polysaccharide serotype 23F, Pneumococcal polysaccharide serotype 4, Pneumococcal polysaccharide serotype 5, Pneumococcal polysaccharide serotype 6B, Pneumococcal polysaccharide serotype 7F, Pneumococcal polysaccharide serotype 9V, Pneumococcal polysaccharide serotype 1, Pneumococcal polysaccharide serotype 14, Pneumococcal polysaccharide serotype 18C, Pneumococcal polysaccharide serotype 19F","['infections', 'pneumoniae chez nourrissons enfants âgés']",Netherlands - Competent Authority,2011-002103-15,['Development of humoral and cellular immune response in infants after pneumococcal conjugate vaccinations with'],['VAC-259'],['No'],['RIVM'],['Netherlands'],['Non-Commercial'],"['Test', 'Test']","['Yes', 'Yes']","['GlaxoSmithKline Biologicals S.A.', 'Wyeth Lederle Vaccines S.A.']","['European Union', 'European Union']","['No', 'No']",Synflorix,"['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['Yes', 'Yes']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['Yes', 'Yes']","['No', 'No']","['No', 'No']","['No', 'No']","['Suspension for injection', 'Suspension for injection']","['Yes', 'Yes']","['1', '2']",['Immunity and immune memory after pneumococcal vaccination against S. pneumoniae serotypes present in either Synflorix or Prevenar-13'],['No'],"To compare immunogenicity (humoral and cellular) induced by PCV10 and PCV13 after the booster dose of a complete vaccination series (3+1, the current NIP schedule)","['To compare immunogenicity (humoral) induced by PCV10 and PCV13 at 5, 8, 11 and 12 months of a complete vaccination series (3+1, the current NIP schedule)']",['No'],"['•\tThe children have to be of normal health (same health criteria apply as used in well-baby clinics when a child receives a vaccination, e.g. also children with small increases in temperature (≤38.5 °C) or cold are seen as children with normal health)']",['Exclusion criteria'],['Pneumococcal serotypes'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['No'],['132'],['Authorised'],['2011-08-01'],['2011-09-07'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To compare immunogenicity (humoral and cellular) induced by PCV10 and PCV13 after the booster dose of a complete vaccination series (3+1, the current NIP schedule)-2011-002103-15-Netherlands - Competent Authority-Pneumococcal polysaccharide serotype 23F, Pneumococcal polysaccharide serotype 4, Pneumococcal polysaccharide serotype 5, Pneumococcal polysaccharide serotype 6B, Pneumococcal polysaccharide serotype 7F, Pneumococcal polysaccharide serotype 9V, Pneumococcal polysaccharide serotype 1, Pneumococcal polysaccharide serotype 14, Pneumococcal polysaccharide serotype 18C, Pneumococcal polysaccharide serotype 19F"
1,Ambirix,"hepatitis A virus (inactivated), hepatitis B surface antigen","['infections', 'infection']",Netherlands - Competent Authority,2008-003280-40,['Response to hepatitis A and B vaccine among children with immunesuppression due to either hiv or immunesuppressive medication'],['A720B20'],['Information not present in EudraCT'],['Public Health Service Amsterdam'],['Netherlands'],['Non-Commercial'],['Test'],['Yes'],['Glaxo Smith Kline s.a.'],['Netherlands'],['No'],Ambirix,['No'],['No'],['No'],['No'],['No'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['Suspension for injection'],['Information not present in EudraCT'],['1'],['The effectiveness of Ambirix will be investigated in 2 groups:'],['No'],How effective is combined vaccination against hepatitis A and B in hiv-infected children and in children using immune-suppressive medication for juvenile idiopathic arthritis?,['Is the degree of immunesuppression related/ associated with the response to vaccination?'],['No'],"['All children from 1 up to and including 15 years of age, known with:']",['Not eligible for inclusion are:'],['Primary end points of this study are:'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['250'],['Authorised'],['2009-03-23'],['2009-06-30'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"How effective is combined vaccination against hepatitis A and B in hiv-infected children and in children using immune-suppressive medication for juvenile idiopathic arthritis?-2008-003280-40-Netherlands - Competent Authority-hepatitis A virus (inactivated), hepatitis B surface antigen"
0,Circadin,melatonin,"['troubles ’ initiation maintien sommeil', 'insomnie primaire caractérisée mauvaise qualité sommeil chez']",UK - MHRA,2009-014388-38,"['A double-blind, parallel group, randomized, placebo controlled study of  the efficacy of Circadin® 2mg in alleviating sleep disturbances in patients with mild to moderate Alzheimer Disease (AD) treated with Acetylcholinesterase (AChE) inhibitor.']",['NEUAZ1'],['Information not present in EudraCT'],['Neurim Pharmaceuticals Ltd'],['Israel'],['Commercial'],['Test'],['Yes'],['RAD Neurim Pharmaceuticals EEC Ltd'],['European Union'],['No'],Circadin,['Yes'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Prolonged-release tablet'],['Information not present in EudraCT'],['1'],['Insomnia in patients with mild to moderate Alzheimers Disease.'],['No'],"To compare the effect of Circadin® to that of placebo, on sleep quality as assessed by the Daily Sleep Diary after 12 weeks of the double-blind treatment period.","['- To compare the effect of Circadin® to that of placebo onCognitive parameters,']",['No'],"['1) Suffering from sleep disturbances, characterized by poor sleep quality']",['1)\tSevere agitation.'],"['The effect of Circadin to that of placebo, on sleep quality as assessed by the Daily Sleep Diary after 12 weeks of double-blind treatment.']",['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['No'],['60'],['Authorised'],['2009-09-02'],['2009-09-28'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To compare the effect of Circadin® to that of placebo, on sleep quality as assessed by the Daily Sleep Diary after 12 weeks of the double-blind treatment period.-2009-014388-38-UK - MHRA-melatonin"
0,Tarceva,erlotinib,"['cancer poumon', 'indiqué traitement entretien substitution chez', 'cancer poumon', 'cancer poumon', 'cancer pancréas tarceva']",UK - MHRA,2005-004508-35,['THE USE OF PET/CT SCANNING TO ASSESS EARLY RESPONDERS TO TARCEVA (ERLOTINIB): A PHASE II STUDY'],['2680'],['Information not present in EudraCT'],['Royal Marsden Hospital'],['United Kingdom'],['Non-Commercial'],['Test'],['Information not present in EudraCT'],['Roche'],['United Kingdom'],['No'],Tarceva,['Yes'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Coated tablet'],['Information not present in EudraCT'],['1'],['Advanced non-small cell lung cancer (NSCLC)'],['No'],To assess whether using PET/CT scans at baseline and at 6 weeks will be more predictive of response to Tarceva than standard scanning methods in patients with NSCLC.,"['To correlate radiological response with symptomatic response, duration of treatment and survival.']",['Information not present in EudraCT'],['1.\tHistologically confirmed diagnosis of stage IIIB/IV NSCLC overexpressing EGFR (i.e ≥10% membrane staining on tumour cells via Dako IHC kit).'],['1. \tAny concurrent anticancer cytostatic or cytotoxic chemotherapy.'],['1.\tDocument early response or progression in patients after 6 weeks of erlotinib by PET/CT scanning.'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Information not present in EudraCT'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['35'],['Authorised'],['2005-11-22'],['2005-12-14'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],To assess whether using PET/CT scans at baseline and at 6 weeks will be more predictive of response to Tarceva than standard scanning methods in patients with NSCLC.-2005-004508-35-UK - MHRA-erlotinib
3,Votrient,pazopanib,['traitement cytokines maladie avancée sarcome tissus mous sts votrient indiqué traitement patients adultes atteints sous-types sélectifs sarcome'],Spain - AEMPS,2011-002441-34,"['Ensayo clínico fase II, abierto, no controlado y multicéntrico de pazopanib en monoterapia para determinar la eficacia y la seguridad en segunda línea de tratamiento en pacientes con carcinoma de células renales (CCR) avanzado que han progresado o que no han tolerado una primera línea de tratamiento con un inhibidor de la tirosina quinasa (TKI)']",['APRO02-2011'],['No'],['Associació Per la Recerca Oncològica (APRO)'],['Spain'],['Non-Commercial'],['Test'],['Yes'],['GLAXO GROUP LTD.'],['Spain'],['No'],Votrient,['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Tablet'],['No'],['1'],['Carcinoma de células renales avanzado.'],['No'],Determinar la tasa de respuestas objetivas (TRO) que ofrece el tratamiento de segunda línea con pazopanib en pacientes con carcinoma de células renales (CCR) avanzado que han progresado o que no han tolerado una primera línea de tratamiento con un TKI.,['Determinar para estos pacientes en tratamiento con pazopanib de segunda línea:'],['Yes'],['1.\tLos pacientes deberán otorgar su consentimiento por escrito para la participación en el estudio antes de la realización de cualquier procedimiento asociado al estudio y deberán mostrarse dispuestos a cumplir con el tratamiento y el seguimiento.'],['1.\tNeoplasia previa. Podrán incluirse en el estudio pacientes que presenten un intervalo libre de enfermedad de 5 años en el momento de la inclusión en el estudio y los pacientes con carcinoma de piel no melanoma completamente resecado o de carcinoma in situ tratado con éxito.'],['Objetivo principal: Determinar la tasa de respuestas objetivas (TRO) que ofrece el tratamiento de segunda línea con pazopanib en pacientes con carcinoma de células renales (CCR) avanzado que han progresado o que no han tolerado una primera línea de tratamiento con un TKI'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['27'],['Authorised'],['2012-01-18'],['2011-12-14'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],Determinar la tasa de respuestas objetivas (TRO) que ofrece el tratamiento de segunda línea con pazopanib en pacientes con carcinoma de células renales (CCR) avanzado que han progresado o que no han tolerado una primera línea de tratamiento con un TKI.-2011-002441-34-Spain - AEMPS-pazopanib
3,Tyverb,lapatinib,"['tumeurs sein tyverb', 'traitement patientes atteintes cancer sein', 'capécitabine chez patientes atteintes maladie', 'inhibiteur ’ aromatase aucune donnée disponible efficacité cette']",Germany - BfArM,2012-000598-22,"['Randomised, open-label phase II study to compare the safety and efficacy of lapatinib plus trastuzumab or lapatinib plus capecitabine in trastuzumab-resistant HER2-overexpressing metastatic breast cancer']",['BNGO/01'],['No'],['Berufsverband der niedergelassenen gynäkologischen Onkologen in Deutschland e.V.; BNGO e.V.'],['Germany'],['Non-Commercial'],"['Test', 'Test', 'Comparator', 'Comparator']","['Yes', 'Yes', 'Yes', 'Yes']","['GlaxoSmithKline', 'Roche Registration Limited', 'GlaxoSmithKline', 'Roche Registration Lmited']","['Germany', 'Germany', 'Germany', 'Germany']","['No', 'No', 'No', 'No']",Tyverb,"['Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Film-coated tablet', 'Powder for concentrate for solution for infusion', 'Film-coated tablet', 'Film-coated tablet']","['No', 'No', 'No', 'No']","['1', '2', '3', '4']",['Trastuzumab-resistant HER2-overexpressing metastatic breast cancer'],['No'],Estimate the clinical benefit of lapatinib plus trastuzumab compared to lapatinib plus capecitabine as measured by investigator-assessed progression-free survival (PFS),['•\tEvaluate overall survival of lapatinib plus trastuzumab relative to lapatinib plus capecitabine'],['No'],"['\tWomen with histologically confirmed breast cancer; measurable metastatic disease; HER2-positive (IHC 3+ or ISH positive); Hormone receptor-negative; prior treatment with trastuzumab, anthracycline and taxanes; progression on trastuzumab as first-line or second-line therapy; no prior treatment with lapatinib within last 6 months; Adequate hematologic, renal and liver function; normal cardiac function with LVEF of ≥50%; ECOG performance status 0-1; No evidence of brain metastases (asymptomatic metastases that have been clinically stable for 3 months are allowed); no significant cardiovascular disease or other serious medical condition; written informed consent to participate in the trial and to the donation of formalin fixed, paraffin embedded tumour sample from the primary or recurrent cancer available for central testing.']",['•\t1. Patients with confirmed brain metastases or a history of primary central nervous system tumours or who have signs/symptoms attributable to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases. Patients with treated brain metastases that are asymptomatic and have been clinically stable for 3 months will be eligible for protocol participation.'],"['The 6-month PFS-rate (PFS6) will be the number of patients without disease progression or death within 6 months from the date of randomization, divided by the number of patients in the respective analysis population. For the purpose of the analysis patients who are lost to follow-up or deceased in at or before 6 months after randomization will be counted as “disease progression”.']",['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['100'],['Authorised'],['2013-03-08'],['2013-03-18'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Prematurely Ended'],Estimate the clinical benefit of lapatinib plus trastuzumab compared to lapatinib plus capecitabine as measured by investigator-assessed progression-free survival (PFS)-2012-000598-22-Germany - BfArM-lapatinib
3,Firazyr,icatibant,['déficit inhibiteur'],Germany - BfArM,2008-000071-25,"['Open-Label, Multicenter Study to Evaluate Safety, Local Tolerability, Convenience, and Efficacy of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema']",['JE049-3101'],['Information not present in EudraCT'],['Jerini AG'],['Germany'],['Commercial'],['Test'],['Yes'],['Jerini AG'],['European Union'],['Yes'],Firazyr,['Yes'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Solution for injection'],['Information not present in EudraCT'],['1'],"['hereditary angioedema, HAE (in adult patients with C1-esterase-inhibitor deficiency)']",['Yes'],The primary objective is to explore clinical safety with self-treatment of acute HAE,"['The secondary objectives are to determine local tolerability, convenience, and clinical']",['No'],['Each patient must meet the following criteria to be enrolled in this study:'],['Patients who meet any of the following criteria will be excluded from the study:'],['The primary endpoint is to show clinical safety with self-treatment of acute HAE'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['20'],['Authorised'],['2009-09-10'],['2009-08-18'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],The primary objective is to explore clinical safety with self-treatment of acute HAE-2008-000071-25-Germany - BfArM-icatibant
3,Firazyr,icatibant,['déficit inhibiteur'],Austria - BASG,2008-000071-25,"['Open-Label, Multicenter Study to Evaluate Safety, Local Tolerability, Convenience, and Efficacy of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema']",['JE049-3101'],['Information not present in EudraCT'],['Jerini AG'],['Germany'],['Commercial'],['Test'],['Yes'],['Jerini AG'],['European Union'],['Yes'],Firazyr,['Yes'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Solution for injection'],['Information not present in EudraCT'],['1'],"['hereditary angioedema, HAE (in adult patients with C1-esterase-inhibitor deficiency)']",['Yes'],The primary objective is to explore clinical safety with self-treatment of acute HAE,"['The secondary objectives are to determine local tolerability, convenience, and clinical']",['No'],['Each patient must meet the following criteria to be enrolled in this study:'],['Patients who meet any of the following criteria will be excluded from the study:'],['The primary endpoint is to show clinical safety with self-treatment of acute HAE'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['Yes'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['20'],['Authorised'],['2009-09-14'],['2009-09-14'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],The primary objective is to explore clinical safety with self-treatment of acute HAE-2008-000071-25-Austria - BASG-icatibant
3,Firazyr,icatibant,['déficit inhibiteur'],UK - MHRA,2008-000071-25,"['Open-Label, Multicenter Study to Evaluate Safety, Local Tolerability, Convenience, and Efficacy of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema']",['JE049-3101'],['Information not present in EudraCT'],['Jerini AG'],['Germany'],['Commercial'],['Test'],['Yes'],['Jerini AG'],['European Union'],['Yes'],Firazyr,['Yes'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Solution for injection'],['Information not present in EudraCT'],['1'],"['hereditary angioedema, HAE (in adult patients with C1-esterase-inhibitor deficiency)']",['Yes'],The primary objective is to explore clinical safety with self-treatment of acute HAE,"['The secondary objectives are to determine local tolerability, convenience, and clinical']",['No'],['Each patient must meet the following criteria to be enrolled in this study:'],['Patients who meet any of the following criteria will be excluded from the study:'],['The primary endpoint is to show clinical safety with self-treatment of acute HAE'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['10'],['Authorised'],['2009-10-21'],['2009-10-22'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],The primary objective is to explore clinical safety with self-treatment of acute HAE-2008-000071-25-UK - MHRA-icatibant
3,Firazyr,icatibant,['déficit inhibiteur'],France - ANSM,2008-000071-25,"['Open-Label, Multicenter Study to Evaluate Safety, Local Tolerability, Convenience, and Efficacy of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema']",['JE049-3101'],['Information not present in EudraCT'],['Jerini AG'],['Germany'],['Commercial'],['Test'],['Yes'],['Jerini AG'],['European Union'],['Yes'],Firazyr,['Yes'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Solution for injection'],['Information not present in EudraCT'],['1'],"['hereditary angioedema, HAE (in adult patients with C1-esterase-inhibitor deficiency)']",['Yes'],The primary objective is to explore clinical safety with self-treatment of acute HAE,"['The secondary objectives are to determine local tolerability, convenience, and clinical']",['No'],['Each patient must meet the following criteria to be enrolled in this study:'],['Patients who meet any of the following criteria will be excluded from the study:'],['The primary endpoint is to show clinical safety with self-treatment of acute HAE'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['20'],['Authorised'],['2009-12-30'],['2010-01-14'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],The primary objective is to explore clinical safety with self-treatment of acute HAE-2008-000071-25-France - ANSM-icatibant
3,Firazyr,icatibant,['déficit inhibiteur'],Denmark - DHMA,2008-000071-25,"['Open-Label, Multicenter Study to Evaluate Safety, Local Tolerability, Convenience, and Efficacy of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema']",['JE049-3101'],['Information not present in EudraCT'],['Jerini AG'],['Germany'],['Commercial'],['Test'],['Yes'],['Jerini AG'],['European Union'],['Yes'],Firazyr,['Yes'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Solution for injection'],['Information not present in EudraCT'],['1'],"['hereditary angioedema, HAE (in adult patients with C1-esterase-inhibitor deficiency)']",['Yes'],The primary objective is to explore clinical safety with self-treatment of acute HAE,"['The secondary objectives are to determine local tolerability, convenience, and clinical']",['No'],['Each patient must meet the following criteria to be enrolled in this study:'],['Patients who meet any of the following criteria will be excluded from the study:'],['The primary endpoint is to show clinical safety with self-treatment of acute HAE'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['Yes'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['10'],['Authorised'],['2010-09-03'],['2010-07-07'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],The primary objective is to explore clinical safety with self-treatment of acute HAE-2008-000071-25-Denmark - DHMA-icatibant
0,Axura,memantine hydrochloride,['atteints maladie alzheimer'],UK - MHRA,2010-020737-50,"['Prospective, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of 10mg memantine in the treatment of memory, concentration or attention problems (subjective cognitive impairment) in the absence of dementia']",['MRZ90001_2267_1'],['Information not present in EudraCT'],['Merz Pharmaceuticals GmbH'],['Germany'],['Commercial'],['Test'],['Yes'],['Merz Pharmaceutical GmbH'],['United Kingdom'],['No'],Axura,['Yes'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Film-coated tablet'],['Information not present in EudraCT'],['1'],"['Subjective memory, concentration or attention problems (subjective cognitive impairment) in the absence of dementia']",['No'],"The primary objective of this study is to investigate the efficacy and safety of 10mg/day memantine in comparison to placebo in the treatment of memory, concentration or attention problems (subjective cognitive impairment) in the absence of dementia.","['To investigate the efficacy of 10mg memantine in comparison to placebo measured by the CogState computer-based neuropsychological test battery [C-NTB], Everyday Cognition 39 [ECog 39], and Hospital Anxiety and Depression Scale [HADS]']",['No'],"['1. Written informed consent obtained from the subject,']","['1. Memory, concentration or attention problems interfere with basic daily activities,  2. Significant neurological disease or major psychiatric disorder (e.g. diagnosis of psychosis or dementia).']","['The primary efficacy endpoint is defined as “Patient Global Impression of Change” (PGI-C) at visit 4. The primary efficacy analysis is the statistical comparison between the placebo group and the memantine group at Visit 4 in the Full Analysis Set [FAS] where missing values will be imputed using the Last observation carried forward [LOCF] approach. The group comparison will be performed by the use of an analysis of covariance (ANCOVA) model, with treatment group, “Patient Global Impression Severity” (PGI-S) at screening, gender, age, education, and pooled center as factors. Additionally a reduced ANCOVA model with treatment group and pooled centers as factors will be used. To consider a possible violation of the assumptions of the non-parametric test a Cochan-Mantel-Haenszel test with modified ridit scores stratified by pooled centers will be performed. Furthermore a responder analysis using a logistic regression model will be performed with treatment group, PGI-S at screening, gender, age, education, and pooled centre as independent variables as well as a reduced responder analysis using treatment group and pooled center as independent variables. Response is defined as any improvement in the Subject Global Assessment of Change. Additionally summary statistics will be provided for raw values and the change to Visit 4. Sensitivity analyses of the results will be based on the FAS using observed cases, on the PPS using LOCF and on the PPS using observed cases.']",['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['150'],['Authorised'],['2010-09-17'],['2010-11-10'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"The primary objective of this study is to investigate the efficacy and safety of 10mg/day memantine in comparison to placebo in the treatment of memory, concentration or attention problems (subjective cognitive impairment) in the absence of dementia.-2010-020737-50-UK - MHRA-memantine hydrochloride"
0,Axura,memantine hydrochloride,['atteints maladie alzheimer'],Germany - BfArM,2010-020737-50,"['Prospective, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of 10mg memantine in the treatment of memory, concentration or attention problems (subjective cognitive impairment) in the absence of dementia']",['MRZ90001_2267_1'],['Information not present in EudraCT'],['Merz Pharmaceuticals GmbH'],['Germany'],['Commercial'],['Test'],['Yes'],['Merz Pharmaceutical GmbH'],['European Union'],['No'],Axura,['Yes'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Film-coated tablet'],['Information not present in EudraCT'],['1'],"['Subjective memory, concentration or attention problems (subjective cognitive impairment) in the absence of dementia']",['No'],"The primary objective of this study is to investigate the efficacy and safety of 10mg/day memantine in comparison to placebo in the treatment of memory, concentration or attention problems (subjective cognitive impairment) in the absence of dementia.","['To investigate the efficacy of 10mg memantine in comparison to placebo measured by the CogState computer-based neuropsychological test battery [C-NTB], Everyday Cognition 39 [ECog 39], and Hospital Anxiety and Depression Scale [HADS]']",['No'],"['1. Written informed consent obtained from the subject, 2. Understanding of study procedures and willingness to abide by all procedures during the course of the study, 3. Age ≥50 and ≤80, 4. Subjective worsening of memory, concentration or attention problems for longer than 6 months, 5. Woman of childbearing potential  must be using a highly effective method of birth control, 6. Subject can confirm that a relative or friend has noticed the memory, concentration or attention problems of the subject, 7.“Patient Global Impression Severity” (PGI-S) score of ≥3, 8. Experience of the memory, concentration or attention problems at least four times per week, 9. MiniCog score of 3 or more']","['1. Memory, concentration or attention problems interfere with basic daily activities,']","['The primary efficacy endpoint is defined as “Patient Global Impression of Change” (PGI-C) at visit 4. The primary efficacy analysis is the statistical comparison between the placebo group and the memantine group at Visit 4 in the Full Analysis Set [FAS] where missing values will be imputed using the Last observation carried forward [LOCF] approach. The group comparison will be performed by the use of an analysis of covariance (ANCOVA) model, with treatment group, “Patient Global Impression Severity” (PGI-S) at screening, gender, age, education, and pooled center as factors. Additionally a reduced ANCOVA model with treatment group and pooled centers as factors will be used. To consider a possible violation of the assumptions of the non-parametric test a Cochan-Mantel-Haenszel test with modified ridit scores stratified by pooled centers will be performed. Furthermore a responder analysis using a logistic regression model will be performed with treatment group, PGI-S at screening, gender, age, education, and pooled centre as independent variables as well as a reduced responder analysis using treatment group and pooled center as independent variables. Response is defined as any improvement in the Subject Global Assessment of Change. Additionally summary statistics will be provided for raw values and the change to Visit 4.']",['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['150'],['Authorised'],['2010-09-21'],['2010-10-21'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"The primary objective of this study is to investigate the efficacy and safety of 10mg/day memantine in comparison to placebo in the treatment of memory, concentration or attention problems (subjective cognitive impairment) in the absence of dementia.-2010-020737-50-Germany - BfArM-memantine hydrochloride"
0,Axura,memantine hydrochloride,['atteints maladie alzheimer'],UK - MHRA,2011-005151-13,['Open-label Pilot Study of Memantine in Chronic Cough Patients Attending a Specialist Clinic'],['MEM-COUGH-01'],['No'],"['University of Manchester', 'University Hospital of South Manchester']","['United Kingdom', 'United Kingdom']","['Non-Commercial', 'Non-Commercial']",['Test'],['Yes'],['Merz Pharmaceuticals GmbH'],['Germany'],['No'],Axura,['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Film-coated tablet'],['No'],['1'],['Idiopathic and treatment resistant Chronic Cough'],['No'],To evaluate the change in cough frequency in chronic cough patients after treatment with Memantine by assessing 24 hour cough recordings.,['(i) To evaluate the change in Cough-Specific Quality-of-Life Questionnaire (CQLQ) score after treatment with Memantine.'],['No'],['- Chronic cough (>8 weeks);'],['- Recent upper respiratory tract infection (<4 weeks);'],['Change from baseline in objectively recorded cough frequency in chronic cough patients after treatment with memantine.'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['15'],['Authorised'],['2012-05-17'],['2011-12-20'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],To evaluate the change in cough frequency in chronic cough patients after treatment with Memantine by assessing 24 hour cough recordings.-2011-005151-13-UK - MHRA-memantine hydrochloride
1,Viramune,nevirapine,"['infections', 'jours']",Italy - Italian Medicines Agency,2016-002413-22,"['Open label, Randomized (1:1), clinical trial to evaluate switching from dual regimens based on Dolutegravir plus a reverse transcriptase inhibitor to  elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in virologically suppressed, HIV-1 infected patients.']",['Be-OnE1/08-03-2016'],['No'],['OSPEDALE SAN RAFFAELE'],['Italy'],['Non-Commercial'],"['Test', 'Test', 'Comparator', 'Comparator', 'Comparator', 'Comparator', 'Comparator', 'Comparator', 'Comparator', 'Comparator']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['Gilead Sciences Int. Ltd', 'VIIV HEALTHCARE UK LTD', 'GILEAD SCIENCE INTERNATIONAL LIMITED', 'MYLAN S.P.A.', 'GILEAD SCIENCE INTERNATIONAL LIMITED', 'GLAXO GROUP LIMITED', 'JANSSEN-CILAG INTERNATIONAL N.V.', 'JANSSEN-CILAG INTERNATIONAL N.V.', 'BRISTOL-MYERS SQUIBB PHARMA EEIG', 'BOEHRINGER INGELHEIM INTERNATIONAL GMBH']","['Ireland', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']",Viramune,"['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'No', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'No', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Film-coated tablet', 'Film-coated tablet', 'Capsule, hard', 'Film-coated tablet', 'Film-coated tablet', 'Film-coated tablet', 'Tablet', 'Tablet', 'Tablet', 'Prolonged-release tablet']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['1', '2', '3', '4', '5', '6', '7', '8', '9', '10']",['HIV infection'],['No'],To investigate Residual Viremia  through 48 weeks in virologically suppressed patients randomized to continue treatment with Dolutegravir plus a single RTI or to switch to E/C/F/TAF.,['Secondary Objectives'],['No'],['1.\tAge >18  years'],['1.\tActive AIDS-defining condition (except Kaposi’s sarcoma non requiring systemic chemotherapy)'],['Proportion of subjects without Residual Viremia  through 48 weeks of follow-up.'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['100'],['Authorised'],['2016-10-31'],['2016-07-14'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Prematurely Ended'],To investigate Residual Viremia  through 48 weeks in virologically suppressed patients randomized to continue treatment with Dolutegravir plus a single RTI or to switch to E/C/F/TAF.-2016-002413-22-Italy - Italian Medicines Agency-nevirapine
2,INOmax,Nitric oxide,"['hypertension', 'hypertension', 'hypertension', 'afin diminuer sélectivement poumons pression']",Sweden - MPA,2008-006776-29,['NO som behandling vid knäproteskirurgi.'],['081016'],['Information not present in EudraCT'],['Karolinska Institutet'],['Sweden'],['Non-Commercial'],['Test'],['Yes'],['INO Therapeutics (IKARIA)'],['Sweden'],['No'],INOmax,['No'],['No'],['No'],['No'],['Yes'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],,['Information not present in EudraCT'],['1'],['Patienter som skall genomgå knäprotesoperation och skall ha bedövning i form av ryggbedövning (spinalanestes/epiduralanestesi).'],['No'],"Att undersöka om NO (nitric oxide, kväveoxid) kan modulerar det inflammatoriska svar som sker vid sk. reperfusionsskada.",,['No'],['Patienter som planeras genomgå elektiv knäprotesoperation pga leddestruktion. Anestesival skall vara ryggbedövning (spinal och eller epidural).'],['Pat med handikappande hjärtsvikt.'],['Inflammaationsmarkörer i blod och muskel.'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Yes'],['Information not present in EudraCT'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['45'],['Authorised'],['2009-02-18'],['2008-12-17'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Ongoing'],"Att undersöka om NO (nitric oxide, kväveoxid) kan modulerar det inflammatoriska svar som sker vid sk. reperfusionsskada.-2008-006776-29-Sweden - MPA-Nitric oxide"
1,Emtriva,emtricitabine,['infections'],UK - MHRA,2005-005672-33,"['A Randomized, Controlled, Open-Label, 48-Week Study of Continuing Successfully Suppressive Treatment in HIV-1 Infected Adults with First-Line Twice-Daily Zidovudine and Lamivudine-Based Regimens versus Proactively Replacing of Zidovudine and Lamivudine by Once-Daily Emtricitabine and Tenofovir Disoproxil Fumarate to Prevent Progression of or Reverse Peripheral Lipoatrophy.']",['PR-0095_01'],['Information not present in EudraCT'],['IATEC B.V.'],['Netherlands'],['Non-Commercial'],"['Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Glaxo Group Ltd', 'Gilead Sciences Intl Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Gilead Sciences Intl Ltd', 'Gilead Sciences Intl Ltd', 'Gilead Sciences Intl Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd']","['United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']",Emtriva,"['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Film-coated tablet', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11']",['HIV-1 infection'],['No'],Antiretroviral regimens containing emtricitabine plus tenofovir disoproxil fumarate might be associated with a lower incidence and severity of lipoatrophy. In this study we compare the effect of proactively switching zidovudine and lamivudine to emtricitabine plus tenofovir disoproxil fumarate on peripheral fat loss with continued lamivudine and zidovudine-based treatment in HIV-1 infected adults also receiving a non-nucleoside reverse transcriptase inhibitor or (boosted) protease inhibitor. In the patients who discontinue the use of zidovudine and switch to emtricitabine and tenofovir disoproxil fumarate we expect to demonstrate a regaining or at least a lack of further loss of peripheral adipose tissue. Primary Objective: to compare the changes in limb fat between the 2 study arms.,"['- To compare the changes in other aspects of body fat distribution, i.e. fat loss, fat gain, as well as in markers of lipid and glucose metabolism, between the 2 study arms.']",['Information not present in EudraCT'],['- HIV-1 infected patients.'],['- Prior treatment with an NRTI other than zidovudine or lamivudine.'],['Difference between the continuation arm and the switch arm in changes in limb fat over 48 weeks as measured by whole body DEXA.'],['No'],['Information not present in EudraCT'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['15'],['Authorised'],['2006-04-01'],['2006-07-26'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],Antiretroviral regimens containing emtricitabine plus tenofovir disoproxil fumarate might be associated with a lower incidence and severity of lipoatrophy. In this study we compare the effect of proactively switching zidovudine and lamivudine to emtricitabine plus tenofovir disoproxil fumarate on peripheral fat loss with continued lamivudine and zidovudine-based treatment in HIV-1 infected adults also receiving a non-nucleoside reverse transcriptase inhibitor or (boosted) protease inhibitor. In the patients who discontinue the use of zidovudine and switch to emtricitabine and tenofovir disoproxil fumarate we expect to demonstrate a regaining or at least a lack of further loss of peripheral adipose tissue. Primary Objective: to compare the changes in limb fat between the 2 study arms.-2005-005672-33-UK - MHRA-emtricitabine
1,Emtriva,emtricitabine,['infections'],Spain - AEMPS,2005-005672-33,"['Estudio randomizado, controlado, abierto, de 48 semanas sobre la continuación']",['PR-0095_01'],['Information not present in EudraCT'],['IATEC B.V.'],['Netherlands'],['Non-Commercial'],"['Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Glaxo Group Ltd', 'Gilead Sciences Intl Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Gilead Sciences Intl Ltd', 'Gilead Sciences Intl Ltd', 'Gilead Sciences Intl Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd']","['Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']",Emtriva,"['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Film-coated tablet', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11']",['HIV-1 infection'],['No'],Antiretroviral regimens containing emtricitabine plus tenofovir disoproxil fumarate might be associated with a lower incidence and severity of lipoatrophy. In this study we compare the effect of proactively switching zidovudine and lamivudine to emtricitabine plus tenofovir disoproxil fumarate on peripheral fat loss with continued lamivudine and zidovudine-based treatment in HIV-1 infected adults also receiving a non-nucleoside reverse transcriptase inhibitor or (boosted) protease inhibitor. In the patients who discontinue the use of zidovudine and switch to emtricitabine and tenofovir disoproxil fumarate we expect to demonstrate a regaining or at least a lack of further loss of peripheral adipose tissue. Primary Objective: to compare the changes in limb fat between the 2 study arms.,"['- To compare the changes in other aspects of body fat distribution, i.e. fat loss, fat gain, as well as in markers of lipid and glucose metabolism, between the 2 study arms.']",['Information not present in EudraCT'],['- HIV-1 infected patients.'],['- Prior treatment with an NRTI other than zidovudine or lamivudine.'],['Difference between the continuation arm and the switch arm in changes in limb fat over 48 weeks as measured by whole body DEXA.'],['No'],['Information not present in EudraCT'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['15'],['Authorised'],['2006-09-08'],['2006-07-11'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Ongoing'],Antiretroviral regimens containing emtricitabine plus tenofovir disoproxil fumarate might be associated with a lower incidence and severity of lipoatrophy. In this study we compare the effect of proactively switching zidovudine and lamivudine to emtricitabine plus tenofovir disoproxil fumarate on peripheral fat loss with continued lamivudine and zidovudine-based treatment in HIV-1 infected adults also receiving a non-nucleoside reverse transcriptase inhibitor or (boosted) protease inhibitor. In the patients who discontinue the use of zidovudine and switch to emtricitabine and tenofovir disoproxil fumarate we expect to demonstrate a regaining or at least a lack of further loss of peripheral adipose tissue. Primary Objective: to compare the changes in limb fat between the 2 study arms.-2005-005672-33-Spain - AEMPS-emtricitabine
1,Emtriva,emtricitabine,['infections'],Finland - Fimea,2005-005672-33,"['A Randomized, Controlled, Open-Label, 48-Week Study of Continuing Successfully Suppressive Treatment in HIV-1 Infected Adults with First-Line Twice-Daily Zidovudine and Lamivudine-Based Regimens versus Proactively Replacing of Zidovudine and Lamivudine by Once-Daily Emtricitabine and Tenofovir Disoproxil Fumarate to Prevent Progression of or Reverse Peripheral Lipoatrophy.']",['PR-0095_01'],['Information not present in EudraCT'],['IATEC B.V.'],['Netherlands'],['Non-Commercial'],"['Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Glaxo Group Ltd', 'Gilead Sciences Intl Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Gilead Sciences Intl Ltd', 'Gilead Sciences Intl Ltd', 'Gilead Sciences Intl Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd']","['Finland', 'Finland', 'Finland', 'Finland', 'Finland', 'Finland', 'Finland', 'Finland', 'Finland', 'Finland', 'Finland']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']",Emtriva,"['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Film-coated tablet', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11']",['HIV-1 infection'],['No'],Antiretroviral regimens containing emtricitabine plus tenofovir disoproxil fumarate might be associated with a lower incidence and severity of lipoatrophy. In this study we compare the effect of proactively switching zidovudine and lamivudine to emtricitabine plus tenofovir disoproxil fumarate on peripheral fat loss with continued lamivudine and zidovudine-based treatment in HIV-1 infected adults also receiving a non-nucleoside reverse transcriptase inhibitor or (boosted) protease inhibitor. In the patients who discontinue the use of zidovudine and switch to emtricitabine and tenofovir disoproxil fumarate we expect to demonstrate a regaining or at least a lack of further loss of peripheral adipose tissue. Primary Objective: to compare the changes in limb fat between the 2 study arms.,"['- To compare the changes in other aspects of body fat distribution, i.e. fat loss, fat gain, as well as in markers of lipid and glucose metabolism, between the 2 study arms.']",['Information not present in EudraCT'],['- HIV-1 infected patients.'],['- Prior treatment with an NRTI other than zidovudine or lamivudine.'],['Difference between the continuation arm and the switch arm in changes in limb fat over 48 weeks as measured by whole body DEXA.'],['No'],['Information not present in EudraCT'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['15'],['Authorised'],['2006-08-28'],['2006-08-01'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],Antiretroviral regimens containing emtricitabine plus tenofovir disoproxil fumarate might be associated with a lower incidence and severity of lipoatrophy. In this study we compare the effect of proactively switching zidovudine and lamivudine to emtricitabine plus tenofovir disoproxil fumarate on peripheral fat loss with continued lamivudine and zidovudine-based treatment in HIV-1 infected adults also receiving a non-nucleoside reverse transcriptase inhibitor or (boosted) protease inhibitor. In the patients who discontinue the use of zidovudine and switch to emtricitabine and tenofovir disoproxil fumarate we expect to demonstrate a regaining or at least a lack of further loss of peripheral adipose tissue. Primary Objective: to compare the changes in limb fat between the 2 study arms.-2005-005672-33-Finland - Fimea-emtricitabine
1,Emtriva,emtricitabine,['infections'],Italy - Italian Medicines Agency,2016-002413-22,"['Open label, Randomized (1:1), clinical trial to evaluate switching from dual regimens based on Dolutegravir plus a reverse transcriptase inhibitor to  elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in virologically suppressed, HIV-1 infected patients.']",['Be-OnE1/08-03-2016'],['No'],['OSPEDALE SAN RAFFAELE'],['Italy'],['Non-Commercial'],"['Test', 'Test', 'Comparator', 'Comparator', 'Comparator', 'Comparator', 'Comparator', 'Comparator', 'Comparator', 'Comparator']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['Gilead Sciences Int. Ltd', 'VIIV HEALTHCARE UK LTD', 'GILEAD SCIENCE INTERNATIONAL LIMITED', 'MYLAN S.P.A.', 'GILEAD SCIENCE INTERNATIONAL LIMITED', 'GLAXO GROUP LIMITED', 'JANSSEN-CILAG INTERNATIONAL N.V.', 'JANSSEN-CILAG INTERNATIONAL N.V.', 'BRISTOL-MYERS SQUIBB PHARMA EEIG', 'BOEHRINGER INGELHEIM INTERNATIONAL GMBH']","['Ireland', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']",Emtriva,"['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'No', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'No', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Film-coated tablet', 'Film-coated tablet', 'Capsule, hard', 'Film-coated tablet', 'Film-coated tablet', 'Film-coated tablet', 'Tablet', 'Tablet', 'Tablet', 'Prolonged-release tablet']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['1', '2', '3', '4', '5', '6', '7', '8', '9', '10']",['HIV infection'],['No'],To investigate Residual Viremia  through 48 weeks in virologically suppressed patients randomized to continue treatment with Dolutegravir plus a single RTI or to switch to E/C/F/TAF.,['Secondary Objectives'],['No'],['1.\tAge >18  years'],['1.\tActive AIDS-defining condition (except Kaposi’s sarcoma non requiring systemic chemotherapy)'],['Proportion of subjects without Residual Viremia  through 48 weeks of follow-up.'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['100'],['Authorised'],['2016-10-31'],['2016-07-14'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Prematurely Ended'],To investigate Residual Viremia  through 48 weeks in virologically suppressed patients randomized to continue treatment with Dolutegravir plus a single RTI or to switch to E/C/F/TAF.-2016-002413-22-Italy - Italian Medicines Agency-emtricitabine
0,Cetrotide,cetrorelix (as acetate),['humaine'],UK - MHRA,2009-012847-40,['A Randomised Study Comparing Two Different Regimens of Ovarian Stimulation Using Pergoveris and Cetrorelix for Controlled Ovarian Superovulation in Assisted Conception Treatment.'],['Pergoveris_Cetrorelix_1'],['Information not present in EudraCT'],"['NHS Lothian', 'The University of Edinburgh']","['United Kingdom', 'United Kingdom']",['Non-Commercial'],"['Test', 'Test']","['Yes', 'Yes']","['Serono Europe Ltd.', 'Serono Europe Ltd']","['European Union', 'European Union']","['No', 'No']",Cetrotide,"['No', 'Yes']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['Yes', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'Information not present in EudraCT']","['No', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Powder and solvent for solution for injection', 'Injection*']","['Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2']",['Subfertility'],['No'],"The aim of this study is to investigate whether controlled ovarian stimulation using Pergoveris with early administration of Cetrorelix (from day 2 of period, i.e. day 1 of gonadotrophin stimulation) versus administration of cetrorelix starting on day 6 of stimulation will result in more top quality embryos.",['- Number and size of follicles on day of hCG.'],['No'],['-\thealthy female;'],['-\tpolycystic ovarian syndrome'],['number of top quality embryos resulted from the treatment cycle'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['80'],['Authorised'],['2009-11-11'],['2009-08-18'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"The aim of this study is to investigate whether controlled ovarian stimulation using Pergoveris with early administration of Cetrorelix (from day 2 of period, i.e. day 1 of gonadotrophin stimulation) versus administration of cetrorelix starting on day 6 of stimulation will result in more top quality embryos.-2009-012847-40-UK - MHRA-cetrorelix (as acetate)"
0,Thyrogen,thyrotropin alfa,"['cancer thyroïde bien différencié', 'maintenus sous traitement', 'risque thyroïde bien différenciée carcinome taux sériques tg indétectables thst aucune augmentation taux tg stimulée tsh rh', 'humaine', 'cancer thyroïde bien différencié', 'signes cancer']",Austria - BASG,2006-004980-79,['Effect of the short –term thyrotropin increase after administration of Recombinant Human Thyrotropin on T lymphocyte cytokine production pattern and bone metabolism in healthy subjects'],['001'],['Information not present in EudraCT'],['Medical University of Vienna'],['Austria'],['Non-Commercial'],['Test'],['Yes'],['genzyme'],['Netherlands'],['No'],Thyrogen,['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['Yes'],['Information not present in EudraCT'],['Powder for injection*'],['Information not present in EudraCT'],['1'],['This is a healthy volunteers trial. Thyrogen is used in patients with thyroid cancer.'],['No'],The main objective of the trial is the effect of recombinant human thyrotropin in bone metabolism and its correlation to the potential changes in the T-lymphocyte cytokine production pattern in healthy volunteers.,,['No'],['Men and women without evidence of thyroid disease. Age between 20-45.'],"['Prior or present history of thyroid disease. Pregnancy or nursing. Significant cardiac, renal, pulmonary or hepatic disease. Recent surgery or trauma. Malnutrition. Ingestion of medications known to affect the thyroid function. Alcohol or drug dependence. Previous administration of rhTSH.']",,['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['20'],['Authorised'],['2006-10-10'],['2006-10-10'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],The main objective of the trial is the effect of recombinant human thyrotropin in bone metabolism and its correlation to the potential changes in the T-lymphocyte cytokine production pattern in healthy volunteers.-2006-004980-79-Austria - BASG-thyrotropin alfa
0,Mycamine,micafungin,['traitement intraveineux approprié avoir'],France - ANSM,2011-005451-14,['Micafungine versus placebo au cours du sepsis nosocomial chez des patients multi-colonisés à candida : Essai randomisé contrôlé EMPIRICUS'],['1126'],['No'],"['University Hospital, Grenoble']",['France'],['Non-Commercial'],['Test'],['Yes'],['Mycamine'],['France'],['No'],Mycamine,['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Powder for solution for infusion'],['No'],['1'],['patients présentant une candidose invasive suspectée'],['No'],Evaluer l’efficacité d’un traitement empirique par micafungine chez des patients adultes présentant une candidose invasive suspectée [survie sans candidose invasive prouvée durant 28 jours].,['•\tEvaluer l’impact du traitement empirique par micafungine chez des patients avec une candidose invasive possible sur :'],['No'],['Les sujets répondant à tous les critères suivants seront éligibles pour participer à l’étude :'],['Les sujets présentant l’une des caractéristiques suivantes à la visite d’inclusion ne pourront pas participer à l’étude :'],['La survie sans candidose invasive prouvée à 28 jours.'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['260'],['Authorised'],['2011-12-02'],['2011-12-07'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Ongoing'],Evaluer l’efficacité d’un traitement empirique par micafungine chez des patients adultes présentant une candidose invasive suspectée [survie sans candidose invasive prouvée durant 28 jours].-2011-005451-14-France - ANSM-micafungin
0,Puregon,follitropin beta,['anovulation compris syndrome ovaires polykystiques sopk chez femmes'],Denmark - DHMA,2005-002679-34,['The effect of LH priming in early follicular phase on the endocrinological function of the ovary and pregnancy rate in GnRh downregulated women stimulated by exogen gonadotophins in IVF-treatment'],['1-2005'],['Information not present in EudraCT'],"['The Fertility Clinic, Sygehus Viborg (Skive)']",['Denmark'],['Non-Commercial'],"['Test', 'Comparator', 'Comparator']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Ferring', 'Organon', 'Organon']","['Denmark', 'Denmark', 'Denmark']","['No', 'No', 'No']",Puregon,"['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Yes', 'Yes', 'Yes']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Injection*', 'Injection*', 'Injection*']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3']",['Infertility'],['No'],Estimate of the effect of LH-priming in early follicular phase after 3 different stimulations regimes in IVF-treatment.,"['Comparism of follicles, oocyte quality and pregnancty rate.']",['Information not present in EudraCT'],['Women aged 18- 38 years in IVF-treatment'],['Male infertility with low sperm count necessitating microinsemination for fertilization'],['Serum oestradiol on the day of hCG administration'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['150'],['Authorised'],['2005-11-02'],['2005-11-02'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],Estimate of the effect of LH-priming in early follicular phase after 3 different stimulations regimes in IVF-treatment.-2005-002679-34-Denmark - DHMA-follitropin beta
0,Eucreas,"vildagliptin, metformin hydrochloride",['complément régime alimentaire exercices physiques améliorer contrôle glycémique chez adultes atteints diabète sucré type 2 chez'],Germany - BfArM,2011-000518-21,['Cross-over study to assess the difference in fasting plasma glucose (FPG) between vildagliptin (Galvus®/Eucreas®) and sitagliptin (Januvia®/Janumet®) after two weeks (FPG-VISIT)'],['CLMF237ADE02'],['No'],['Novartis Pharma GmbH'],['Germany'],['Commercial'],"['Test', 'Comparator']","['Yes', 'Yes']","['Novartis Europharm Limited', 'Merck Sharp & Dohme, Inc.']","['European Union', 'European Union']","['No', 'No']",Eucreas,"['Yes', 'Yes']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['Film-coated tablet', 'Film-coated tablet']","['No', 'No']","['1', '2']",['Diabetes mellitus type 2'],['No'],To assess the difference in FPG between vildagliptin and sitagliptin after two weeks in patients with type 2 diabetes mellitus pre-treated with metformin.,['To assess the difference in FPG between vildagliptin and sitagliptin after a missed dose of either drug in patients with type 2 diabetes mellitus on concomitant treatment with metformin.'],['No'],['1.\tType 2 diabetic patients stabilized on metformin monotherapy (stable dose for at least 4 weeks prior to Screening) ≥ 1000 mg/day and ≤ 2000 mg/day.'],['1.\tFPG ≥ 270mg/dL (15mmol/L) at Visit 1 and Visit 102.'],['The primary objective of the study is to demonstrate that the FPG after 14 days of treatment with Vildagliptin is superior to the FPG after 14 days of treatment with.'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['100'],['Authorised'],['2011-04-29'],['2011-06-20'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To assess the difference in FPG between vildagliptin and sitagliptin after two weeks in patients with type 2 diabetes mellitus pre-treated with metformin.-2011-000518-21-Germany - BfArM-vildagliptin, metformin hydrochloride"
0,Eucreas,"vildagliptin, metformin hydrochloride",['complément régime alimentaire exercices physiques améliorer contrôle glycémique chez adultes atteints diabète sucré type 2 chez'],Germany - BfArM,2011-003818-16,"['A randomized, open-label, cross-over study to evaluate patient preferences for Eucreas® versus Victoza® as add-on to Metformin in Type 2 Diabetes mellitus patients who did not have adequate glycaemic control with metformin']",['CLMF237ADE03'],['No'],['Novartis Pharma GmbH'],['Germany'],['Commercial'],"['Test', 'Comparator', 'Comparator']","['Yes', 'Yes', 'No']","['Novartis Europharm Limited', 'Novo Nordisk A/S', 'Stadapharm GmbH']","['European Union', 'European Union', 'Germany']","['No', 'No', 'No']",Eucreas,"['Yes', 'No', 'Yes']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'Yes', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'Yes', 'No']","['Film-coated tablet', 'Solution for injection in pre-filled pen', 'Film-coated tablet']","['No', 'No', 'No']","['1', '2', '3']",['type 2 diabetes mellitus'],['No'],The primary objective of this trial is to demonstrate that a higher proportion of subjects with T2DM and inadequate glycemic control have a preference for an oral treatment with the SPC of vildagliptin/metformin compared to an injectable treatment with liraglutide as add-on to metformin after experiencing both treatments.,['•\tTo evaluate the subjective reason of preference for an oral or and injectable treatment after experiencing both treatments.'],['No'],['1. Age: > 18 and < 80 years at Visit 1.'],['1.\tFPG ≥270mg/dL (15.0 mmol/L) at Visit 1.'],['The primary outcome variable is the patient´s preference for one treatment.'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['60'],['Authorised'],['2011-12-21'],['2011-11-21'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"The primary objective of this trial is to demonstrate that a higher proportion of subjects with T2DM and inadequate glycemic control have a preference for an oral treatment with the SPC of vildagliptin/metformin compared to an injectable treatment with liraglutide as add-on to metformin after experiencing both treatments.-2011-003818-16-Germany - BfArM-vildagliptin, metformin hydrochloride"
0,Mimpara,cinacalcet hydrochloride,['tels définis directives thérapeutiques pertinentes'],Sweden - MPA,2012-005374-57,['Primary hyperparathyroidism: Short-term calcimimetics treatment – Relevance for parathyroid surgery decisions?'],['Calcimimetics'],['No'],"['Department of Breast and Endocrine Surgery, Karolinska University Hospital']",['Sweden'],['Non-Commercial'],['Test'],['Yes'],['Amgen Europe B.V.'],['Sweden'],['No'],Mimpara,['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Tablet'],['No'],['1'],"['Primary hyperparathyroidism (PHPT) is a common disease, characterized by a high-normal calcium concentration and an inappropriately increased parathyroid hormone (PTH) level']",['No'],To determine the relevance of short-term calcimimetics treatment in primary hyperparathyroidism for decision of parathyroid surgery,['•To assess the feasibility of the study design'],['No'],"['•Primary hyperparathyroidism, scheduled for parathyroid surgery']",['•Pregnancy'],['•If four weeks of treatment with Mimpara will normalize hypercalcemia in patients with PHPT'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['100'],['Authorised'],['2013-02-15'],['2013-02-13'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Ongoing'],To determine the relevance of short-term calcimimetics treatment in primary hyperparathyroidism for decision of parathyroid surgery-2012-005374-57-Sweden - MPA-cinacalcet hydrochloride
0,Taxotere,docetaxel,"['ganglions positifs cancer sein opérable sans ganglions négatifs patientes atteintes cancer sein opérable sans ganglions négatifs traitement', 'traitement primaire cancer sein', 'traitement patientes atteintes cancer sein localement', 'cancer sein localement', 'capécitabine indiqué traitement patientes atteintes cancer sein localement avancé métastatique après échec', 'cancer poumon', 'cancer poumon', 'cancer prostate']",Spain - AEMPS,2005-001499-10,"[""'Pilot trial of Pegilated Liposomal Doxorrubicin (Caelyx) in combination with Docetaxel (Taxotere) in advanced breast cancer patients'""]",['CO34'],['Information not present in EudraCT'],['Dr. José Ramón Mel Lorenzo'],['Spain'],,"['Test', 'Test']","['Information not present in EudraCT', 'Information not present in EudraCT']","['SP EUROPE', 'AVENTIS PHARMA S.A.']","['Spain', 'Spain']","['No', 'No']",Taxotere,"['Yes', 'Yes']","['No', 'No']","['No', 'No']","['No', 'No']","['Yes', 'Yes']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Concentrate for solution for infusion', 'Solution for infusion']","['Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2']",['Advanced Breast Cancer'],['No'],To value efficiency of Caelyx (30mg/m2) in combination with Docetaxel (60mg/m2) in a pilot trial administrated in 3 weeks-cicles during 6 cicles in advanced breast cancer patients,['To value segurity and tolerance of the combination Pegilated Liposomal Doxorubicin (Caelyx) and Docetaxel (Taxotere) as teraphy in advanced breast cancer'],['Information not present in EudraCT'],['Aged > 18 years'],['No cardiopathy history'],['Overall response rate'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['Yes'],['No'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['30'],['Authorised'],['2005-05-19'],['2004-12-10'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Ongoing'],To value efficiency of Caelyx (30mg/m2) in combination with Docetaxel (60mg/m2) in a pilot trial administrated in 3 weeks-cicles during 6 cicles in advanced breast cancer patients-2005-001499-10-Spain - AEMPS-docetaxel
0,Herceptin,trastuzumab,"['tumeurs estomac', 'sein cancer', 'également avoir échoué traitement hormonal sauf si', 'cancer sein', 'atteintes cancer sein', 'traitement']",Germany - BfArM,2012-000598-22,"['Randomised, open-label phase II study to compare the safety and efficacy of lapatinib plus trastuzumab or lapatinib plus capecitabine in trastuzumab-resistant HER2-overexpressing metastatic breast cancer']",['BNGO/01'],['No'],['Berufsverband der niedergelassenen gynäkologischen Onkologen in Deutschland e.V.; BNGO e.V.'],['Germany'],['Non-Commercial'],"['Test', 'Test', 'Comparator', 'Comparator']","['Yes', 'Yes', 'Yes', 'Yes']","['GlaxoSmithKline', 'Roche Registration Limited', 'GlaxoSmithKline', 'Roche Registration Lmited']","['Germany', 'Germany', 'Germany', 'Germany']","['No', 'No', 'No', 'No']",Herceptin,"['Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Film-coated tablet', 'Powder for concentrate for solution for infusion', 'Film-coated tablet', 'Film-coated tablet']","['No', 'No', 'No', 'No']","['1', '2', '3', '4']",['Trastuzumab-resistant HER2-overexpressing metastatic breast cancer'],['No'],Estimate the clinical benefit of lapatinib plus trastuzumab compared to lapatinib plus capecitabine as measured by investigator-assessed progression-free survival (PFS),['•\tEvaluate overall survival of lapatinib plus trastuzumab relative to lapatinib plus capecitabine'],['No'],"['\tWomen with histologically confirmed breast cancer; measurable metastatic disease; HER2-positive (IHC 3+ or ISH positive); Hormone receptor-negative; prior treatment with trastuzumab, anthracycline and taxanes; progression on trastuzumab as first-line or second-line therapy; no prior treatment with lapatinib within last 6 months; Adequate hematologic, renal and liver function; normal cardiac function with LVEF of ≥50%; ECOG performance status 0-1; No evidence of brain metastases (asymptomatic metastases that have been clinically stable for 3 months are allowed); no significant cardiovascular disease or other serious medical condition; written informed consent to participate in the trial and to the donation of formalin fixed, paraffin embedded tumour sample from the primary or recurrent cancer available for central testing.']",['•\t1. Patients with confirmed brain metastases or a history of primary central nervous system tumours or who have signs/symptoms attributable to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases. Patients with treated brain metastases that are asymptomatic and have been clinically stable for 3 months will be eligible for protocol participation.'],"['The 6-month PFS-rate (PFS6) will be the number of patients without disease progression or death within 6 months from the date of randomization, divided by the number of patients in the respective analysis population. For the purpose of the analysis patients who are lost to follow-up or deceased in at or before 6 months after randomization will be counted as “disease progression”.']",['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['100'],['Authorised'],['2013-03-08'],['2013-03-18'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Prematurely Ended'],Estimate the clinical benefit of lapatinib plus trastuzumab compared to lapatinib plus capecitabine as measured by investigator-assessed progression-free survival (PFS)-2012-000598-22-Germany - BfArM-trastuzumab
0,Herceptin,trastuzumab,"['tumeurs estomac', 'sein cancer', 'également avoir échoué traitement hormonal sauf si', 'cancer sein', 'atteintes cancer sein', 'traitement']",Germany - PEI,2007-000348-28,"['A single arm, multi-centre, international, continuation trial of recombinant humanized antibody Herceptin® (trastuzumab) in patients with HER2 overexpressing tumors.']",['BO15943'],['Information not present in EudraCT'],['F. Hoffmann-La Roche Ltd'],['Switzerland'],['Commercial'],['Test'],['Yes'],['Roche Registration Limited'],['European Union'],['No'],Herceptin,['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Powder for concentrate for solution for infusion'],['Information not present in EudraCT'],['1'],['To continue to provide treatment to those patients that may still be on treatment at the moment of the final data base closure/clinical cut-off of a clinical trials in which Herceptin® is investigated and that further benefit from treatment with Herceptin®.'],['No'],To provide long term follow-up and safety data in patients receiving Herceptin® following completion of a global Roche sponsored Herceptin® trial.,,['No'],['1. Signed informed consent'],['1. Pregnant or nursing women; women of childbearing potential unless using effective contraception as determined by the investigator.'],['• To provide Herceptin® to patients with HER2 overexpressing disease following completion of any global Roche sponsored Herceptin® study.'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['6'],['Authorised'],['2007-08-14'],['2007-08-30'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],To provide long term follow-up and safety data in patients receiving Herceptin® following completion of a global Roche sponsored Herceptin® trial.-2007-000348-28-Germany - PEI-trastuzumab
0,Herceptin,trastuzumab,"['tumeurs estomac', 'sein cancer', 'également avoir échoué traitement hormonal sauf si', 'cancer sein', 'atteintes cancer sein', 'traitement']",Portugal - INFARMED,2007-000348-28,"['A single arm, multi-centre, international, continuation trial of recombinant humanized antibody Herceptin® (trastuzumab) in patients with HER2 overexpressing tumors.']",['BO15943'],['Information not present in EudraCT'],['F. Hoffman-La Roche Ltd'],['Switzerland'],['Commercial'],['Test'],['Yes'],['Roche Registration Limited'],['European Union'],['No'],Herceptin,['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Powder for concentrate for solution for infusion'],['Information not present in EudraCT'],['1'],['To continue to provide treatment to those patients that may still be on treatment at the moment of the final data base closure/clinical cut-off of a clinical trials in which Herceptin® is investigated and that further benefit from treatment with Herceptin®.'],['No'],To provide long term follow-up and safety data in patients receiving Herceptin® following completion of a global Roche sponsored Herceptin® trial.,,['No'],['1. Signed informed consent'],['1. Pregnant or nursing women; women of childbearing potential unless using effective contraception as determined by the investigator.'],['• To provide Herceptin® to patients with HER2 overexpressing disease following completion of any global Roche sponsored Herceptin® study.'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['Yes'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['1'],['Authorised'],['2007-08-20'],['2007-11-09'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],To provide long term follow-up and safety data in patients receiving Herceptin® following completion of a global Roche sponsored Herceptin® trial.-2007-000348-28-Portugal - INFARMED-trastuzumab
0,Herceptin,trastuzumab,"['tumeurs estomac', 'sein cancer', 'également avoir échoué traitement hormonal sauf si', 'cancer sein', 'atteintes cancer sein', 'traitement']",France - ANSM,2007-000348-28,"['A single arm, multi-centre, international, continuation trial of recombinant humanized antibody Herceptin® (trastuzumab) in patients with HER2 overexpressing tumors.']",['BO15943'],['Information not present in EudraCT'],['F. Hoffman-La Roche Ltd'],['Switzerland'],['Commercial'],['Test'],['Yes'],['Roche Registration Limited'],['European Union'],['No'],Herceptin,['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Powder for concentrate for solution for infusion'],['Information not present in EudraCT'],['1'],['To continue to provide treatment to those patients that may still be on treatment at the moment of the final data base closure/clinical cut-off of a clinical trials in which Herceptin® is investigated and that further benefit from treatment with Herceptin®.'],['No'],To provide long term follow-up and safety data in patients receiving Herceptin® following completion of a global Roche sponsored Herceptin® trial.,['n/a'],['No'],['1. Signed informed consent'],['1. Pregnant or nursing women; women of childbearing potential unless using effective contraception as determined by the investigator.'],['long term follow-up and safety'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['Yes'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['1'],['Authorised'],['2009-12-14'],['2009-12-09'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],To provide long term follow-up and safety data in patients receiving Herceptin® following completion of a global Roche sponsored Herceptin® trial.-2007-000348-28-France - ANSM-trastuzumab
0,Avastin,bevacizumab,"['côlon rectum bevacizumab', 'récepteur 2 facteur croissance', 'humain', 'capécitabine indiqué', 'comme', 'adultes atteints cancer poumon', 'adultes atteints cancer poumon', 'récepteur facteur croissance', 'adultes atteints cancer', 'adultes atteints cancer', 'cancer']",Austria - BASG,2008-008852-18,['Profile of soluble and cellular biomarkers and of functional imaging during antiangiogenic therapies in cancer patients'],['PRAEMARKERAAT08'],['Information not present in EudraCT'],['Medizinische Universität Innsbruck Innere Medizin V'],['Austria'],['Non-Commercial'],,"['Yes', 'Yes', 'Yes']","['Pfizer Ltd', 'Bayer Health Care AG', 'Roche']","['United Kingdom', 'Germany']","['No', 'No', 'No']",Avastin,"['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Yes', 'Yes', 'Yes']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'Yes']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Tablet', 'Tablet', 'Concentrate and solvent for solution for injection']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3']","['The present project is an academic clinical trial in which patient suffering from hepatocellular carcinoma, non-small cell lung cancer, renal cell cancer and colorectal cancer treated routinely with antiangiogenic agents. The study protocol intends to include ten patients per tumour entitity (n=40), treated either with Sorafenib (Nexavar), Bevacizumab (Avastin) or Sunitinib (Sutent), which are all approved antiangiogenic drugs in Austria in one of the cancer types defined above.']",['No'],"Biomarker evaluation under antiannagiogenic therapy with Nexavar, Sutent and Avastin. Eligible patients are suffering from hepatocellular carcinoma, non small cell lung cancer, renal cell cancer and colorectal cancer routinely treated with the abov mentioned antiangiogenic agents.",,['No'],"['Histological confirmed Tumor specimen RCC, HCC, CRC or NSCLC']",['Prior or concurrent antitumor therapy (<3 weeks)'],['Evaluation of biomarker analyses'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['40'],['Authorised'],['2009-06-10'],['2009-06-10'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"Biomarker evaluation under antiannagiogenic therapy with Nexavar, Sutent and Avastin. Eligible patients are suffering from hepatocellular carcinoma, non small cell lung cancer, renal cell cancer and colorectal cancer routinely treated with the abov mentioned antiangiogenic agents.-2008-008852-18-Austria - BASG-bevacizumab"
0,NovoSeven,eptacog alfa (activated),['viii ix coagulation 5 unités bethesda ub patients atteints hémophilie congénitale susceptibles avoir réponse anamnestique élevée administration facteur viii facteur ix chez patients atteints hémophilie acquise chez'],Italy - Italian Medicines Agency,2004-000088-92,"['A randomised, double-blind,placebo-controlled, multi-centre, dose escalation study to evaluate the safety and the preliminary efficacy of recombinant factor VIIa (NovoSeven/Niastase) in subjects with brain contusions.']",['F7CBI-1600'],['Information not present in EudraCT'],['NOVO NORDISK'],['Italy'],['Commercial'],['Test'],['Information not present in EudraCT'],['NOVO NORDISK-DK'],['Denmark'],['No'],NovoSeven,['No'],['No'],['No'],['No'],['No'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Powder and solvent for solution for injection'],['Information not present in EudraCT'],['1'],['Prevention of early haemorragic progression in brain contusion'],['Information not present in EudraCT'],,,['Information not present in EudraCT'],,,,['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['Yes'],['Yes'],['No'],['15'],['Authorised'],['2004-08-04'],['2004-07-29'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],-2004-000088-92-Italy - Italian Medicines Agency-eptacog alfa (activated)
3,Aloxi,palonosetron hydrochloride,['vomissement cancer'],Poland - Office for Medicinal Products,2007-005068-29,"['A Pivotal Phase 3 Observer-Blind, Randomized Clinical Trial of the Efficacy and Safety of APF530 Compared to Aloxi® for the Prevention of Acute-Onset and Delayed-Onset Chemotherapy-Induced Nausea and Vomiting Following the Administration of either Moderately or Highly Emetogenic Chemotherapy Regimens']",['C2006-01'],['Information not present in EudraCT'],"['A.P. Pharma, Inc.']",['United States'],['Commercial'],"['Test', 'Test', 'Comparator']","['No', 'No', 'Yes']","['Helsinn Birex Pharmaceuticals, Ltd']",['European Union'],"['No', 'No', 'No']",Aloxi,"['Yes', 'Yes', 'Yes']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Solution for injection', 'Solution for injection', 'Solution for injection']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3']",['Chemotherapy Induced Nausea and Vomiting'],['No'],The primary objectives of the study are to evaluate in the first qualifying chemotherapy treatment the efficacy of a single dose of a sustained release formulation of granisetron (APF530) in comparison to Aloxi® for the prevention of acute-onset and delayed-onset CINV in subjects currently undergoing moderately or highly emetogenic chemotherapy:,"['The secondary objectives are to evaluate the safety and tolerability, sustained efficacy, and pharmacokinetics of APF530 in subjects undergoing moderately or highly emetogenic chemotherapy over multiple qualifying chemotherapy  treatments:']",['No'],['Diagnosis and main criteria for inclusion and exclusion:'],"['Exclusion:  Treatment with chemotherapeutic regimens which are mildly or unlikely to be emetogenic (Hesketh Level 1 and 2); allergy or hypersensitivity to 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists or to local anesthetics; ECOG performance status of 3, 4 or 5; head and neck cancers that have compromised the brain vomiting and nausea centers, primary brain tumors and active/symptomatic brain metastases, or GI cancers with gastric or intestinal obstruction that may result in symptoms of nausea and vomiting; a psychological problem that, in the investigator’s opinion, is severe enough to preclude reliable study participation; recent history (within 1 year) of alcohol or drug abuse; greater than mild nausea or any vomiting within 24 hours prior to study drug administration; pregnancy (confirmed by serum or urine test) or breastfeeding; any concomitant condition that, in the opinion of the investigator, could affect assessment of the study drug or could interfere with the nausea/vomiting response, including severe renal or hepatic impairment; use of investigational drug within 30 days before study entry;  subjects with QTc interval > 500 msec or with a cardiac abnormality predisposing the subject to arrhythmia.']",['The following efficacy measures will be evaluated daily during the first 5 days after administration of chemotherapy:'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['400'],['Authorised'],['2008-01-02'],,['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],The primary objectives of the study are to evaluate in the first qualifying chemotherapy treatment the efficacy of a single dose of a sustained release formulation of granisetron (APF530) in comparison to Aloxi® for the prevention of acute-onset and delayed-onset CINV in subjects currently undergoing moderately or highly emetogenic chemotherapy:-2007-005068-29-Poland - Office for Medicinal Products-palonosetron hydrochloride
2,Rasilez,aliskiren,"['hypertension', 'hypertension']",Germany - BfArM,2008-008287-28,['Effect of direct renin-inhibition aliskiren on renal haemodynamic and metabolic parameters in patients with prediabetes'],['ALI-FRA-0030-I'],['No'],['University Hospital Erlangen'],['Germany'],['Non-Commercial'],"['Test', 'Test']","['Yes', 'Yes']","['Novartis', 'Novartis']","['Germany', 'Germany']","['No', 'No']",Rasilez,"['Yes', 'Yes']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['Tablet', 'Tablet']","['No', 'No']","['1', '2']",['Patients with prediabetes (either impaired glucose tolerance or imparied fasting glucose) and no obvious diabetes mellitus'],['No'],"The primary aim of this study is to examine the effect of Aliskiren (150mg/daily for 1 week, 300 mg/daily for 4 weeks) on renal hemodynamics in patients with prediabetes and eleveted blood pressure.","['The effect of a 5 week lasting therapy with Aliskiren on metabolic parameters (HbA1c, high sensitive CRP, Adiponectin), in patients with impaired glucose tolerance and arterial.']",['No'],['Adults aged > 18 to < 70 years'],['Diabetes Mellitus Type 1/2'],"['Renal haemodynamic parameters (glomerular filtration rate, renal plasma flow, filtration fraction) under direct renin blockade']",['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['20'],['Authorised'],['2010-05-11'],,['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"The primary aim of this study is to examine the effect of Aliskiren (150mg/daily for 1 week, 300 mg/daily for 4 weeks) on renal hemodynamics in patients with prediabetes and eleveted blood pressure.-2008-008287-28-Germany - BfArM-aliskiren"
0,Zonegran,zonisamide,['nouvellement diagnostiquée traitement appoint traitement crises partielles sans généralisation secondaire chez adultes adolescents enfants âgés'],Sweden - MPA,2005-001982-33,['An open label study of Zonegran (zonisamide) in patients with partial onset seizures.'],['E2090-E044-401'],['Information not present in EudraCT'],['Eisai Limited'],['United Kingdom'],['Commercial'],"['Test', 'Test', 'Test']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Eisai Limited', 'Eisai Limited', 'Eisai Limited']","['Sweden', 'Sweden', 'Sweden']","['No', 'No', 'No']",Zonegran,"['Yes', 'Yes', 'Yes']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Capsule*', 'Capsule*', 'Capsule*']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3']","['Indicated as adjunctive therapy in the treatment of adult patients with partial seizures, with or without secondary generalisation.']",['No'],To determine the efficacy and safety of adjunctive open label zonisamide treatment in patients with refractory partial seizures,['None stated.'],['Information not present in EudraCT'],['1) Male or female adult patients aged 18-75'],['1) History of status epilepticus within the last 5 years'],"['The primary endpoint is the change from baseline to end of week 19 in partial seizure frequency. This will allow for a direct comparison of seizure frequency in the fixed dose period (beginning of week 16 to end of week 19) with the baseline seizure frequency, calculated as the average number of seizures/4 week period during 8 consecutive weeks prior to the baseline visit.']",['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['15'],['Authorised'],['2006-01-18'],['2006-03-16'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],To determine the efficacy and safety of adjunctive open label zonisamide treatment in patients with refractory partial seizures-2005-001982-33-Sweden - MPA-zonisamide
0,Zonegran,zonisamide,['nouvellement diagnostiquée traitement appoint traitement crises partielles sans généralisation secondaire chez adultes adolescents enfants âgés'],Denmark - DHMA,2005-001982-33,['An open label study of Zonegran (zonisamide) in patients with partial onset seizures.'],['E2090-E044-401'],['Information not present in EudraCT'],['Eisai Limited'],['United Kingdom'],['Commercial'],"['Test', 'Test', 'Test']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Eisai Limited', 'Eisai Limited', 'Eisai Limited']","['Denmark', 'Denmark', 'Denmark']","['No', 'No', 'No']",Zonegran,"['Yes', 'Yes', 'Yes']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Capsule*', 'Capsule*', 'Capsule*']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3']","['Indicated as adjunctive therapy in the treatment of adult patients with partial seizures, with or without secondary generalisation.']",['No'],To determine the efficacy and safety of adjunctive open label zonisamide treatment in patients with refractory partial seizures,['None stated.'],['Information not present in EudraCT'],['1) Male or female adult patients aged 18-75'],['1) History of status epilepticus within the last 5 years'],"['The primary endpoint is the change from baseline to end of week 19 in partial seizure frequency. This will allow for a direct comparison of seizure frequency in the fixed dose period (beginning of week 16 to end of week 19) with the baseline seizure frequency, calculated as the average number of seizures/4 week period during 8 consecutive weeks prior to the baseline visit.']",['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],,['Authorised'],['2006-01-17'],['2006-03-23'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],To determine the efficacy and safety of adjunctive open label zonisamide treatment in patients with refractory partial seizures-2005-001982-33-Denmark - DHMA-zonisamide
0,Zonegran,zonisamide,['nouvellement diagnostiquée traitement appoint traitement crises partielles sans généralisation secondaire chez adultes adolescents enfants âgés'],Finland - Fimea,2005-001982-33,['An open label study of Zonegran (zonisamide) in patients with partial onset seizures.'],['E2090-E044-401'],['Information not present in EudraCT'],['Eisai Limited'],['United Kingdom'],['Commercial'],"['Test', 'Test', 'Test']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']",,,"['No', 'No', 'No']",Zonegran,"['Yes', 'Yes', 'Yes']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Capsule*', 'Capsule*', 'Capsule*']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3']","['Indicated as adjunctive therapy in the treatment of adult patients with partial seizures, with or without secondary generalisation.']",['No'],To determine the efficacy and safety of adjunctive open label zonisamide treatment in patients with refractory partial seizures,['None stated.'],['Information not present in EudraCT'],['1) Male or female adult patients aged 18-75'],['1) History of status epilepticus within the last 5 years'],"['The primary endpoint is the change from baseline to end of week 19 in partial seizure frequency. This will allow for a direct comparison of seizure frequency in the fixed dose period (beginning of week 16 to end of week 19) with the baseline seizure frequency, calculated as the average number of seizures/4 week period during 8 consecutive weeks prior to the baseline visit.']",['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['40'],['Authorised'],['2006-08-04'],['2006-08-08'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],To determine the efficacy and safety of adjunctive open label zonisamide treatment in patients with refractory partial seizures-2005-001982-33-Finland - Fimea-zonisamide
0,Zonegran,zonisamide,['nouvellement diagnostiquée traitement appoint traitement crises partielles sans généralisation secondaire chez adultes adolescents enfants âgés'],Italy - Italian Medicines Agency,2005-001982-33,['An Open Label Study of ZONEGRANTM  Zonisamide  in patients with partial onset seizures'],['E2090-E044-401'],['Information not present in EudraCT'],['EISAI LTD UK'],['United Kingdom'],['Commercial'],['Test'],['Yes'],,['United States'],['No'],Zonegran,['Yes'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],"['Capsule, hard']",['Information not present in EudraCT'],['1'],['Epilepsy patients with partial onset seizures with or without secondary generalization'],['No'],,,['Information not present in EudraCT'],,,,['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Yes'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['160'],['Authorised'],['2005-10-26'],['2005-10-18'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],-2005-001982-33-Italy - Italian Medicines Agency-zonisamide
1,Truvada,"emtricitabine, tenofovir disoproxil fumarate","['infections', 'traitement infection', 'contracter vih-1 sexuellement acquis infection']",UK - MHRA,2005-005672-33,"['A Randomized, Controlled, Open-Label, 48-Week Study of Continuing Successfully Suppressive Treatment in HIV-1 Infected Adults with First-Line Twice-Daily Zidovudine and Lamivudine-Based Regimens versus Proactively Replacing of Zidovudine and Lamivudine by Once-Daily Emtricitabine and Tenofovir Disoproxil Fumarate to Prevent Progression of or Reverse Peripheral Lipoatrophy.']",['PR-0095_01'],['Information not present in EudraCT'],['IATEC B.V.'],['Netherlands'],['Non-Commercial'],"['Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Glaxo Group Ltd', 'Gilead Sciences Intl Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Gilead Sciences Intl Ltd', 'Gilead Sciences Intl Ltd', 'Gilead Sciences Intl Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd']","['United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']",Truvada,"['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Film-coated tablet', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11']",['HIV-1 infection'],['No'],Antiretroviral regimens containing emtricitabine plus tenofovir disoproxil fumarate might be associated with a lower incidence and severity of lipoatrophy. In this study we compare the effect of proactively switching zidovudine and lamivudine to emtricitabine plus tenofovir disoproxil fumarate on peripheral fat loss with continued lamivudine and zidovudine-based treatment in HIV-1 infected adults also receiving a non-nucleoside reverse transcriptase inhibitor or (boosted) protease inhibitor. In the patients who discontinue the use of zidovudine and switch to emtricitabine and tenofovir disoproxil fumarate we expect to demonstrate a regaining or at least a lack of further loss of peripheral adipose tissue. Primary Objective: to compare the changes in limb fat between the 2 study arms.,"['- To compare the changes in other aspects of body fat distribution, i.e. fat loss, fat gain, as well as in markers of lipid and glucose metabolism, between the 2 study arms.']",['Information not present in EudraCT'],['- HIV-1 infected patients.'],['- Prior treatment with an NRTI other than zidovudine or lamivudine.'],['Difference between the continuation arm and the switch arm in changes in limb fat over 48 weeks as measured by whole body DEXA.'],['No'],['Information not present in EudraCT'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['15'],['Authorised'],['2006-04-01'],['2006-07-26'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"Antiretroviral regimens containing emtricitabine plus tenofovir disoproxil fumarate might be associated with a lower incidence and severity of lipoatrophy. In this study we compare the effect of proactively switching zidovudine and lamivudine to emtricitabine plus tenofovir disoproxil fumarate on peripheral fat loss with continued lamivudine and zidovudine-based treatment in HIV-1 infected adults also receiving a non-nucleoside reverse transcriptase inhibitor or (boosted) protease inhibitor. In the patients who discontinue the use of zidovudine and switch to emtricitabine and tenofovir disoproxil fumarate we expect to demonstrate a regaining or at least a lack of further loss of peripheral adipose tissue. Primary Objective: to compare the changes in limb fat between the 2 study arms.-2005-005672-33-UK - MHRA-emtricitabine, tenofovir disoproxil fumarate"
1,Truvada,"emtricitabine, tenofovir disoproxil fumarate","['infections', 'traitement infection', 'contracter vih-1 sexuellement acquis infection']",Spain - AEMPS,2005-005672-33,"['Estudio randomizado, controlado, abierto, de 48 semanas sobre la continuación']",['PR-0095_01'],['Information not present in EudraCT'],['IATEC B.V.'],['Netherlands'],['Non-Commercial'],"['Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Glaxo Group Ltd', 'Gilead Sciences Intl Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Gilead Sciences Intl Ltd', 'Gilead Sciences Intl Ltd', 'Gilead Sciences Intl Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd']","['Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']",Truvada,"['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Film-coated tablet', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11']",['HIV-1 infection'],['No'],Antiretroviral regimens containing emtricitabine plus tenofovir disoproxil fumarate might be associated with a lower incidence and severity of lipoatrophy. In this study we compare the effect of proactively switching zidovudine and lamivudine to emtricitabine plus tenofovir disoproxil fumarate on peripheral fat loss with continued lamivudine and zidovudine-based treatment in HIV-1 infected adults also receiving a non-nucleoside reverse transcriptase inhibitor or (boosted) protease inhibitor. In the patients who discontinue the use of zidovudine and switch to emtricitabine and tenofovir disoproxil fumarate we expect to demonstrate a regaining or at least a lack of further loss of peripheral adipose tissue. Primary Objective: to compare the changes in limb fat between the 2 study arms.,"['- To compare the changes in other aspects of body fat distribution, i.e. fat loss, fat gain, as well as in markers of lipid and glucose metabolism, between the 2 study arms.']",['Information not present in EudraCT'],['- HIV-1 infected patients.'],['- Prior treatment with an NRTI other than zidovudine or lamivudine.'],['Difference between the continuation arm and the switch arm in changes in limb fat over 48 weeks as measured by whole body DEXA.'],['No'],['Information not present in EudraCT'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['15'],['Authorised'],['2006-09-08'],['2006-07-11'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Ongoing'],"Antiretroviral regimens containing emtricitabine plus tenofovir disoproxil fumarate might be associated with a lower incidence and severity of lipoatrophy. In this study we compare the effect of proactively switching zidovudine and lamivudine to emtricitabine plus tenofovir disoproxil fumarate on peripheral fat loss with continued lamivudine and zidovudine-based treatment in HIV-1 infected adults also receiving a non-nucleoside reverse transcriptase inhibitor or (boosted) protease inhibitor. In the patients who discontinue the use of zidovudine and switch to emtricitabine and tenofovir disoproxil fumarate we expect to demonstrate a regaining or at least a lack of further loss of peripheral adipose tissue. Primary Objective: to compare the changes in limb fat between the 2 study arms.-2005-005672-33-Spain - AEMPS-emtricitabine, tenofovir disoproxil fumarate"
1,Truvada,"emtricitabine, tenofovir disoproxil fumarate","['infections', 'traitement infection', 'contracter vih-1 sexuellement acquis infection']",Finland - Fimea,2005-005672-33,"['A Randomized, Controlled, Open-Label, 48-Week Study of Continuing Successfully Suppressive Treatment in HIV-1 Infected Adults with First-Line Twice-Daily Zidovudine and Lamivudine-Based Regimens versus Proactively Replacing of Zidovudine and Lamivudine by Once-Daily Emtricitabine and Tenofovir Disoproxil Fumarate to Prevent Progression of or Reverse Peripheral Lipoatrophy.']",['PR-0095_01'],['Information not present in EudraCT'],['IATEC B.V.'],['Netherlands'],['Non-Commercial'],"['Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Glaxo Group Ltd', 'Gilead Sciences Intl Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Gilead Sciences Intl Ltd', 'Gilead Sciences Intl Ltd', 'Gilead Sciences Intl Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd']","['Finland', 'Finland', 'Finland', 'Finland', 'Finland', 'Finland', 'Finland', 'Finland', 'Finland', 'Finland', 'Finland']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']",Truvada,"['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Film-coated tablet', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11']",['HIV-1 infection'],['No'],Antiretroviral regimens containing emtricitabine plus tenofovir disoproxil fumarate might be associated with a lower incidence and severity of lipoatrophy. In this study we compare the effect of proactively switching zidovudine and lamivudine to emtricitabine plus tenofovir disoproxil fumarate on peripheral fat loss with continued lamivudine and zidovudine-based treatment in HIV-1 infected adults also receiving a non-nucleoside reverse transcriptase inhibitor or (boosted) protease inhibitor. In the patients who discontinue the use of zidovudine and switch to emtricitabine and tenofovir disoproxil fumarate we expect to demonstrate a regaining or at least a lack of further loss of peripheral adipose tissue. Primary Objective: to compare the changes in limb fat between the 2 study arms.,"['- To compare the changes in other aspects of body fat distribution, i.e. fat loss, fat gain, as well as in markers of lipid and glucose metabolism, between the 2 study arms.']",['Information not present in EudraCT'],['- HIV-1 infected patients.'],['- Prior treatment with an NRTI other than zidovudine or lamivudine.'],['Difference between the continuation arm and the switch arm in changes in limb fat over 48 weeks as measured by whole body DEXA.'],['No'],['Information not present in EudraCT'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['15'],['Authorised'],['2006-08-28'],['2006-08-01'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"Antiretroviral regimens containing emtricitabine plus tenofovir disoproxil fumarate might be associated with a lower incidence and severity of lipoatrophy. In this study we compare the effect of proactively switching zidovudine and lamivudine to emtricitabine plus tenofovir disoproxil fumarate on peripheral fat loss with continued lamivudine and zidovudine-based treatment in HIV-1 infected adults also receiving a non-nucleoside reverse transcriptase inhibitor or (boosted) protease inhibitor. In the patients who discontinue the use of zidovudine and switch to emtricitabine and tenofovir disoproxil fumarate we expect to demonstrate a regaining or at least a lack of further loss of peripheral adipose tissue. Primary Objective: to compare the changes in limb fat between the 2 study arms.-2005-005672-33-Finland - Fimea-emtricitabine, tenofovir disoproxil fumarate"
1,Truvada,"emtricitabine, tenofovir disoproxil fumarate","['infections', 'traitement infection', 'contracter vih-1 sexuellement acquis infection']",UK - MHRA,2010-018878-21,"['A phase III, open-label, single centre, single-arm, pilot study to assess the feasibility of switching, individuals receiving efavirenz with continuing Central Nervous System (CNS) toxicity, to raltegravir']",['SSAT036'],['Information not present in EudraCT'],"[""St Stephen's AIDS Trust""]",['United Kingdom'],['Non-Commercial'],"['Test', 'Test']","['Yes', 'Yes']","['Merck Sharp & Dohme Limited', 'Gilead Sciences Ltd']","['United Kingdom', 'United Kingdom']","['No', 'No']",Truvada,"['Yes', 'Yes']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Film-coated tablet', 'Coated tablet']","['Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2']",['HIV'],['No'],To investigate whether switching individuals who have central nervous system (CNS) side effects from taking Efavirenz-containing treatment (as Atripla) to Truvada/Raltegravir resolves the CNS side effects after 4 weeks,['To investigate whether switching individuals who have central nervous system (CNS) side effects from taking Efavirenz-containing treatment (as Atripla) to Truvada/Raltegravir resolves the CNS side effects after 12 weeks.'],['No'],['Male or female aged 18 years or above'],['is infected with HIV-2'],['The rate of neuropsychiatric and central nervous system (CNS) toxicity as measured (as defined by the ACTG adverse event scale) after 4 weeks of raltegravir therapy as measured by :'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['40'],['Authorised'],['2010-07-05'],['2010-08-16'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To investigate whether switching individuals who have central nervous system (CNS) side effects from taking Efavirenz-containing treatment (as Atripla) to Truvada/Raltegravir resolves the CNS side effects after 4 weeks-2010-018878-21-UK - MHRA-emtricitabine, tenofovir disoproxil fumarate"
0,Helicobacter Test INFAI,urea (13C),"['infections helicobacter helicobacter', 'infection', 'pylori chez adultes', 'pylori']",Czech Republic - SUKL,2006-000789-35,['Two-way Crossover Comparison of the Sensitivity and Specificity of the Modified Helicobacter Test INFAI Using New Test Meal vs. Standard 13C-Urea Breath Test in Helicobacter Pylori Positive and Negative Patients with Dyspepsia Taking Proton Pump Inhibitors'],['HPTM06/J/05'],['Information not present in EudraCT'],['INFAI GmbH'],['Germany'],['Commercial'],['Test'],['No'],['INFAI GmbH'],['European Union'],['No'],Helicobacter Test INFAI,['Yes'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Powder for oral solution'],['Information not present in EudraCT'],['1'],['Diagnosis of Helicobacter pylori infection for patients taking proton pump inhibitors (PPI) without interuption of medication two weeks prior to test.'],['No'],To compare the sensitivity of the 13C-UBT test using the new test meal and the standard test meal for Hp in patients with dyspepsia taking PPI,['To compare the specificity of the 13C-UBT using the new test meal and the standard test meal for Hp patients with dyspepsia taking PPI'],['No'],['- Male and female patients of at least 18 years of age'],['Previous Hp eradication therapy'],"['Patients taking PPI, a positive test remains reliable for detection of Hp but the number of false negative tests risesdramatically reducing the sensitivity of these tests. Clinicians are frequently confronted with making a diagnosis of Hp infection in patients who may knowingly be taking PPI. Currently available breath and stool tests are reliable 12-14 days after discontinuation of PPI.']",['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['105'],['Authorised'],['2006-10-06'],['2006-06-28'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],To compare the sensitivity of the 13C-UBT test using the new test meal and the standard test meal for Hp in patients with dyspepsia taking PPI-2006-000789-35-Czech Republic - SUKL-urea (13C)
0,Metalyse,tenecteplase,['infarctus aigu myocarde'],Austria - BASG,2005-001070-27,"['Open, randomised, monosite pilot trial for comparison of thrombolytic efficacy of tenecteplase and alteplase in patients with acute pulmonary embolism']",['EP-PAE Metalyse'],['Information not present in EudraCT'],['Division of Angiology Graz'],['Austria'],['Non-Commercial'],['Test'],['Information not present in EudraCT'],['Boehringer Ingelheim International'],['Austria'],['No'],Metalyse,['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Powder and solvent for solution for infusion'],['Information not present in EudraCT'],['1'],['Patients with acute pulmonary embolism and indication for thrombolytic therapy are included in the study'],['Yes'],Evaluation of the efficacy of the tested substances by size reduction of pulmonary embolism respectively size reduction of the venous thrombus and recurrence rate,['Evaluation of the safety of the tested substances by occurence of SAEs and SUSARs and severe bleeding complications'],['Information not present in EudraCT'],['1. written Informed Consent'],['1. contraindikation for thrombolytic therapy'],['reduction of the size of pulmonary embolism and venous thrombus measured by magnet resonance phlebography'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['20'],['Authorised'],['2005-07-07'],['2005-07-07'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],Evaluation of the efficacy of the tested substances by size reduction of pulmonary embolism respectively size reduction of the venous thrombus and recurrence rate-2005-001070-27-Austria - BASG-tenecteplase
3,Atriance,nelarabine,['rechuté après traitement moins deux schémas chimiothérapie raison petites'],UK - MHRA,2009-012717-22,['UKALL14 - A randomized trial for adults with newly diagnosed acute lymphoblastic leukemia'],['UCL/08/0167'],['Information not present in EudraCT'],['University College London'],['United Kingdom'],['Non-Commercial'],"['Test', 'Test', 'Test', 'Test', 'Test']","['Yes', 'Yes', 'Yes', 'Yes', 'No']","['Novartis Europharm Limited', 'Biovitrum AB (publ)', 'Baxalta Innovations GmbH', 'Roche Registration GmbH (RRG)']","['European Union', 'Netherlands', 'Portugal', 'United Kingdom']","['Yes', 'No', 'No', 'No', 'No']",Atriance,"['Yes', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'Yes', 'No', 'Yes', 'Yes']","['No', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['Solution for infusion', 'Powder for solution for injection', 'Solution for injection', 'Concentrate for solution for infusion']","['No', 'No', 'No', 'No', 'No']","['1', '2', '3', '4', '5']",['Acute Lymphoblastic Leukemia (ALL)'],['No'],To determine if the addition of monoclonal antibody to standard induction chemotherapy results in improved event free survival in patients with precursor B-cell ALL (aim 1B).,['To determine the tolerability of pegylated asparaginase in induction treatment of all patients (aim 2) and to compare anti-asparaginase antibody levels between patients in the 2 randomisation groups from aim 1B (patients with B lineage ALL only).'],['No'],['1 - Subjects must be aged ≥ 25 and ≤ 65 years old with acute lymphoblastic leukaemia OR ≥ 19 and ≤ 65 years old with Philadelphia Chromosome positive acute lymphoblastic leukaemia.'],['1 - Known HIV infection'],['- Event free survival (applies to all interventions)'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['811'],['Authorised'],['2010-01-13'],['2010-01-13'],['Reason(s) for unfavourable opinion:'],['Favourable'],['GB - no longer in EU/EEA'],To determine if the addition of monoclonal antibody to standard induction chemotherapy results in improved event free survival in patients with precursor B-cell ALL (aim 1B).-2009-012717-22-UK - MHRA-nelarabine
0,Aclasta,zoledronic acid,"['hanche', 'traitement maladie osseuse paget']",Germany - BfArM,2010-019110-24,"['A PHASE 2, SINGLE-CENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF ZOLEDRONATE IN SUBJECTS WITH EROSIVE HAND OSTEOARTHRITIS']",['CZOL446HDE43T'],['Information not present in EudraCT'],['Universitätsklinikum Erlangen'],['Germany'],['Non-Commercial'],['Test'],['Yes'],['Novartis'],['European Union'],['No'],Aclasta,['Yes'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Solution for infusion'],['Information not present in EudraCT'],['1'],['Erosive hand osteoarthritis'],['No'],"To evaluate the 90-day symptomatic efficacy of a single dose zoledronate (Aclasta ®) 5 mg IV, compared with placebo, for the treatment of erosive hand osteoarthritis","['• To determine the effect of a single dose zoledronate (Aclasta ®) 5 mg IV, compared with placebo, on pain and function in patients with erosive hand osteoarthritis']",['No'],['1.\t1.\tMust understand and voluntarily sign an informed consent form'],['1.\t1.\tHistory of malignancy within the previous 5 years'],['Proportion of subjects in each treatment group who achieve a 50% improvement in Australian/Canadian hand arthrosis pain scale (AUSCAN) Index at Day 90 compared with baseline.'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['70'],['Authorised'],['2010-12-27'],['2010-10-27'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Prematurely Ended'],"To evaluate the 90-day symptomatic efficacy of a single dose zoledronate (Aclasta ®) 5 mg IV, compared with placebo, for the treatment of erosive hand osteoarthritis-2010-019110-24-Germany - BfArM-zoledronic acid"
0,Toviaz,fesoterodine fumarate,['vessie urinaire hyperactive traitement symptômes augmentation fréquence urinaire impériosité incontinence'],UK - MHRA,2008-004124-23,"['A 12 week, multicentre, open label study to evaluate the efficacy, tolerability and safety of a Fesoterodine flexible dose regimen in patients with overactive bladder']",['A0221058'],['Information not present in EudraCT'],['Pfizer Limited'],['United Kingdom'],['Commercial'],"['Test', 'Test']","['Yes', 'Yes']","['Pfizer Limited', 'Pfizer Limited']","['European Union', 'European Union']","['No', 'No']",Toviaz,"['Yes', 'Yes']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Prolonged-release tablet', 'Prolonged-release tablet']","['Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2']",['Treatment of the symptoms (increased urinary frequency and/or urgency and/or urgency incontinence) that may occur in patients with overactive bladder syndrome.'],['No'],"The primary objective is to demonstrate the efficacy, in terms of reduction of icturations, of 12 weeks flexible dose fesoterodine in subjects with OAB compared to baseline.",['To assess the use of flexible dosing of fesoterodine on other bladder diary variables after 4 and 12 weeks compared to baseline.'],['No'],['Subjects must meet all of the following inclusion criteria to be eligible for enrolment into the trial:'],"['1.Any condition that would contraindicate the usage of fesoterodine including, but not limited to: hypersensitivity to the active substance (fesoterodine fumarate) or any of the excipients, or to peanut or soya; urinary retention; gastric retention; uncontrolled narrow angle glaucoma; myasthenia gravis; moderate or severe hepatic impairment (Child Pugh C); severe renal impairment; severe ulcerative colitis, and toxic megacolon.']",['Change in mean number of micturitions per 24 hours at Week 12 relative to baseline.'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['326'],['Authorised'],['2008-12-08'],['2009-01-29'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"The primary objective is to demonstrate the efficacy, in terms of reduction of icturations, of 12 weeks flexible dose fesoterodine in subjects with OAB compared to baseline.-2008-004124-23-UK - MHRA-fesoterodine fumarate"
0,Protopic,tacrolimus,['réponse initiale traitement durée maximale six semaines pommade tacrolimus deux fois jour lésions guéries presque guéries légèrement'],UK - MHRA,2004-004467-29,['An open label pilot study to evaluate the efficacy and safety of topical tacrolimus 0l1% (Protopic) in the treatment of varicose eczema'],,['Information not present in EudraCT'],['Craigavon Area Hospital Group Trust'],['United Kingdom'],['Non-Commercial'],['Test'],['Information not present in EudraCT'],['Fujisawa Ltd (being amended to Astellas Pharma Ltd)'],['United Kingdom'],['No'],Protopic,['Yes'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Ointment'],['Information not present in EudraCT'],['1'],['Varicose eczema'],['No'],To evaluate the effeicacy of tacrolimus ointment 0.1% in the treatment of varicose eczema.,['To evaluate the safety of tacrolimus ointment 0.1% in the treatment of varicose eczema'],['Information not present in EudraCT'],['Written informed consent'],['Patients with any other skin disease that may interfere with disease assessments.'],['The primary endpoint will be the difference between baseline and study completion with respect to number of active lesions.  This will be measured by:'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['12'],['Authorised'],['2004-12-30'],['2005-07-27'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],To evaluate the effeicacy of tacrolimus ointment 0.1% in the treatment of varicose eczema.-2004-004467-29-UK - MHRA-tacrolimus
1,Viread,tenofovir disoproxil fumarate,"['infections', 'infection', 'infection', 'compensée signes maladie immunitaire active est-à-dire réplication virale active taux sériques alt élevés manière persistante signes histologiques modéré inflammation sévère fibrose concernant décision instauration traitement chez', 'infection', 'infection', 'compensée preuves maladie immunitaire active est-à-dire réplication virale active taux sériques alt élevés manière persistante preuves histologiques inflammation fibrose modérée sévère concernant décision instauration traitement chez', 'infection', 'infection', 'compensée preuves maladie immunitaire active est-à-dire réplication virale active taux sériques alt élevés manière persistante preuves histologiques inflammation fibrose', 'infection', 'infection', 'compensée signes réplication', 'inflammation', 'compensée signes maladie immunitaire active est-à-dire réplication virale active taux sériques alt élevés manière persistante signes histologiques inflammation fibrose']",UK - MHRA,2005-005672-33,"['A Randomized, Controlled, Open-Label, 48-Week Study of Continuing Successfully Suppressive Treatment in HIV-1 Infected Adults with First-Line Twice-Daily Zidovudine and Lamivudine-Based Regimens versus Proactively Replacing of Zidovudine and Lamivudine by Once-Daily Emtricitabine and Tenofovir Disoproxil Fumarate to Prevent Progression of or Reverse Peripheral Lipoatrophy.']",['PR-0095_01'],['Information not present in EudraCT'],['IATEC B.V.'],['Netherlands'],['Non-Commercial'],"['Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Glaxo Group Ltd', 'Gilead Sciences Intl Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Gilead Sciences Intl Ltd', 'Gilead Sciences Intl Ltd', 'Gilead Sciences Intl Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd']","['United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']",Viread,"['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Film-coated tablet', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11']",['HIV-1 infection'],['No'],Antiretroviral regimens containing emtricitabine plus tenofovir disoproxil fumarate might be associated with a lower incidence and severity of lipoatrophy. In this study we compare the effect of proactively switching zidovudine and lamivudine to emtricitabine plus tenofovir disoproxil fumarate on peripheral fat loss with continued lamivudine and zidovudine-based treatment in HIV-1 infected adults also receiving a non-nucleoside reverse transcriptase inhibitor or (boosted) protease inhibitor. In the patients who discontinue the use of zidovudine and switch to emtricitabine and tenofovir disoproxil fumarate we expect to demonstrate a regaining or at least a lack of further loss of peripheral adipose tissue. Primary Objective: to compare the changes in limb fat between the 2 study arms.,"['- To compare the changes in other aspects of body fat distribution, i.e. fat loss, fat gain, as well as in markers of lipid and glucose metabolism, between the 2 study arms.']",['Information not present in EudraCT'],['- HIV-1 infected patients.'],['- Prior treatment with an NRTI other than zidovudine or lamivudine.'],['Difference between the continuation arm and the switch arm in changes in limb fat over 48 weeks as measured by whole body DEXA.'],['No'],['Information not present in EudraCT'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['15'],['Authorised'],['2006-04-01'],['2006-07-26'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],Antiretroviral regimens containing emtricitabine plus tenofovir disoproxil fumarate might be associated with a lower incidence and severity of lipoatrophy. In this study we compare the effect of proactively switching zidovudine and lamivudine to emtricitabine plus tenofovir disoproxil fumarate on peripheral fat loss with continued lamivudine and zidovudine-based treatment in HIV-1 infected adults also receiving a non-nucleoside reverse transcriptase inhibitor or (boosted) protease inhibitor. In the patients who discontinue the use of zidovudine and switch to emtricitabine and tenofovir disoproxil fumarate we expect to demonstrate a regaining or at least a lack of further loss of peripheral adipose tissue. Primary Objective: to compare the changes in limb fat between the 2 study arms.-2005-005672-33-UK - MHRA-tenofovir disoproxil fumarate
1,Viread,tenofovir disoproxil fumarate,"['infections', 'infection', 'infection', 'compensée signes maladie immunitaire active est-à-dire réplication virale active taux sériques alt élevés manière persistante signes histologiques modéré inflammation sévère fibrose concernant décision instauration traitement chez', 'infection', 'infection', 'compensée preuves maladie immunitaire active est-à-dire réplication virale active taux sériques alt élevés manière persistante preuves histologiques inflammation fibrose modérée sévère concernant décision instauration traitement chez', 'infection', 'infection', 'compensée preuves maladie immunitaire active est-à-dire réplication virale active taux sériques alt élevés manière persistante preuves histologiques inflammation fibrose', 'infection', 'infection', 'compensée signes réplication', 'inflammation', 'compensée signes maladie immunitaire active est-à-dire réplication virale active taux sériques alt élevés manière persistante signes histologiques inflammation fibrose']",Spain - AEMPS,2005-005672-33,"['Estudio randomizado, controlado, abierto, de 48 semanas sobre la continuación']",['PR-0095_01'],['Information not present in EudraCT'],['IATEC B.V.'],['Netherlands'],['Non-Commercial'],"['Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Glaxo Group Ltd', 'Gilead Sciences Intl Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Gilead Sciences Intl Ltd', 'Gilead Sciences Intl Ltd', 'Gilead Sciences Intl Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd']","['Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']",Viread,"['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Film-coated tablet', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11']",['HIV-1 infection'],['No'],Antiretroviral regimens containing emtricitabine plus tenofovir disoproxil fumarate might be associated with a lower incidence and severity of lipoatrophy. In this study we compare the effect of proactively switching zidovudine and lamivudine to emtricitabine plus tenofovir disoproxil fumarate on peripheral fat loss with continued lamivudine and zidovudine-based treatment in HIV-1 infected adults also receiving a non-nucleoside reverse transcriptase inhibitor or (boosted) protease inhibitor. In the patients who discontinue the use of zidovudine and switch to emtricitabine and tenofovir disoproxil fumarate we expect to demonstrate a regaining or at least a lack of further loss of peripheral adipose tissue. Primary Objective: to compare the changes in limb fat between the 2 study arms.,"['- To compare the changes in other aspects of body fat distribution, i.e. fat loss, fat gain, as well as in markers of lipid and glucose metabolism, between the 2 study arms.']",['Information not present in EudraCT'],['- HIV-1 infected patients.'],['- Prior treatment with an NRTI other than zidovudine or lamivudine.'],['Difference between the continuation arm and the switch arm in changes in limb fat over 48 weeks as measured by whole body DEXA.'],['No'],['Information not present in EudraCT'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['15'],['Authorised'],['2006-09-08'],['2006-07-11'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Ongoing'],Antiretroviral regimens containing emtricitabine plus tenofovir disoproxil fumarate might be associated with a lower incidence and severity of lipoatrophy. In this study we compare the effect of proactively switching zidovudine and lamivudine to emtricitabine plus tenofovir disoproxil fumarate on peripheral fat loss with continued lamivudine and zidovudine-based treatment in HIV-1 infected adults also receiving a non-nucleoside reverse transcriptase inhibitor or (boosted) protease inhibitor. In the patients who discontinue the use of zidovudine and switch to emtricitabine and tenofovir disoproxil fumarate we expect to demonstrate a regaining or at least a lack of further loss of peripheral adipose tissue. Primary Objective: to compare the changes in limb fat between the 2 study arms.-2005-005672-33-Spain - AEMPS-tenofovir disoproxil fumarate
1,Viread,tenofovir disoproxil fumarate,"['infections', 'infection', 'infection', 'compensée signes maladie immunitaire active est-à-dire réplication virale active taux sériques alt élevés manière persistante signes histologiques modéré inflammation sévère fibrose concernant décision instauration traitement chez', 'infection', 'infection', 'compensée preuves maladie immunitaire active est-à-dire réplication virale active taux sériques alt élevés manière persistante preuves histologiques inflammation fibrose modérée sévère concernant décision instauration traitement chez', 'infection', 'infection', 'compensée preuves maladie immunitaire active est-à-dire réplication virale active taux sériques alt élevés manière persistante preuves histologiques inflammation fibrose', 'infection', 'infection', 'compensée signes réplication', 'inflammation', 'compensée signes maladie immunitaire active est-à-dire réplication virale active taux sériques alt élevés manière persistante signes histologiques inflammation fibrose']",Finland - Fimea,2005-005672-33,"['A Randomized, Controlled, Open-Label, 48-Week Study of Continuing Successfully Suppressive Treatment in HIV-1 Infected Adults with First-Line Twice-Daily Zidovudine and Lamivudine-Based Regimens versus Proactively Replacing of Zidovudine and Lamivudine by Once-Daily Emtricitabine and Tenofovir Disoproxil Fumarate to Prevent Progression of or Reverse Peripheral Lipoatrophy.']",['PR-0095_01'],['Information not present in EudraCT'],['IATEC B.V.'],['Netherlands'],['Non-Commercial'],"['Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Glaxo Group Ltd', 'Gilead Sciences Intl Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Gilead Sciences Intl Ltd', 'Gilead Sciences Intl Ltd', 'Gilead Sciences Intl Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd']","['Finland', 'Finland', 'Finland', 'Finland', 'Finland', 'Finland', 'Finland', 'Finland', 'Finland', 'Finland', 'Finland']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']",Viread,"['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Film-coated tablet', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11']",['HIV-1 infection'],['No'],Antiretroviral regimens containing emtricitabine plus tenofovir disoproxil fumarate might be associated with a lower incidence and severity of lipoatrophy. In this study we compare the effect of proactively switching zidovudine and lamivudine to emtricitabine plus tenofovir disoproxil fumarate on peripheral fat loss with continued lamivudine and zidovudine-based treatment in HIV-1 infected adults also receiving a non-nucleoside reverse transcriptase inhibitor or (boosted) protease inhibitor. In the patients who discontinue the use of zidovudine and switch to emtricitabine and tenofovir disoproxil fumarate we expect to demonstrate a regaining or at least a lack of further loss of peripheral adipose tissue. Primary Objective: to compare the changes in limb fat between the 2 study arms.,"['- To compare the changes in other aspects of body fat distribution, i.e. fat loss, fat gain, as well as in markers of lipid and glucose metabolism, between the 2 study arms.']",['Information not present in EudraCT'],['- HIV-1 infected patients.'],['- Prior treatment with an NRTI other than zidovudine or lamivudine.'],['Difference between the continuation arm and the switch arm in changes in limb fat over 48 weeks as measured by whole body DEXA.'],['No'],['Information not present in EudraCT'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['15'],['Authorised'],['2006-08-28'],['2006-08-01'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],Antiretroviral regimens containing emtricitabine plus tenofovir disoproxil fumarate might be associated with a lower incidence and severity of lipoatrophy. In this study we compare the effect of proactively switching zidovudine and lamivudine to emtricitabine plus tenofovir disoproxil fumarate on peripheral fat loss with continued lamivudine and zidovudine-based treatment in HIV-1 infected adults also receiving a non-nucleoside reverse transcriptase inhibitor or (boosted) protease inhibitor. In the patients who discontinue the use of zidovudine and switch to emtricitabine and tenofovir disoproxil fumarate we expect to demonstrate a regaining or at least a lack of further loss of peripheral adipose tissue. Primary Objective: to compare the changes in limb fat between the 2 study arms.-2005-005672-33-Finland - Fimea-tenofovir disoproxil fumarate
1,Viread,tenofovir disoproxil fumarate,"['infections', 'infection', 'infection', 'compensée signes maladie immunitaire active est-à-dire réplication virale active taux sériques alt élevés manière persistante signes histologiques modéré inflammation sévère fibrose concernant décision instauration traitement chez', 'infection', 'infection', 'compensée preuves maladie immunitaire active est-à-dire réplication virale active taux sériques alt élevés manière persistante preuves histologiques inflammation fibrose modérée sévère concernant décision instauration traitement chez', 'infection', 'infection', 'compensée preuves maladie immunitaire active est-à-dire réplication virale active taux sériques alt élevés manière persistante preuves histologiques inflammation fibrose', 'infection', 'infection', 'compensée signes réplication', 'inflammation', 'compensée signes maladie immunitaire active est-à-dire réplication virale active taux sériques alt élevés manière persistante signes histologiques inflammation fibrose']",Italy - Italian Medicines Agency,2016-002413-22,"['Open label, Randomized (1:1), clinical trial to evaluate switching from dual regimens based on Dolutegravir plus a reverse transcriptase inhibitor to  elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in virologically suppressed, HIV-1 infected patients.']",['Be-OnE1/08-03-2016'],['No'],['OSPEDALE SAN RAFFAELE'],['Italy'],['Non-Commercial'],"['Test', 'Test', 'Comparator', 'Comparator', 'Comparator', 'Comparator', 'Comparator', 'Comparator', 'Comparator', 'Comparator']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['Gilead Sciences Int. Ltd', 'VIIV HEALTHCARE UK LTD', 'GILEAD SCIENCE INTERNATIONAL LIMITED', 'MYLAN S.P.A.', 'GILEAD SCIENCE INTERNATIONAL LIMITED', 'GLAXO GROUP LIMITED', 'JANSSEN-CILAG INTERNATIONAL N.V.', 'JANSSEN-CILAG INTERNATIONAL N.V.', 'BRISTOL-MYERS SQUIBB PHARMA EEIG', 'BOEHRINGER INGELHEIM INTERNATIONAL GMBH']","['Ireland', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']",Viread,"['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'No', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'No', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Film-coated tablet', 'Film-coated tablet', 'Capsule, hard', 'Film-coated tablet', 'Film-coated tablet', 'Film-coated tablet', 'Tablet', 'Tablet', 'Tablet', 'Prolonged-release tablet']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['1', '2', '3', '4', '5', '6', '7', '8', '9', '10']",['HIV infection'],['No'],To investigate Residual Viremia  through 48 weeks in virologically suppressed patients randomized to continue treatment with Dolutegravir plus a single RTI or to switch to E/C/F/TAF.,['Secondary Objectives'],['No'],['1.\tAge >18  years'],['1.\tActive AIDS-defining condition (except Kaposi’s sarcoma non requiring systemic chemotherapy)'],['Proportion of subjects without Residual Viremia  through 48 weeks of follow-up.'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['100'],['Authorised'],['2016-10-31'],['2016-07-14'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Prematurely Ended'],To investigate Residual Viremia  through 48 weeks in virologically suppressed patients randomized to continue treatment with Dolutegravir plus a single RTI or to switch to E/C/F/TAF.-2016-002413-22-Italy - Italian Medicines Agency-tenofovir disoproxil fumarate
0,Dificlir,fidaxomicin,"['également connues sous nom diarrhée associée difficile madc chez patients adultes pédiatriques pesant moins', 'également connues sous nom diarrhée associée difficile madc chez adultes']",Germany - BfArM,2013-000508-40,"['A Phase 3, Multicenter, Investigator-blind, Randomized, Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h, and Vancomycin Oral Liquid or Capsules Taken q6h, for 10 Days in Pediatric Subjects with Clostridium difficile-associated Diarrhea']",['2819-CL-0202'],['Yes'],['Astellas Pharma Europe B.V.'],['Netherlands'],['Commercial'],"['Test', 'Test', 'Comparator', 'Comparator']","['No', 'Yes', 'Yes', 'Yes']","['Astellas Pharma Europe B.V.', 'Hospira SpA', 'Xellia Pharmaceutica ApS']","['European Union', 'Italy', 'United Kingdom']","['No', 'No', 'No', 'No']",Dificlir,"['Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Granules for oral suspension', 'Film-coated tablet', 'Powder for oral solution', 'Capsule, hard']","['Yes', 'No', 'No', 'No']","['1', '2', '3', '4']",['Treatment of enterocolitis caused by Clostridium difficile'],['No'],The primary objective of this study is to investigate the clinical response to fidaxomicin oral suspension or tablets and vancomycin oral liquid or capsules of pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) aged ≥ 6 months to < 18 years.,"['The secondary objectives of this study are to investigate the recurrence/sustained clinical response to and safety of fidaxomicin and vancomycin in pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) aged ≥ 6 months to < 18 years, as well as acceptance of the fidaxomicin oral suspension formulation.']",['No'],"['1. Institutional Review Board (IRB)-/Independent Ethics Committee (IEC)-approved written Informed Consent/ assent ( if applicable) and privacy language as per national regulations (e.g., HIPAA Authorization for U.S. sites) must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).']","['1. Concurrent use of metronidazole, oral vancomycin or any other antibiotic treatments for CDAD. If the investigator feels the clinical imperative is to begin treatment before knowing the laboratory result for toxigenic C. difficile, up to four doses but no more than 24 hours of treatment with metronidazole, oral vancomycin or any other effective treatment for CDAD are allowed.']",['Confirmed clinical response based on the assessment by the investigator at EOT+2 days TC/visit'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['14'],['Authorised'],['2014-10-24'],['2014-11-18'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],The primary objective of this study is to investigate the clinical response to fidaxomicin oral suspension or tablets and vancomycin oral liquid or capsules of pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) aged ≥ 6 months to < 18 years.-2013-000508-40-Germany - BfArM-fidaxomicin
0,Dificlir,fidaxomicin,"['également connues sous nom diarrhée associée difficile madc chez patients adultes pédiatriques pesant moins', 'également connues sous nom diarrhée associée difficile madc chez adultes']",Belgium - FPS Health-DGM,2013-000508-40,"['A Phase 3, Multicenter, Investigator-blind, Randomized, Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h, and Vancomycin Oral Liquid or Capsules Taken q6h, for 10 Days in Pediatric Subjects with Clostridium difficile-associated Diarrhea']",['2819-CL-0202'],['Yes'],['Astellas Pharma Europe B.V.'],['Netherlands'],['Commercial'],"['Test', 'Test', 'Comparator', 'Comparator']","['No', 'Yes', 'Yes', 'Yes']","['Astellas Pharma Europe B.V.', 'Hospira SpA', 'Xellia Pharmaceutica ApS']","['European Union', 'Italy', 'United Kingdom']","['No', 'No', 'No', 'No']",Dificlir,"['Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Granules for oral suspension', 'Tablet', 'Powder for oral solution', 'Capsule']","['Yes', 'No', 'No', 'No']","['1', '2', '3', '4']",['Treatment of enterocolitis caused by Clostridium difficile'],['No'],The primary objective of this study is to investigate the clinical response to fidaxomicin oral suspension or tablets and vancomycin oral liquid or capsules of pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) from birth to < 18 years of age.,"['The secondary objectives of this study are to investigate the recurrence/sustained clinical response to and safety of fidaxomicin and vancomycin in pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) from birth to < 18 years of age, as well as acceptance of the fidaxomicin oral suspension formulation.']",['No'],"['1. Institutional Review Board (IRB)-/Independent Ethics Committee (IEC)-approved written Informed Consent/ assent ( if applicable) and privacy language as per national regulations (e.g., HIPAA Authorization for U.S. sites) must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).']","['1. Concurrent use of metronidazole, oral vancomycin or any other antibiotic treatments for CDAD. If the investigator feels the clinical imperative is to begin treatment before knowing the laboratory result for toxigenic C. difficile, up to four doses but no more than 24 hours of treatment with metronidazole, oral vancomycin or any other effective treatment for CDAD are allowed.']",['Confirmed clinical response based on the assessment by the investigator at EOT+2 days TC/visit'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],,['Authorised'],['2014-09-03'],['2014-09-29'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],The primary objective of this study is to investigate the clinical response to fidaxomicin oral suspension or tablets and vancomycin oral liquid or capsules of pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) from birth to < 18 years of age.-2013-000508-40-Belgium - FPS Health-DGM-fidaxomicin
0,Dificlir,fidaxomicin,"['également connues sous nom diarrhée associée difficile madc chez patients adultes pédiatriques pesant moins', 'également connues sous nom diarrhée associée difficile madc chez adultes']",Slovakia - SIDC (Slovak),2013-000508-40,"['A Phase 3, Multicenter, Investigator-blind, Randomized, Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h, and Vancomycin Oral Liquid or Capsules Taken q6h, for 10 Days in Pediatric Subjects with Clostridium difficile-associated Diarrhea']",['2819-CL-0202'],['Yes'],['Astellas Pharma Europe B.V.'],['Netherlands'],['Commercial'],"['Test', 'Test', 'Comparator', 'Comparator']","['No', 'Yes', 'Yes', 'Yes']","['Astellas Pharma Europe B.V.', 'Hospira SpA', 'Xellia Pharmaceutica ApS']","['European Union', 'Italy', 'United Kingdom']","['No', 'No', 'No', 'No']",Dificlir,"['Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Granules for oral suspension', 'Tablet', 'Powder for oral solution', 'Capsule']","['Yes', 'No', 'No', 'No']","['1', '2', '3', '4']",['Treatment of enterocolitis caused by Clostridium difficile'],['No'],The primary objective of this study is to investigate the clinical response to fidaxomicin oral suspension or tablets and vancomycin oral liquid or capsules of pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) from birth to < 18 years of age.,"['The secondary objectives of this study are to investigate the recurrence/sustained clinical response to and safety of fidaxomicin and vancomycin in pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) from birth to < 18 years of age, as well as acceptance of the fidaxomicin oral suspension formulation.']",['No'],"['1. Institutional Review Board (IRB)-/Independent Ethics Committee (IEC)-approved written Informed Consent/ assent ( if applicable) and privacy language as per national regulations (e.g., HIPAA Authorization for U.S. sites) must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).']","['1. Concurrent use of metronidazole, oral vancomycin or any other antibiotic treatments for CDAD. If the investigator feels the clinical imperative is to begin treatment before knowing the laboratory result for toxigenic C. difficile, up to four doses but no more than 24 hours of treatment with metronidazole, oral vancomycin or any other effective treatment for CDAD are allowed.']",['Confirmed clinical response based on the assessment by the investigator at EOT+2 days TC/visit'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['4'],['Authorised'],['2014-11-13'],['2014-09-09'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],The primary objective of this study is to investigate the clinical response to fidaxomicin oral suspension or tablets and vancomycin oral liquid or capsules of pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) from birth to < 18 years of age.-2013-000508-40-Slovakia - SIDC (Slovak)-fidaxomicin
0,Dificlir,fidaxomicin,"['également connues sous nom diarrhée associée difficile madc chez patients adultes pédiatriques pesant moins', 'également connues sous nom diarrhée associée difficile madc chez adultes']",Poland - Office for Medicinal Products,2013-000508-40,"['A Phase 3, Multicenter, Investigator-blind, Randomized, Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h, and Vancomycin Oral Liquid or Capsules Taken q6h, for 10 Days in Pediatric Subjects with Clostridium difficile-associated Diarrhea']",['2819-CL-0202'],['Yes'],['Astellas Pharma Europe B.V.'],['Netherlands'],['Commercial'],"['Test', 'Test', 'Comparator', 'Comparator']","['No', 'Yes', 'Yes', 'Yes']","['Astellas Pharma Europe B.V.', 'Hospira SpA', 'Xellia Pharmaceutica ApS']","['European Union', 'Italy', 'United Kingdom']","['No', 'No', 'No', 'No']",Dificlir,"['Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Granules for oral suspension', 'Film-coated tablet', 'Powder for oral solution', 'Capsule, hard']","['Yes', 'No', 'No', 'No']","['1', '2', '3', '4']",['Treatment of enterocolitis caused by Clostridium difficile'],['No'],The primary objective of this study is to investigate the clinical response to fidaxomicin oral suspension or tablets and vancomycin oral liquid or capsules of pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) from birth to < 18 years of age.,"['The secondary objectives of this study are to investigate the recurrence/sustained clinical response to and safety of fidaxomicin and vancomycin in pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) from birth to < 18 years of age, as well as acceptance of the fidaxomicin oral suspension formulation.']",['No'],"['1. Institutional Review Board (IRB)-/Independent Ethics Committee (IEC)-approved written Informed Consent/ assent ( if applicable) and privacy language as per national regulations (e.g., HIPAA Authorization for U.S. sites) must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).']","['1. Concurrent use of metronidazole, oral vancomycin or any other antibiotic treatments for CDAD. If the investigator feels the clinical imperative is to begin treatment before knowing the laboratory result for toxigenic C. difficile, up to four doses but no more than 24 hours of treatment with metronidazole, oral vancomycin or any other effective treatment for CDAD are allowed.']",['Confirmed clinical response based on the assessment by the investigator at EOT+2 days TC/visit'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['12'],['Authorised'],['2014-10-29'],,['Reason(s) for unfavourable opinion:'],,['Completed'],The primary objective of this study is to investigate the clinical response to fidaxomicin oral suspension or tablets and vancomycin oral liquid or capsules of pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) from birth to < 18 years of age.-2013-000508-40-Poland - Office for Medicinal Products-fidaxomicin
0,Dificlir,fidaxomicin,"['également connues sous nom diarrhée associée difficile madc chez patients adultes pédiatriques pesant moins', 'également connues sous nom diarrhée associée difficile madc chez adultes']",Italy - Italian Medicines Agency,2013-000508-40,"['A Phase 3, Multicenter, Investigator-blind, Randomized, Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h, and Vancomycin Oral Liquid or Capsules Taken q6h, for 10 Days in Pediatric Subjects with Clostridium difficile-associated Diarrhea']",['2819-CL-0202'],['Yes'],['Astellas Pharma Europe B.V.'],['Netherlands'],['Commercial'],"['Test', 'Test', 'Comparator', 'Comparator']","['No', 'Yes', 'Yes', 'Yes']","['Astellas Pharma Europe B.V.', 'Hospira SpA', 'Xellia Pharmaceutica ApS']","['European Union', 'Italy', 'United Kingdom']","['No', 'No', 'No', 'No']",Dificlir,"['Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Granules for oral suspension', 'Film-coated tablet', 'Powder for oral solution', 'Capsule, hard']","['Yes', 'No', 'No', 'No']","['1', '2', '3', '4']",['Treatment of enterocolitis caused by Clostridium difficile'],['No'],The primary objective of this study is to investigate the clinical response to fidaxomicin oral suspension or tablets and vancomycin oral liquid or capsules of pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) aged ≥ 6 months to < 18 years.,"['The secondary objectives of this study are to investigate the recurrence/sustained clinical response to and safety of fidaxomicin and vancomycin in pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) aged ≥ 6 months to < 18 years, as well as acceptance of the fidaxomicin oral suspension formulation.']",['No'],"['1. Institutional Review Board (IRB)-/Independent Ethics Committee (IEC)-approved written Informed Consent/ assent ( if applicable) and privacy language as per national regulations (e.g., HIPAA Authorization for U.S. sites) must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).']","['1. Concurrent use of metronidazole, oral vancomycin or any other antibiotic treatments for CDAD. If the investigator feels the clinical imperative is to begin treatment before knowing the laboratory result for toxigenic C. difficile, up to four doses but no more than 24 hours of treatment with metronidazole, oral vancomycin or any other effective treatment for CDAD are allowed.']",['Confirmed clinical response based on the assessment by the investigator at EOT+2 days TC/visit'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['8'],['Authorised'],['2014-10-29'],['2014-12-03'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],The primary objective of this study is to investigate the clinical response to fidaxomicin oral suspension or tablets and vancomycin oral liquid or capsules of pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) aged ≥ 6 months to < 18 years.-2013-000508-40-Italy - Italian Medicines Agency-fidaxomicin
0,Dificlir,fidaxomicin,"['également connues sous nom diarrhée associée difficile madc chez patients adultes pédiatriques pesant moins', 'également connues sous nom diarrhée associée difficile madc chez adultes']",Spain - AEMPS,2013-000508-40,"['A Phase 3, Multicenter, Investigator-blind, Randomized, Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h, and Vancomycin Oral Liquid or Capsules Taken q6h, for 10 Days in Pediatric Subjects with Clostridium difficile-associated Diarrhea']",['2819-CL-0202'],['Yes'],['Astellas Pharma Europe B.V.'],['Netherlands'],['Commercial'],"['Test', 'Test', 'Comparator', 'Comparator']","['No', 'Yes', 'Yes', 'Yes']","['Astellas Pharma Europe B.V.', 'Hospira SpA', 'Xellia Pharmaceutica ApS']","['European Union', 'Italy', 'United Kingdom']","['No', 'No', 'No', 'No']",Dificlir,"['Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Granules for oral suspension', 'Film-coated tablet', 'Powder for oral solution', 'Capsule, hard']","['Yes', 'No', 'No', 'No']","['1', '2', '3', '4']",['Treatment of enterocolitis caused by Clostridium difficile'],['No'],The primary objective of this study is to investigate the clinical response to fidaxomicin oral suspension or tablets and vancomycin oral liquid or capsules of pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) aged ? 6 months to < 18 years.,"['The secondary objectives of this study are to investigate the recurrence/sustained clinical response to and safety of fidaxomicin and vancomycin in pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) aged ? 6 months to < 18 years, as well as acceptance of the fidaxomicin oral suspension formulation.']",['No'],"['1. Institutional Review Board (IRB)-/Independent Ethics Committee (IEC)-approved written Informed Consent/ assent ( if applicable) and privacy language as per national regulations (e.g., HIPAA Authorization for U.S. sites) must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).']","['1. Concurrent use of metronidazole, oral vancomycin or any other antibiotic treatments for CDAD. If the investigator feels the clinical imperative is to begin treatment before knowing the laboratory result for toxigenic C. difficile, up to four doses but no more than 24 hours of treatment with metronidazole, oral vancomycin or any other effective treatment for CDAD are allowed.']",['Confirmed clinical response based on the assessment by the investigator at EOT+2 days TC/visit'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['10'],['Authorised'],['2014-12-09'],['2014-11-14'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],The primary objective of this study is to investigate the clinical response to fidaxomicin oral suspension or tablets and vancomycin oral liquid or capsules of pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) aged ? 6 months to < 18 years.-2013-000508-40-Spain - AEMPS-fidaxomicin
0,Dificlir,fidaxomicin,"['également connues sous nom diarrhée associée difficile madc chez patients adultes pédiatriques pesant moins', 'également connues sous nom diarrhée associée difficile madc chez adultes']",Hungary - National Institute of Pharmacy,2013-000508-40,"['A Phase 3, Multicenter, Investigator-blind, Randomized, Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h, and Vancomycin Oral Liquid or Capsules Taken q6h, for 10 Days in Pediatric Subjects with Clostridium difficile-associated Diarrhea']",['2819-CL-0202'],['Yes'],['Astellas Pharma Europe B.V.'],['Netherlands'],['Commercial'],"['Test', 'Test', 'Comparator', 'Comparator']","['No', 'Yes', 'Yes', 'Yes']","['Astellas Pharma Europe B.V.', 'Hospira SpA', 'Xellia Pharmaceutica ApS']","['European Union', 'Italy', 'United Kingdom']","['No', 'No', 'No', 'No']",Dificlir,"['Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Granules for oral suspension', 'Tablet', 'Powder for oral solution', 'Capsule']","['Yes', 'No', 'No', 'No']","['1', '2', '3', '4']",['Treatment of enterocolitis caused by Clostridium difficile'],['No'],The primary objective of this study is to investigate the clinical response to fidaxomicin oral suspension or tablets and vancomycin oral liquid or capsules of pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) from birth to < 18 years of age.,"['The secondary objectives of this study are to investigate the recurrence/sustained clinical response to and safety of fidaxomicin and vancomycin in pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) from birth to < 18 years of age, as well as acceptance of the fidaxomicin oral suspension formulation.']",['No'],"['1. Institutional Review Board (IRB)-/Independent Ethics Committee (IEC)-approved written Informed Consent/ assent ( if applicable) and privacy language as per national regulations (e.g., HIPAA Authorization for U.S. sites) must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).']","['1. Concurrent use of metronidazole, oral vancomycin or any other antibiotic treatments for CDAD. If the investigator feels the clinical imperative is to begin treatment before knowing the laboratory result for toxigenic C. difficile, up to four doses but no more than 24 hours of treatment with metronidazole, oral vancomycin or any other effective treatment for CDAD are allowed.']",['Confirmed clinical response based on the assessment by the investigator at EOT+2 days TC/visit'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['10'],['Authorised'],['2014-09-30'],['2014-09-15'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],The primary objective of this study is to investigate the clinical response to fidaxomicin oral suspension or tablets and vancomycin oral liquid or capsules of pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) from birth to < 18 years of age.-2013-000508-40-Hungary - National Institute of Pharmacy-fidaxomicin
0,Dificlir,fidaxomicin,"['également connues sous nom diarrhée associée difficile madc chez patients adultes pédiatriques pesant moins', 'également connues sous nom diarrhée associée difficile madc chez adultes']",France - ANSM,2013-000508-40,"['A Phase 3, Multicenter, Investigator-blind, Randomized, Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h, and Vancomycin Oral Liquid or Capsules Taken q6h, for 10 Days in Pediatric Subjects with Clostridium difficile-associated Diarrhea']",['2819-CL-0202'],['Yes'],['Astellas Pharma Europe B.V.'],['Netherlands'],['Commercial'],"['Test', 'Test', 'Comparator', 'Comparator']","['No', 'Yes', 'Yes', 'Yes']","['Astellas Pharma Europe B.V.', 'Hospira SpA', 'Xellia Pharmaceutica ApS']","['European Union', 'Italy', 'United Kingdom']","['No', 'No', 'No', 'No']",Dificlir,"['Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Granules for oral suspension', 'Film-coated tablet', 'Powder for oral solution', 'Capsule, hard']","['Yes', 'No', 'No', 'No']","['1', '2', '3', '4']",['Treatment of enterocolitis caused by Clostridium difficile'],['No'],The primary objective of this study is to investigate the clinical response to fidaxomicin oral suspension or tablets and vancomycin oral liquid or capsules of pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) aged ≥ 6 months to < 18 years.,"['The secondary objectives of this study are to investigate the recurrence/sustained clinical response to and safety of fidaxomicin and vancomycin in pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) aged ≥ 6 months to < 18 years, as well as acceptance of the fidaxomicin oral suspension formulation.']",['No'],"['1. Institutional Review Board (IRB)-/Independent Ethics Committee (IEC)-approved written Informed Consent/ assent ( if applicable) and privacy language as per national regulations (e.g., HIPAA Authorization for U.S. sites) must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).']","['1. Concurrent use of metronidazole, oral vancomycin or any other antibiotic treatments for CDAD. If the investigator feels the clinical imperative is to begin treatment before knowing the laboratory result for toxigenic C. difficile, up to four doses but no more than 24 hours of treatment with metronidazole, oral vancomycin or any other effective treatment for CDAD are allowed.']",['Confirmed clinical response based on the assessment by the investigator at EOT+2 days TC/visit'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['14'],['Authorised'],['2014-10-24'],,['Reason(s) for unfavourable opinion:'],,['Completed'],The primary objective of this study is to investigate the clinical response to fidaxomicin oral suspension or tablets and vancomycin oral liquid or capsules of pediatric subjects with Clostridium difficile-associated diarrhea (CDAD) aged ≥ 6 months to < 18 years.-2013-000508-40-France - ANSM-fidaxomicin
3,Humira,adalimumab,['psoriasis'],Sweden - MPA,2009-017163-42,"['Pain modulation in RA – Influence of adalimumab. A randomized, placebo-controlled study using functional magnetic resonance imaging']",['MR2010'],['Information not present in EudraCT'],['Karolinska Institute'],['Sweden'],['Non-Commercial'],['Test'],['Yes'],['Abbott'],['Sweden'],['No'],Humira,['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Solution for injection'],['Information not present in EudraCT'],['1'],['Rheumatoid arthritis (RA)'],['No'],"The overall aim with this project is to investigate central pain mechanisms in RA and healthy controls, and how these mechanisms are influenced by TNF-blockade with Humira","['To investigate effects of Humira on peripheral pain, fatigue and autonomic function in RA']",['No'],"['RA patients: Age ≥18 , Fulfilling ACR criteria for RA, Disease duration ≤ 10 years.']",['RA patients: Fulfilling ACR criteria for fibromyalgia. For fMRI – left handedness and all forms of metallic implants. Severe ischemic heart disease. Concurrent treatment with antidepressant drugs.'],['Not applicable as this is not a trial of a new drug and the goal is to investigate mechanisms of pain processing before and after Humira treatment. The reason for using placebo-control in the study is to minimize inter-individual differences that can greatly affect the fMRI results and make conclusions diffucult'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['120'],['Authorised'],['2010-05-18'],['2010-05-18'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"The overall aim with this project is to investigate central pain mechanisms in RA and healthy controls, and how these mechanisms are influenced by TNF-blockade with Humira-2009-017163-42-Sweden - MPA-adalimumab"
1,Cubicin,daptomycin,"['infections', 'infections', 'aureus', 'infections']",Germany - BfArM,2010-022348-18,['Application of Daptomycin in MRSA infected diabetic foot  in comparison to vancomycin treatment'],['MCBC134ADE02T'],['Information not present in EudraCT'],['Heart- and Diabetescenter NRW'],['Germany'],['Non-Commercial'],"['Test', 'Test', 'Comparator', 'Test']","['Yes', 'Yes', 'Yes', 'Yes']","['Novartis Europharm Limited UK', 'Hikma Farmaceutica (Portugal), S. A.', 'Hikma Farmaceutica (Portugal), S.A.', 'Novartis Europharm Limited UK']","['European Union', 'Germany', 'Germany', 'European Union']","['No', 'No', 'No', 'No']",Cubicin,"['Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Powder for solution for infusion', 'Powder for solution for infusion', 'Powder for solution for infusion', 'Powder for solution for infusion']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3', '4']",['Patients eligible for this study suffer from diabetic foot infections.'],['No'],Clinical response of the infectionat test-of-cure (TOC) 14 days post therapy,['• Duration of therapy'],['No'],['•Type 1 and Type 2 Diabetes mellitus'],['•Osteomyelitis according to international consensus guideline* (3 of 5 criteria apply for diagnosis)'],['Clinical response of the infection at test-of-cure (TOC) 14 days post therapy'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['120'],['Authorised'],['2010-11-08'],['2010-09-15'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Prematurely Ended'],Clinical response of the infectionat test-of-cure (TOC) 14 days post therapy-2010-022348-18-Germany - BfArM-daptomycin
1,Cubicin,daptomycin,"['infections', 'infections', 'aureus', 'infections']",Germany - BfArM,2009-014391-22,"['An open label, multi-center, randomized, comparative Phase IIIb study to compare efficacy and safety of intravenous (i.v.) daptomycin with that of Semi-synthetic Penicillins (SSPs) or vancomycin in the treatment of elderly patients (aged ≥ 65 years) with complicated Skin and Soft Tissue Infections (cSSTIs)']",['CCBC134A2404'],['Information not present in EudraCT'],['Novartis Pharma AG'],['Switzerland'],['Commercial'],"['Test', 'Test', 'Comparator', 'Comparator', 'Comparator']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['Novartis Europharm Limited', 'Novartis Europharm Limited']","['European Union', 'European Union']","['No', 'No', 'No', 'No', 'No']",Cubicin,"['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Powder for solution for injection', 'Powder for solution for injection', 'Powder for solution for infusion', 'Injection*', 'Injection*']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3', '4', '5']",['complicated skin and soft tissue infections.'],['No'],"To evaluate and descriptively compare clinical success at the Test-Of-Cure visit (TOC) in elderly patients (aged ≥ 65 years) with cSSTIs, treated with either 4 or 6 mg/kg once daily i.v. daptomycin and with comparator.",['To descriptively evaluate the microbiological outcome of daptomycin in comparison to that of comparator in the treatment of cSSTIs as measured by the proportion of patients achieving bacteriological eradication of Gram-positive baseline pathogens at the TOC visit.'],['No'],['Patients eligible for inclusion in this study have to fulfill all of the following criteria:'],['Patients fulfilling any of the following criteria are not eligible for inclusion in this study:'],['(see main objective section)'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['No'],['34'],['Authorised'],['2010-01-27'],,['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To evaluate and descriptively compare clinical success at the Test-Of-Cure visit (TOC) in elderly patients (aged ≥ 65 years) with cSSTIs, treated with either 4 or 6 mg/kg once daily i.v. daptomycin and with comparator.-2009-014391-22-Germany - BfArM-daptomycin"
1,Cubicin,daptomycin,"['infections', 'infections', 'aureus', 'infections']",Italy - Italian Medicines Agency,2009-014391-22,"['An open label, multi-center, randomized, comparative  Phase IIIb study to compare efficacy and safety of  intravenous (i.v.) daptomycin with that of Semi-synthetic  Penicillins (SSPs) or vancomycin in the treatment of elderly  patients (aged &#8805; 65 years) with complicated Skin and Soft  Tissue Infections (cSSTIs)']",['CCBC134A2404'],['Information not present in EudraCT'],['Novartis Pharma AG'],['Switzerland'],['Commercial'],"['Test', 'Comparator', 'Comparator', 'Test']","['Yes', 'Yes', 'Yes', 'Yes']","['Novartis Europharm Limited', 'HOSPIRA SpA', 'BRISTOL-MYERS SQUIBB Srl', 'Novartis Europharm Limited']","['United Kingdom', 'Italy', 'Italy', 'United Kingdom']","['No', 'No', 'No', 'No']",Cubicin,"['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Yes', 'Yes', 'Yes', 'Yes']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Yes', 'Yes', 'Yes', 'Yes']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Powder for solution for injection', 'Powder for solution for injection', 'Powder and solvent for solution for injection', 'Powder for solution for injection']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3', '4']",['Complicated skin and soft tissue infections'],['No'],"To evaluate and descriptively compare clinical success at the Test-Of-Cure visit (TOC) in elderly patients (aged &#8805;  65 years) with cSSTIs, treated with either 4 or 6 mg/kg once daily i.v. daptomycin and with comparator.","['To descriptively evaluate the microbiological outcome of daptomycin in comparison to that of comparator in the treatment of cSSTIs as measured by the proportion of patients achieving bacteriological eradication of Grampositive baseline pathogens at the TOC visit.  To evaluate the duration of treatment (i.v., i.v. + oral).  To evaluate and descriptively compare adverse event frequencies and laboratory abnormalities in elderly patients treated with 4 and 6 mg/kg once daily of i.v. daptomycin and with comparator (Safety evaluation).']",['No'],"['Patients eligible for inclusion in this study have to fulfill all of the following criteria:  1. Written informed consent to participate in the study. In the event that the patient is unable to give consent, the patient`s legally authorized representative may do so by means approved by the investigator s EC.  2. Patients with age of 65 years or older.  3. Infection of sufficient severity to require in-patient hospitalization, with parenteral antimicrobial therapy for at least 96 hours.  4. Patients who have a diagnosis of Gram-positive complicated skin and soft tissue infections (cSSTIs) with or  without bacteremia, e.g.:    wound infections due to:  o traumatic injury (e.g., crush, puncture, laceration, gunshot, etc.),  o surgical incision,  o foreign body (e.g., septic phlebitis associated with intravenous catheter sites).  Infected foreign bodies (e.g., implanted pacemakers) are to be removed within 24 hours following study enrolment.    major abscesses which are defined as meeting all the following criteria:  o involve the subcutaneous or deeper tissues  o require surgical incision and drainage,  o require antibiotic therapy in addition to drainage.    severe carbunculosis,    infected ulcers (except patients with multiple infected ulcers, see exclusion criteria)  associated with: diabetes, vascular insufficiency, pressure (i.e., decubitus ulcers),    presence of a complicating factor, including:  o a pre-existing skin lesion or underlying condition that adversely affected the delivery of drug to the affected area, the immunologic response, or tissue healing,  o requirement for significant surgical intervention,  o suspected or confirmed involvement of deep soft tissues, fascia, or muscle,  o chronic systemic steroids (> 20 mg prednisone daily or equivalent),  o diabetes mellitus requiring treatment with oral hypoglycemic agents or insulin.  5. Presence of at least 3 of the following signs and symptoms of skin infection:    temperature > 38.0C rectal or > 37.5C oral/tympanic,    elevated WBC >12x 103/&#956;L or with > 10 % bands (immature neutrophils),    drainage and/ or discharge from the infection site,    erythema (extending at least 1 cm beyond wound edge),    fluctuance,    heat and/ or localized warmth,    pain and/ or tenderness to palpation,    edema and/ or induration.']","['Non-complicated SSTI:  1.Conditions requiring surgery that in and of itself would cure the infection or remove the infected site (e.g.,  amputation).  2.Minor or superficial skin infections (e.g., furuncles, simple abscesses, acne, impetigo).  3.Cellulitis, including erysipelas, not associated with complicating factors. However, patients with cellulitis associated with more serious infection (e.g., surgical wound, diabetic ulcer, deep tissue) can be enrolled (proportion of these patients will be limited to 30%).  Infections for which outcome is difficult to assess:  4.Perirectal abscess  5.Hidradenitis suppurativa  6.Gangrene  7.Infected human or animal bites  8.Multiple infected ulcers at distant sites  9.Infected burns (only 3rd degree burn wound or wound area of more than 10 cm diameter)  10.Conditions requiring emergency surgery including necrotizing fasciitis.  Medical conditions:  11.History of significant allergy or intolerance to vancomycin or daptomycin.  Hypersensitivity to the selected SSPs is not an exclusion criterion.  12.Concomitant clinically suspected or confirmed other site of infection or disorder at study entry that may  interfere with the evaluation in this protocol such as primary muscle disorders, pneumonia, endocarditis,  osteomyelitis, septic arthritis, meningitis, spinal epidural abscess, intraabdominal infection (peritonitis, etc.) and intravascular devicerelated bacteremia.  13.Infections associated with a permanent prosthetic device that will not be removed within 24 hours after  enrolment.  14.Shock or hypotension (supine systolic blood pressure < 80 mm Hg) refractory to fluid or short course pressor  challenge (> 4 hours).  15.Neutrophil count < 1000/&#956;L.  16.Known or suspected HIV infection with a CD4+ T-cell count < 500/&#956;L (HIV testing is not required).  17.Severe hepatic disease (Child-Pugh Class C) or ALT and/or AST > 5 times ULN and/ or total bilirubin > 2  times ULN at screening.  18.Calculated creatinine clearance by the Cockcroft-Gault equation using actual body weight < 30 mL/min or  any type of dialysis.  19.Life expectancy less than six months.  20.Treatment with any investigational agent or device within 30 days of study drug administration.  21.Patients unwilling or unable to adhere to study-designated procedures and restrictions.  22.Patients admitted to the hospital for drug abuse or other conditions associated with rhabdomyolysis.  Exclusion criteria related to microbiology  23.Patients with an infection due to an organism known to be resistant to daptomycin or vancomycin at study  entry.  24.cSSTIs suspected or documented as being due exclusively to Gram-negative or anaerobic organisms based on  the epidemiology or on direct examination of a Gram- stained specimen.  Exclusion criteria related to medications  25.Need at study entry, for a non-study systemic antibacterial (for concomitant infection) to which the target  pathogen is susceptible.  26.Previous systemic antibacterial therapy for the treatment of Gram-positive cSSTIs for more than 24 hours  within 48 hours prior to the day of first infusion of study drug unless:    the infecting Gram-positive pathogen is intermediate or resistant in vitro to the previous antibacterial therapy; or    the previous antibacterial therapy was administered for 3 or more calendar days with either worsening or no  improvement in the clinical signs and symptoms of cSSTI, and was not vancomycin or SSP.']",['See primary objective section'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['No'],['18'],['Authorised'],['2010-02-09'],['2009-12-17'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To evaluate and descriptively compare clinical success at the Test-Of-Cure visit (TOC) in elderly patients (aged &#8805;  65 years) with cSSTIs, treated with either 4 or 6 mg/kg once daily i.v. daptomycin and with comparator.-2009-014391-22-Italy - Italian Medicines Agency-daptomycin"
1,Intelence,Etravirine,['infections'],Italy - Italian Medicines Agency,2016-002413-22,"['Open label, Randomized (1:1), clinical trial to evaluate switching from dual regimens based on Dolutegravir plus a reverse transcriptase inhibitor to  elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in virologically suppressed, HIV-1 infected patients.']",['Be-OnE1/08-03-2016'],['No'],['OSPEDALE SAN RAFFAELE'],['Italy'],['Non-Commercial'],"['Test', 'Test', 'Comparator', 'Comparator', 'Comparator', 'Comparator', 'Comparator', 'Comparator', 'Comparator', 'Comparator']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['Gilead Sciences Int. Ltd', 'VIIV HEALTHCARE UK LTD', 'GILEAD SCIENCE INTERNATIONAL LIMITED', 'MYLAN S.P.A.', 'GILEAD SCIENCE INTERNATIONAL LIMITED', 'GLAXO GROUP LIMITED', 'JANSSEN-CILAG INTERNATIONAL N.V.', 'JANSSEN-CILAG INTERNATIONAL N.V.', 'BRISTOL-MYERS SQUIBB PHARMA EEIG', 'BOEHRINGER INGELHEIM INTERNATIONAL GMBH']","['Ireland', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']",Intelence,"['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'No', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'No', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Film-coated tablet', 'Film-coated tablet', 'Capsule, hard', 'Film-coated tablet', 'Film-coated tablet', 'Film-coated tablet', 'Tablet', 'Tablet', 'Tablet', 'Prolonged-release tablet']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['1', '2', '3', '4', '5', '6', '7', '8', '9', '10']",['HIV infection'],['No'],To investigate Residual Viremia  through 48 weeks in virologically suppressed patients randomized to continue treatment with Dolutegravir plus a single RTI or to switch to E/C/F/TAF.,['Secondary Objectives'],['No'],['1.\tAge >18  years'],['1.\tActive AIDS-defining condition (except Kaposi’s sarcoma non requiring systemic chemotherapy)'],['Proportion of subjects without Residual Viremia  through 48 weeks of follow-up.'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['100'],['Authorised'],['2016-10-31'],['2016-07-14'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Prematurely Ended'],To investigate Residual Viremia  through 48 weeks in virologically suppressed patients randomized to continue treatment with Dolutegravir plus a single RTI or to switch to E/C/F/TAF.-2016-002413-22-Italy - Italian Medicines Agency-Etravirine
0,Tasmar,tolcapone,['atteints maladie parkinson idiopathique'],Germany - BfArM,2008-006905-18,['Pharmakotherapie kognitiver Defizite bei schizophrenen Störungen – Randomisierte placebokontrollierte Doppelblindstudie mit Pergolid versus Tolcapon'],['MP-TOCTAP-2008'],['Information not present in EudraCT'],['RWTH Aachen University'],['Germany'],['Non-Commercial'],"['Test', 'Test', 'Test']","['Yes', 'Yes', 'Yes']","['Valeant Pharmaceuticals Ltd.', 'Lilly Deutschland GmbH', 'Lilly Deutschland GmbH']","['European Union', 'European Union', 'European Union']","['No', 'No', 'No']",Tasmar,"['Yes', 'Yes', 'Yes']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Tablet', 'Tablet', 'Tablet']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3']","['Das vorliegende Projektvorhaben dient der Untersuchung, inwieweit bei Patienten mit schizophrenen Störungen neben einer bestehenden Monotherapie mit Paliperidon (Invega), dem zuletzt zugelassenen neuartigen Antipsychotikum der sog. zweiten Generation, eine additive prodopaminerge Psychopharmakotherapie mit Tolcapon (Tasmar) oder Pergolid (Parkotil) die präfrontalen kognitiven Funktionen beeinflusst.']",['No'],Verbesserung präfrontaler kognitiver Funktionen bei Patienten mit schizophrenen Störungen. Hauptzielparameter ist die Veränderung des MCCB nach 6 Wochen gegenüber dem Vor-wert.,['Kenntnisse über die Modulierbarkeit beeinträchtigter kognitiver Funktionen bei Patienten mit schizophrenen Störungen gewonnen werden. Dies bietet die Basis für neue therapeutische Optionen zur Verbesserung des sozialen Funktionsniveaus bei Erkrankten.'],['No'],['-\tunterschirebene Einverständniserklärung'],['-\tAbhängigkeit von illegalen Drogen'],['Ergebnisse der neuropsychologischen Testung (t-Werte)'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['60'],['Authorised'],['2010-07-22'],['2010-01-11'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Prematurely Ended'],Verbesserung präfrontaler kognitiver Funktionen bei Patienten mit schizophrenen Störungen. Hauptzielparameter ist die Veränderung des MCCB nach 6 Wochen gegenüber dem Vor-wert.-2008-006905-18-Germany - BfArM-tolcapone
0,Javlor,vinflunine,['carcinome cellule transitionnelle tumeurs urologiques javlor indiqué monothérapie traitement'],Austria - BASG,2005-001463-64,['A Phase II Study of Intravenous (IV) Vinflunine in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium'],['CA183-001'],['Information not present in EudraCT'],['Bristol-Myers Squibb International Corporation'],['Belgium'],['Commercial'],"['Test', 'Test']","['Information not present in EudraCT', 'Information not present in EudraCT']",,,"['No', 'No']",Javlor,"['Yes', 'Yes']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Concentrate for solution for infusion', 'Concentrate for solution for infusion']","['Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2']","['Advanced Cancer, IV, Nos']",['No'],"To estimate the objective response rate (as defined by the WHO criteria modified by the SWOG) in patients with TCC receiving vinflunine, who have had documented",['1) To estimate duration of response.'],['Information not present in EudraCT'],['1) Provided signed written informed consent.'],['1) WOCBP who are unwilling or unable to use an acceptable method to avoid'],['Efficacy:'],['No'],['Information not present in EudraCT'],['Yes'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['5'],['Authorised'],['2005-07-14'],['2005-07-14'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To estimate the objective response rate (as defined by the WHO criteria modified by the SWOG) in patients with TCC receiving vinflunine, who have had documented-2005-001463-64-Austria - BASG-vinflunine"
0,Javlor,vinflunine,['carcinome cellule transitionnelle tumeurs urologiques javlor indiqué monothérapie traitement'],Spain - AEMPS,2005-001463-64,['Estudio en fase II de Vinflunina administrada por vía intravenosa (IV) a pacientes con un carcinoma de células transicionales (CCT) del urotelio localmente avanzado o metastásico.'],['CA183-001'],['Information not present in EudraCT'],['Bristol-Myers Squibb International Corporation'],['Belgium'],['Commercial'],"['Test', 'Test']","['Information not present in EudraCT', 'Information not present in EudraCT']",,,"['No', 'No']",Javlor,"['Yes', 'Yes']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Concentrate for solution for infusion', 'Concentrate for solution for infusion']","['Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2']","['Cáncer Avanzado, grado IV, Nos']",['No'],"Calcular el índice de respuesta objetiva (definida por los criterios modificados de la OMS) en pacientes con CCT del urotelio que reciban Vinflunina, que hayan tenido una evidencia de progresión documentada en cualquier momento en los 12 meses posteriores a la última dosis de una terapia con platino y no sean candidatos a una cistectomía..",['1) Calcular la duración de la respuesta'],['Information not present in EudraCT'],['1)El paciente firmará un consentimiento informado por escrito'],['1)MEF que no quieran o no puedan usar un método anticonceptivo aceptable durante todo el estudio y hasta 12 semanas después de finalizado el mismo.'],['Eficacia :'],['No'],['Information not present in EudraCT'],['Yes'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['12'],['Authorised'],['2006-01-17'],['2005-10-11'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"Calcular el índice de respuesta objetiva (definida por los criterios modificados de la OMS) en pacientes con CCT del urotelio que reciban Vinflunina, que hayan tenido una evidencia de progresión documentada en cualquier momento en los 12 meses posteriores a la última dosis de una terapia con platino y no sean candidatos a una cistectomía..-2005-001463-64-Spain - AEMPS-vinflunine"
0,Javlor,vinflunine,['carcinome cellule transitionnelle tumeurs urologiques javlor indiqué monothérapie traitement'],Sweden - MPA,2005-001463-64,['A Phase II Study of Intravenous (IV) Vinflunine in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium'],['CA183-001'],['Information not present in EudraCT'],['Bristol-Myers Squibb International Corporation'],['Belgium'],['Commercial'],"['Test', 'Test']","['No', 'No']",,,"['No', 'No']",Javlor,"['Yes', 'Yes']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Concentrate for solution for infusion', 'Concentrate for solution for infusion']","['Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2']","['Advanced Cancer, IV, Nos']",['No'],"To estimate the objective response rate (as defined by the WHO criteria modified by the SWOG) in patients with TCC receiving vinflunine, who have had documented",['1) To estimate duration of response.'],['No'],['1) Provided signed written informed consent.'],['1) WOCBP who are unwilling or unable to use an acceptable method to avoid'],['Efficacy:'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['10'],['Authorised'],['2005-11-02'],['2005-12-15'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To estimate the objective response rate (as defined by the WHO criteria modified by the SWOG) in patients with TCC receiving vinflunine, who have had documented-2005-001463-64-Sweden - MPA-vinflunine"
0,Javlor,vinflunine,['carcinome cellule transitionnelle tumeurs urologiques javlor indiqué monothérapie traitement'],Italy - Italian Medicines Agency,2005-001463-64,['A phase II study of intravenous  IV  vinflunine in patients with locally advanced or metastatic transitional cell carcinoma  TCC  of the urothelium.'],['CA183-001'],['Information not present in EudraCT'],['BRISTOL-M.SQUIBB'],['Italy'],['Commercial'],"['Test', 'Test']","['No', 'No']",,,"['No', 'No']",Javlor,"['Yes', 'Yes']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Concentrate for solution for infusion', 'Concentrate for solution for infusion']","['Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2']",['TCC treatment'],['No'],,,['Information not present in EudraCT'],,,,['No'],['Information not present in EudraCT'],['Yes'],['No'],['Information not present in EudraCT'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['15'],['Authorised'],['2005-12-16'],['2005-10-26'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],-2005-001463-64-Italy - Italian Medicines Agency-vinflunine
0,Aranesp,darbepoetin alfa,"['rénale chronique traitement anémie symptomatique associée insuffisance rénale chronique irc chez adultes', 'cancéreux atteints tumeurs malignes']",Denmark - DHMA,2007-007137-38,"['En åbent randomiseret fase II undersøgelse af effekten af darbepoietin alfa (Aranesp®) til behandling af anæmi hos patienter med hormonrefraktær prostatacancer, der behandles med Taxotere']",['48110359'],['Information not present in EudraCT'],['Vejle Hospital'],['Denmark'],['Non-Commercial'],['Comparator'],['Yes'],['Amgen Europe B.V.'],['European Union'],['No'],Aranesp,['No'],['No'],['No'],['No'],['No'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['Yes'],['Information not present in EudraCT'],['Solution for injection'],['Information not present in EudraCT'],['1'],['Patients with advanced prostate cancer and anaemia'],['No'],"Formålet med dette studie er primært at vurdere effekten af Aranesp® på den hæmatopoietiske reaktion hos patienter med fremskreden prostatacancer og anæmi, der modtager 1.linie kemoterapi. Desuden vurderes effekten af Aranesp® på behov for transfusion med røde blodlegemer. Antal hospitalsindlæggelser og tidsforbruget ved blodtransfusion og Aranesp® behandling vil blive bedømt.","['Sekundært vil man vurdere livskvalitet, og om der er en forskel i respons af kemoterapien hos patienter der får Aranesp® sammenlignet med patienter, der ikke får Aranesp®.']",['No'],['Inklusionskriterier'],"['•Kendt primær hæmatologisk lidelse, som kan forårsage anæmi.']","['1.Hæmoglobinniveau 0, 3, 6, 9, 12, 15, 18 og 21 uger efter starten på darbepoetin alfa. Dosis og varighed af Darbepoetin behandling registreres.']",['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['100'],['Authorised'],['2008-04-07'],['2008-04-09'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Ongoing'],"Formålet med dette studie er primært at vurdere effekten af Aranesp® på den hæmatopoietiske reaktion hos patienter med fremskreden prostatacancer og anæmi, der modtager 1.linie kemoterapi. Desuden vurderes effekten af Aranesp® på behov for transfusion med røde blodlegemer. Antal hospitalsindlæggelser og tidsforbruget ved blodtransfusion og Aranesp® behandling vil blive bedømt.-2007-007137-38-Denmark - DHMA-darbepoetin alfa"
2,Exforge,"valsartan, amlodipine (as amlodipine besilate)","['hypertension', 'hypertension']",France - ANSM,2006-006733-41,['Effet de l’association fixe amlodipine/valsartan sur la Pression artérielle centrale chez des hypertendus essentiels non contrôlés par amlodipine 5mg'],['CVAA 489 A FR02'],['Information not present in EudraCT'],['Novartis Pharma S.A.S.'],['France'],['Commercial'],"['Test', 'Test', 'Comparator', 'Comparator', 'Comparator', 'Comparator']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['Novartis Europharm Limited', 'Novartis Europharm Limited', 'Pfizer', 'Pfizer', 'Biogaran', 'Biogaran']","['European Union', 'European Union', 'France', 'France', 'France', 'France']","['No', 'No', 'No', 'No', 'No', 'No']",Exforge,"['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Film-coated tablet', 'Film-coated tablet', 'Capsule, hard', 'Capsule, hard', 'Film-coated tablet', 'Film-coated tablet']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3', '4', '5', '6']",['Hypertension artérielle essentielle'],['No'],"Comparer la baisse de pression artérielle systolique centrale entre V2 et  V4 entre 2 groupes de patients présentant une HTA essentielle légère à modérée (140 mmHg ≥ PAS ≤ 179 mmHg et/ou  90mmHg ≥ PAD ≤ 109 mmHg et 130mmHg ≥ PAS ≤ 179 mmHg et/ou  80mmHg ≥ PAD ≤ 109 mmHg si diabète ou insuffisance rénale), non contrôlée par amlodipine 5 mg en monothérapie pendant 4 semaines, et traités soit par Exforge® (association fixe amlodipine/valsartan) soit par l’association libre aténolol/amlodipine pendant 24 semaines",['Tonometrie :'],['No'],"['− Agés de plus de 18 ans,']","['− Femmes en âge de procréer sans contraception efficace,']","[""L'objectif principal de l'étude est de comparer la baisse de la pression artérielle systolique centrale entre V2 et V4, entre deux groupes de patients présentant une HTA essentielle légère à modérée, non contrôlée par amlodipine 5 mg en monothérapie pendant 4 semaines et traités soit par Exforge, soit par l'association libre aténolol/amlodipine pendant 24 semaines.""]",['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['532'],['Authorised'],['2007-11-30'],['2007-11-27'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"Comparer la baisse de pression artérielle systolique centrale entre V2 et  V4 entre 2 groupes de patients présentant une HTA essentielle légère à modérée (140 mmHg ≥ PAS ≤ 179 mmHg et/ou  90mmHg ≥ PAD ≤ 109 mmHg et 130mmHg ≥ PAS ≤ 179 mmHg et/ou  80mmHg ≥ PAD ≤ 109 mmHg si diabète ou insuffisance rénale), non contrôlée par amlodipine 5 mg en monothérapie pendant 4 semaines, et traités soit par Exforge® (association fixe amlodipine/valsartan) soit par l’association libre aténolol/amlodipine pendant 24 semaines-2006-006733-41-France - ANSM-valsartan, amlodipine (as amlodipine besilate)"
0,Effentora,fentanyl,"['cancer', 'déjà traitement entretien opioïde douleur chronique cancéreuse btp exacerbation transitoire douleur survient contexte douleur persistante autrement contrôlée patients recevant traitement entretien opioïdes ceux prennent moins']",Germany - BfArM,2011-005797-32,"['Effentora® for Dyspnoea (EffenDys) - Fentanyl buccal tablet (FBT) for the relief of episodic dyspnoea (ED) in cancer patients: an open label, randomized, morphine-controlled, crossover, phase II trial']",['Uni-Koeln-1412'],['No'],['University of Cologne'],['Germany'],['Non-Commercial'],"['Test', 'Comparator', 'Test', 'Test', 'Test']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['Teva Pharmaceutical Industries Ltd. (TEVA Ltd.) (former Cephalon Inc.)', 'Merck Serono GmbH', 'Teva Pharmaceutical Industries Ltd. (TEVA Ltd.) (former Cephalon Inc.)', 'Teva Pharmaceutical Industries Ltd. (TEVA Ltd.) (former Cephalon Inc.)', 'Teva Pharmaceutical Industries Ltd. (TEVA Ltd.) (former Cephalon Inc.)']","['Germany', 'Germany', 'Germany', 'Germany', 'Germany']","['No', 'No', 'No', 'No', 'No']",Effentora,"['Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['Buccal tablet', 'Solution for use in drinking water', 'Buccal tablet', 'Buccal tablet', 'Buccal tablet']","['No', 'No', 'No', 'No', 'No']","['1', '2', '3', '4', '5']",['Patients with cancer suffering from episodes of dyspnoea (ED)'],['No'],To determine the time to onset of meaningful dyspnoea relief of fentanyl buccal tablet (FBT) in comparison to immediate-release morphine (IRM),['•\tTo assess safety of opioids in patients with dyspnoea'],['No'],['Principal inclusion criteria:'],['Principal exclusion criteria:'],['•\tTime to onset of meaningful dyspnoea relief'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['30'],['Authorised'],['2012-11-26'],['2013-02-28'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],To determine the time to onset of meaningful dyspnoea relief of fentanyl buccal tablet (FBT) in comparison to immediate-release morphine (IRM)-2011-005797-32-Germany - BfArM-fentanyl
1,Edurant,rilpivirine hydrochloride,['infections'],Italy - Italian Medicines Agency,2016-002413-22,"['Open label, Randomized (1:1), clinical trial to evaluate switching from dual regimens based on Dolutegravir plus a reverse transcriptase inhibitor to  elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in virologically suppressed, HIV-1 infected patients.']",['Be-OnE1/08-03-2016'],['No'],['OSPEDALE SAN RAFFAELE'],['Italy'],['Non-Commercial'],"['Test', 'Test', 'Comparator', 'Comparator', 'Comparator', 'Comparator', 'Comparator', 'Comparator', 'Comparator', 'Comparator']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['Gilead Sciences Int. Ltd', 'VIIV HEALTHCARE UK LTD', 'GILEAD SCIENCE INTERNATIONAL LIMITED', 'MYLAN S.P.A.', 'GILEAD SCIENCE INTERNATIONAL LIMITED', 'GLAXO GROUP LIMITED', 'JANSSEN-CILAG INTERNATIONAL N.V.', 'JANSSEN-CILAG INTERNATIONAL N.V.', 'BRISTOL-MYERS SQUIBB PHARMA EEIG', 'BOEHRINGER INGELHEIM INTERNATIONAL GMBH']","['Ireland', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy', 'Italy']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']",Edurant,"['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'No', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'No', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Film-coated tablet', 'Film-coated tablet', 'Capsule, hard', 'Film-coated tablet', 'Film-coated tablet', 'Film-coated tablet', 'Tablet', 'Tablet', 'Tablet', 'Prolonged-release tablet']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['1', '2', '3', '4', '5', '6', '7', '8', '9', '10']",['HIV infection'],['No'],To investigate Residual Viremia  through 48 weeks in virologically suppressed patients randomized to continue treatment with Dolutegravir plus a single RTI or to switch to E/C/F/TAF.,['Secondary Objectives'],['No'],['1.\tAge >18  years'],['1.\tActive AIDS-defining condition (except Kaposi’s sarcoma non requiring systemic chemotherapy)'],['Proportion of subjects without Residual Viremia  through 48 weeks of follow-up.'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['100'],['Authorised'],['2016-10-31'],['2016-07-14'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Prematurely Ended'],To investigate Residual Viremia  through 48 weeks in virologically suppressed patients randomized to continue treatment with Dolutegravir plus a single RTI or to switch to E/C/F/TAF.-2016-002413-22-Italy - Italian Medicines Agency-rilpivirine hydrochloride
0,Xeloda,capecitabine,"['côlon tumeurs mammaires', 'cancer côlon stade iii stade dukes', 'traitement cancer colorectal', 'traitement patientes atteintes cancer sein localement', 'cancer sein localement avancé métastatique après échec']",Germany - BfArM,2012-000598-22,"['Randomised, open-label phase II study to compare the safety and efficacy of lapatinib plus trastuzumab or lapatinib plus capecitabine in trastuzumab-resistant HER2-overexpressing metastatic breast cancer']",['BNGO/01'],['No'],['Berufsverband der niedergelassenen gynäkologischen Onkologen in Deutschland e.V.; BNGO e.V.'],['Germany'],['Non-Commercial'],"['Test', 'Test', 'Comparator', 'Comparator']","['Yes', 'Yes', 'Yes', 'Yes']","['GlaxoSmithKline', 'Roche Registration Limited', 'GlaxoSmithKline', 'Roche Registration Lmited']","['Germany', 'Germany', 'Germany', 'Germany']","['No', 'No', 'No', 'No']",Xeloda,"['Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['No', 'No', 'No', 'No']","['Film-coated tablet', 'Powder for concentrate for solution for infusion', 'Film-coated tablet', 'Film-coated tablet']","['No', 'No', 'No', 'No']","['1', '2', '3', '4']",['Trastuzumab-resistant HER2-overexpressing metastatic breast cancer'],['No'],Estimate the clinical benefit of lapatinib plus trastuzumab compared to lapatinib plus capecitabine as measured by investigator-assessed progression-free survival (PFS),['•\tEvaluate overall survival of lapatinib plus trastuzumab relative to lapatinib plus capecitabine'],['No'],"['\tWomen with histologically confirmed breast cancer; measurable metastatic disease; HER2-positive (IHC 3+ or ISH positive); Hormone receptor-negative; prior treatment with trastuzumab, anthracycline and taxanes; progression on trastuzumab as first-line or second-line therapy; no prior treatment with lapatinib within last 6 months; Adequate hematologic, renal and liver function; normal cardiac function with LVEF of ≥50%; ECOG performance status 0-1; No evidence of brain metastases (asymptomatic metastases that have been clinically stable for 3 months are allowed); no significant cardiovascular disease or other serious medical condition; written informed consent to participate in the trial and to the donation of formalin fixed, paraffin embedded tumour sample from the primary or recurrent cancer available for central testing.']",['•\t1. Patients with confirmed brain metastases or a history of primary central nervous system tumours or who have signs/symptoms attributable to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases. Patients with treated brain metastases that are asymptomatic and have been clinically stable for 3 months will be eligible for protocol participation.'],"['The 6-month PFS-rate (PFS6) will be the number of patients without disease progression or death within 6 months from the date of randomization, divided by the number of patients in the respective analysis population. For the purpose of the analysis patients who are lost to follow-up or deceased in at or before 6 months after randomization will be counted as “disease progression”.']",['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['100'],['Authorised'],['2013-03-08'],['2013-03-18'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Prematurely Ended'],Estimate the clinical benefit of lapatinib plus trastuzumab compared to lapatinib plus capecitabine as measured by investigator-assessed progression-free survival (PFS)-2012-000598-22-Germany - BfArM-capecitabine
0,Xeloda,capecitabine,"['côlon tumeurs mammaires', 'cancer côlon stade iii stade dukes', 'traitement cancer colorectal', 'traitement patientes atteintes cancer sein localement', 'cancer sein localement avancé métastatique après échec']",UK - MHRA,2004-001926-26,['XERXES: Examining the role of early neoadjuvant and synchronous Erbitux in pre-operative chemo-radiotherapy using Xeloda followed by excisional surgery.'],['XERXES'],['Information not present in EudraCT'],['University College London'],['United Kingdom'],['Non-Commercial'],"['Test', 'Test']","['Yes', 'Information not present in EudraCT']",['Merck KGaA'],,"['No', 'No']",Xeloda,"['No', 'Yes']","['No', 'No']","['No', 'No']","['No', 'No']","['Yes', 'No']","['Yes', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Solution for infusion', 'Tablet']","['Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2']",['Locally advanced rectal cancer'],['No'],"To evaluate the safety and toxicity of the combination of erbitux, capecitabine and radiotherapy. This will be determined through an assessment of the patient’s toxicity",['To determine the efficacy of the treatment schedules.  This will be determined through an evaluation of disease-free survival.'],['Information not present in EudraCT'],['Biopsy proven adenocarcinoma of the rectum (tumour <15cm from anal verge); Indication for pre-operative chemoradiotherapy by virtue of partially fixed/unresectable disease and locally advanced disease (T3/T4) where the preoperative MRI confirms the surgeon is unlikely to perform a R0 resection; WHO performance status 0 or 1; Age ≥18 and fit for surgery.'],"['Uncontrolled cardiac, respiratory or other disease, or any serious medical or psychiatric disorder that would preclude trial therapy or informed consent; Previous radiotherapy to the pelvis; Previous chemotherapy or radiation for rectal cancer']",['Acute Toxicity (grade 3 or above in defined Dose Limiting Toxicities)'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['48'],['Authorised'],['2005-06-10'],['2005-04-05'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To evaluate the safety and toxicity of the combination of erbitux, capecitabine and radiotherapy. This will be determined through an assessment of the patient’s toxicity-2004-001926-26-UK - MHRA-capecitabine"
1,Invanz,ertapenem sodium,"['infections', 'infections', 'infections', 'infections', 'infections', 'infections', 'infections', 'infections']",Estonia - SAM,2009-015948-42,['Pharmacokinetics of ertapenem in patients with severe sepsis and intraabdominal infection'],['179'],['Information not present in EudraCT'],"['University of Tartu, Faculty of Medicine']",['Estonia'],['Non-Commercial'],['Test'],['Yes'],['Merck Sharp & Dohme Limited'],['European Union'],['No'],Invanz,['Yes'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Powder for concentrate for solution for infusion'],['Information not present in EudraCT'],['1'],['Severe sepsis caused by intraabdominal infection either peritonitis or pancreatitis'],['No'],To study penetration of ertapenem into abdominal cavity during severe sepsis caused by intrabdominal infection,['To relate measured intraabdominal concentration to pharmacodynamic measure of antimicrobial efficiency: time over MIC.'],['No'],['adult aged 18-65 years'],"['renal dysfunction, defined as creatinine clearance less than 30 ml/min calculated using Cockroft-Gault formula']",['concentration of ertapenem in abdominal cavity'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['8'],['Authorised'],['2009-10-28'],['2008-04-28'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Ongoing'],To study penetration of ertapenem into abdominal cavity during severe sepsis caused by intrabdominal infection-2009-015948-42-Estonia - SAM-ertapenem sodium
1,Isentress,Raltegravir,"['infections', 'traitement infection']",UK - MHRA,2010-018878-21,"['A phase III, open-label, single centre, single-arm, pilot study to assess the feasibility of switching, individuals receiving efavirenz with continuing Central Nervous System (CNS) toxicity, to raltegravir']",['SSAT036'],['Information not present in EudraCT'],"[""St Stephen's AIDS Trust""]",['United Kingdom'],['Non-Commercial'],"['Test', 'Test']","['Yes', 'Yes']","['Merck Sharp & Dohme Limited', 'Gilead Sciences Ltd']","['United Kingdom', 'United Kingdom']","['No', 'No']",Isentress,"['Yes', 'Yes']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Film-coated tablet', 'Coated tablet']","['Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2']",['HIV'],['No'],To investigate whether switching individuals who have central nervous system (CNS) side effects from taking Efavirenz-containing treatment (as Atripla) to Truvada/Raltegravir resolves the CNS side effects after 4 weeks,['To investigate whether switching individuals who have central nervous system (CNS) side effects from taking Efavirenz-containing treatment (as Atripla) to Truvada/Raltegravir resolves the CNS side effects after 12 weeks.'],['No'],['Male or female aged 18 years or above'],['is infected with HIV-2'],['The rate of neuropsychiatric and central nervous system (CNS) toxicity as measured (as defined by the ACTG adverse event scale) after 4 weeks of raltegravir therapy as measured by :'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['40'],['Authorised'],['2010-07-05'],['2010-08-16'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],To investigate whether switching individuals who have central nervous system (CNS) side effects from taking Efavirenz-containing treatment (as Atripla) to Truvada/Raltegravir resolves the CNS side effects after 4 weeks-2010-018878-21-UK - MHRA-Raltegravir
1,Isentress,Raltegravir,"['infections', 'traitement infection']",France - ANSM,2009-017742-31,['ISENTRESS® + TRUVADA® : Etude multicentrique relative à la tolérance d’une nouvelle trithérapie antirétrovirale prescrite dans le cadre de la prophylaxie post-exposition de personnes récemment soumises au risque de transmission d’une infection par le VIH'],['382426005_1'],['Information not present in EudraCT'],['Groupe d’étude sur le risque d’exposition des soignants aux agents infectieux (GERES)'],['France'],['Non-Commercial'],"['Test', 'Test']","['Yes', 'Yes']","['Merck Sharp & Dohme Limited', 'Gilead Sciences International Limited']",['France'],"['No', 'No']",Isentress,"['Yes', 'Yes']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'Information not present in EudraCT']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Buccal tablet', 'Buccal tablet']","['Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2']",[' prophylaxis treatment post HIV exposure'],['No'],"Evaluer la nature et l’incidence des intolérances médicamenteuses observées sous une nouvelle trithérapie antirétrovirale contenant une nouvelle classe d’antirétroviral (raltégravir Isentress®, un inhibiteur d’intégrase) : Truvada® [0-0-1] + Isentress® comprimés 400mg [1-0-1] prescrite dans le cadre de la prise en charge de personnes récemment exposées au risque de transmission d’une infection par le VIH.",['\uf0a7 Décrire la population des personnes récemment soumises au risque de transmission d’une infection par le VIH et son évolution par rapport aux études précédentes conduites dans les mêmes conditions.'],['No'],['\uf0a7 âge égal ou supérieur à 18 ans'],"['\uf0a7 les sujets récemment exposés au risque de transmission d’une infection par le VIH dont le patient source est connu infecté par le VIH et traité, et dont l’histoire thérapeutique justifie l’introduction d’un TPE différent de celui proposé dans cette étude']","['Proportion de patients ayant arrêté le TPE avant les 28 jours prévus, en raison d’effet(s) indésirable(s).']",['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['200'],['Authorised'],['2010-05-19'],['2010-02-04'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Ongoing'],"Evaluer la nature et l’incidence des intolérances médicamenteuses observées sous une nouvelle trithérapie antirétrovirale contenant une nouvelle classe d’antirétroviral (raltégravir Isentress®, un inhibiteur d’intégrase) : Truvada® [0-0-1] + Isentress® comprimés 400mg [1-0-1] prescrite dans le cadre de la prise en charge de personnes récemment exposées au risque de transmission d’une infection par le VIH.-2009-017742-31-France - ANSM-Raltegravir"
1,Isentress,Raltegravir,"['infections', 'traitement infection']",Spain - AEMPS,2008-001611-38,['Estudio piloto prospectivo de la farmacocinética y farmacodinamia de la interaciión entre tipranavir/ritonavir y raltegravir en pacientes infectados por el VIH-1'],['PK12-RAL/TPV'],['Information not present in EudraCT'],['Jose M Gatell - Hospital Clinic de Barcelona'],['Spain'],['Non-Commercial'],"['Test', 'Test', 'Test']","['Yes', 'Yes', 'Yes']","['Merck Sharp & Dohme Ltd.', 'Boehringer Ingelheim International GmbH', 'Abbot Laboratories Ltd']","['Spain', 'Spain']","['No', 'No', 'No']",Isentress,"['Yes', 'Yes', 'Yes']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Film-coated tablet', 'Capsule, soft', 'Capsule, soft']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3']",['Pacientes con infección crónica por VIH-1'],['No'],Evaluar la interacción farmacocinética entre raltegravir y la combinación de tipranavir/ritonavir en pacientes VIH que reciben ambos fármacos en una pauta de rescate.,['Evaluación de la respuesta virológica e inmunológica a las 24 semanas'],['No'],['Pacientes con infección por VIH'],"['Embarazo, lactancia o previsión de embarazo durante el periodo de estudio']","['Comparación de los niveles plasmáticos de raltegravir administrado sin TPV/r ( basal : día 5) y tras su administración conjunta con TPV/r (tras alcanzado el equilibrio estacionario (steady state) de éste a partir de las dos semanas de su coadministración, aproximadamente en el día 20)']",['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['Yes'],['Yes'],['No'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['10'],['Authorised'],['2008-06-27'],['2008-05-23'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Ongoing'],Evaluar la interacción farmacocinética entre raltegravir y la combinación de tipranavir/ritonavir en pacientes VIH que reciben ambos fármacos en una pauta de rescate.-2008-001611-38-Spain - AEMPS-Raltegravir
3,Tygacil,Tigecycline,"['infections bactériennes maladies', 'partir huit ans traitement infections', 'infections', 'infections', 'infections']",Germany - BfArM,2012-005617-39,['Pharmacokinetics of Tigecycline in Patients Receiving Continuous Renal Replacement Therapy'],['WS2030571'],['No'],['University Hospital Tuebingen'],['Germany'],['Non-Commercial'],['Test'],['Yes'],['Pfizer'],['European Union'],['No'],Tygacil,['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Powder for solution for infusion'],['No'],['1'],['Surgical ICU patients with severe infection and renal replacement therapy'],['No'],"The aim of the present study is to assess the pharmacokinetics of tigecycline in patients with acute renal failure receiving continuous veno-venous hemodialysis (CVVHD) with regional citrate anticoagulation or continuous veno-venous hemodiafiltration (CVVHDF) with conventional heparin-based anticoagulation. Particularly, the following parameters should be evaluated:",['Not applicable'],['No'],['* Male and female patients'],['* Pregnant women'],['AUC of tigecycline during renal replacement therapy in comparison to published pharamkokinetic data in healthy adults'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['16'],['Authorised'],['2014-01-14'],['2013-10-14'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"The aim of the present study is to assess the pharmacokinetics of tigecycline in patients with acute renal failure receiving continuous veno-venous hemodialysis (CVVHD) with regional citrate anticoagulation or continuous veno-venous hemodiafiltration (CVVHDF) with conventional heparin-based anticoagulation. Particularly, the following parameters should be evaluated:-2012-005617-39-Germany - BfArM-Tigecycline"
1,Epivir,lamivudine,"['infections', 'humaine']",UK - MHRA,2006-000977-31,"['PHASE IIIB, RANDOMIZED, OPEN LABEL STUDY OF PEGYLATED INTERFERON ALFA-2A IN COMBINATION WITH LAMIVUDINE OR ENTECAVIR COMPARED WITH UNTREATED CONTROL PATIENTS IN CHILDREN WITH HBEAG POSITIVE CHRONIC HEPATITIS B IN THE IMMUNE TOLERANT PHASE']",['NV25361'],['Yes'],['F. Hoffmann-La Roche Ltd'],['Switzerland'],['Commercial'],"['Test', 'Test', 'Test', 'Test', 'Test']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['Roche Registration Ltd', 'ViiV Healthcare UK Ltd.', 'TEVA Pharma B.V', 'BRISTOL-MYERS SQUIBB PHARMA EEIG', 'BRISTOL-MYERS SQUIBB PHARMA EEIG']","['European Union', 'European Union', 'European Union', 'European Union', 'European Union']","['No', 'No', 'No', 'No', 'No']",Epivir,"['No', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['Yes', 'No', 'No', 'No', 'No']","['Yes', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['Yes', 'No', 'No', 'No', 'No']","['Injection', 'Oral solution', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet']","['No', 'No', 'No', 'No', 'No']","['1', '2', '3', '4', '5']",['Chronic Hepatitis B Virus infection'],['No'],"To evaluate the efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by loss of HBsAg 24 weeks post-end of treatment/end of untreated observation.","['•To evaluate efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by seroconversion to anti-HBs, seroconversion to anti-HBe, loss of HBeAg, and HBV DNA levels, at 24 weeks post-end of treatment/end of untreated observation.']",['No'],['• Male and female patients 3 to less than 18 years of age at baseline (12< 18 years of age at baseline in Russia and India)'],"['Patients who have had any previous anti-HBV treatment, or who are co-infected with hepatitis A virus (HAV), HCV, hepatitis D virus (HDV) or HIV, or who have decompensated liver disease will beexcluded.']",['Loss of HBsAg at 24 weeks post-end of treatment (follow-up Week 24)/end of untreated observation (Week 80).'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['10'],['Authorised'],['2006-04-27'],['2006-05-05'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To evaluate the efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by loss of HBsAg 24 weeks post-end of treatment/end of untreated observation.-2006-000977-31-UK - MHRA-lamivudine"
1,Epivir,lamivudine,"['infections', 'humaine']",Belgium - FPS Health-DGM,2006-000977-31,"['PHASE IIIB, RANDOMIZED, OPEN LABEL STUDY OF PEGYLATED INTERFERON ALFA-2A IN COMBINATION WITH LAMIVUDINE OR ENTECAVIR COMPARED WITH UNTREATED CONTROL PATIENTS IN CHILDREN WITH HBEAG POSITIVE CHRONIC HEPATITIS B IN THE IMMUNE TOLERANT PHASE']",['NV25361'],['Yes'],['F. Hoffmann-La Roche Ltd'],['Switzerland'],['Commercial'],"['Test', 'Test', 'Test', 'Test', 'Test']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['Roche Registration Ltd', 'ViiV Healthcare UK Ltd.', 'TEVA Pharma B.V', 'BRISTOL-MYERS SQUIBB PHARMA EEIG', 'BRISTOL-MYERS SQUIBB PHARMA EEIG']","['European Union', 'European Union', 'European Union', 'European Union', 'European Union']","['No', 'No', 'No', 'No', 'No']",Epivir,"['No', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['Yes', 'No', 'No', 'No', 'No']","['Yes', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['Yes', 'No', 'No', 'No', 'No']","['Injection', 'Oral solution', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet']","['No', 'No', 'No', 'No', 'No']","['1', '2', '3', '4', '5']",['Chronic Hepatitis B Virus infection'],['No'],"To evaluate the efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by loss of HBsAg 24 weeks post-end of treatment/end of untreated observation.","['•To evaluate efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by seroconversion to anti-HBs, seroconversion to anti-HBe, loss of HBeAg, and HBV DNA levels, at 24 weeks post-end of treatment/end of untreated observation.']",['No'],['• Male and female patients 3 to less than 18 years of age at baseline (12< 18 years of age at baseline in Russia and India)'],"['Patients who have had any previous anti-HBV treatment, or who are co-infected with hepatitis A virus (HAV), HCV, hepatitis D virus (HDV) or HIV, or who have decompensated liver disease will beexcluded.']",['Loss of HBsAg at 24 weeks post-end of treatment (follow-up Week 24)/end of untreated observation (Week 80).'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],,['Authorised'],['2015-10-29'],['2015-11-02'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To evaluate the efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by loss of HBsAg 24 weeks post-end of treatment/end of untreated observation.-2006-000977-31-Belgium - FPS Health-DGM-lamivudine"
1,Epivir,lamivudine,"['infections', 'humaine']",Italy - Italian Medicines Agency,2006-000977-31,"['PHASE IIIB, RANDOMIZED, OPEN LABEL STUDY OF PEGYLATED INTERFERON ALFA-2A IN COMBINATION WITH LAMIVUDINE OR']",['NV25361'],['Yes'],['F. HOFFMANN - LA ROCHE LTD.'],['Switzerland'],['Commercial'],"['Test', 'Test', 'Test']","['Yes', 'Yes', 'Yes']","['Roche Registration Ltd', 'ViiV Healthcare UK Ltd.', 'TEVA Pharma B.V']","['United Kingdom', 'United Kingdom', 'United Kingdom']","['No', 'No', 'No']",Epivir,"['No', 'Yes', 'Yes']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Yes', 'No', 'No']","['Yes', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Yes', 'No', 'No']","['Solution for injection', 'Oral solution', 'Film-coated tablet']","['Yes', 'No', 'No']","['1', '2', '3']",['Chronic Hepatitis B Virus infection in children.'],['No'],"To evaluate the efficacy of Pegasys¿ + lamivudine compared with an untreated control in children with CHB, as measured by loss of HBsAg 24 weeks post-end of treatment/end of untreated observation.","['¿To evaluate efficacy of Pegasys¿ + lamivudine compared with an untreated control in children with CHB, as measured by seroconversion to anti-HBs, seroconversion to anti-HBe, loss of HBeAg, and HBV DNA levels, at 24 weeks post-end of treatment/end of untreated observation']",['No'],['• Male and female patients 3 to less than 18 years of age at baseline (12– 17 years of age at baseline in Russia)'],"['Patients who have had any previous anti-HBV treatment, or who are co-infected with hepatitis A virus (HAV), HCV, hepatitis D virus (HDV) or HIV, or who have decompensated liver disease will be excluded.']",['The primary efficacy endpoint is defined as loss of HBsAg at 24 weeks post-end of treatment (follow-up Week 24)/end of untreated observation (Week 80).'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['4'],['Authorised'],['2015-08-10'],,['Reason(s) for unfavourable opinion:'],,['Completed'],"To evaluate the efficacy of Pegasys¿ + lamivudine compared with an untreated control in children with CHB, as measured by loss of HBsAg 24 weeks post-end of treatment/end of untreated observation.-2006-000977-31-Italy - Italian Medicines Agency-lamivudine"
1,Epivir,lamivudine,"['infections', 'humaine']",Germany - BfArM,2006-000977-31,"['PHASE IIIB, RANDOMIZED, OPEN-LABEL STUDY OF PEGYLATED INTERFERON ALFA-2A IN COMBINATION WITH LAMIVUDINE OR ENTECAVIR COMPARED WITH UNTREATED CONTROL PATIENTS IN CHILDREN WITH HBEAG-POSITIVE CHRONIC HEPATITIS B IN THE IMMUNE-TOLERANT PHASE']",['NV25361'],['No'],['F. Hoffmann-La Roche Ltd'],['Switzerland'],['Commercial'],"['Test', 'Test', 'Test', 'Test', 'Test']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['Roche Registration GmbH', 'ViiV Healthcare UK Ltd.', 'TEVA Pharma B.V', 'BRISTOL-MYERS SQUIBB PHARMA EEIG', 'BRISTOL-MYERS SQUIBB PHARMA EEIG']","['European Union', 'European Union', 'European Union', 'European Union', 'European Union']","['No', 'No', 'No', 'No', 'No']",Epivir,"['No', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['Yes', 'No', 'No', 'No', 'No']","['Yes', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['Yes', 'No', 'No', 'No', 'No']","['Injection', 'Oral solution', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet']","['No', 'No', 'No', 'No', 'No']","['1', '2', '3', '4', '5']",['Chronic Hepatitis B Virus infection'],['No'],"To evaluate the efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by loss of HBsAg 24 weeks post-end of treatment/end of untreated observation.","['•To evaluate efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by seroconversion to anti-HBs, seroconversion to anti-HBe, loss of HBeAg, and HBV DNA levels, at 24 weeks post-end of']",['No'],['• Male and female patients 3 to less than 18 years of age at baseline (12 to < 18 years of age at baseline in Russia and India)'],"['Patients who have had any previous anti-HBV treatment, or']",['Loss of HBsAg at 24 weeks post-end of treatment (follow-up Week 24)/end of untreated observation (Week 80).'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['10'],['Authorised'],['2014-10-06'],['2015-01-19'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To evaluate the efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by loss of HBsAg 24 weeks post-end of treatment/end of untreated observation.-2006-000977-31-Germany - BfArM-lamivudine"
1,Combivir,"lamivudine, zidovudine","['infections', 'traitement infection', 'humaine']",UK - MHRA,2005-005672-33,"['A Randomized, Controlled, Open-Label, 48-Week Study of Continuing Successfully Suppressive Treatment in HIV-1 Infected Adults with First-Line Twice-Daily Zidovudine and Lamivudine-Based Regimens versus Proactively Replacing of Zidovudine and Lamivudine by Once-Daily Emtricitabine and Tenofovir Disoproxil Fumarate to Prevent Progression of or Reverse Peripheral Lipoatrophy.']",['PR-0095_01'],['Information not present in EudraCT'],['IATEC B.V.'],['Netherlands'],['Non-Commercial'],"['Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Glaxo Group Ltd', 'Gilead Sciences Intl Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Gilead Sciences Intl Ltd', 'Gilead Sciences Intl Ltd', 'Gilead Sciences Intl Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd']","['United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']",Combivir,"['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Film-coated tablet', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11']",['HIV-1 infection'],['No'],Antiretroviral regimens containing emtricitabine plus tenofovir disoproxil fumarate might be associated with a lower incidence and severity of lipoatrophy. In this study we compare the effect of proactively switching zidovudine and lamivudine to emtricitabine plus tenofovir disoproxil fumarate on peripheral fat loss with continued lamivudine and zidovudine-based treatment in HIV-1 infected adults also receiving a non-nucleoside reverse transcriptase inhibitor or (boosted) protease inhibitor. In the patients who discontinue the use of zidovudine and switch to emtricitabine and tenofovir disoproxil fumarate we expect to demonstrate a regaining or at least a lack of further loss of peripheral adipose tissue. Primary Objective: to compare the changes in limb fat between the 2 study arms.,"['- To compare the changes in other aspects of body fat distribution, i.e. fat loss, fat gain, as well as in markers of lipid and glucose metabolism, between the 2 study arms.']",['Information not present in EudraCT'],['- HIV-1 infected patients.'],['- Prior treatment with an NRTI other than zidovudine or lamivudine.'],['Difference between the continuation arm and the switch arm in changes in limb fat over 48 weeks as measured by whole body DEXA.'],['No'],['Information not present in EudraCT'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['15'],['Authorised'],['2006-04-01'],['2006-07-26'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"Antiretroviral regimens containing emtricitabine plus tenofovir disoproxil fumarate might be associated with a lower incidence and severity of lipoatrophy. In this study we compare the effect of proactively switching zidovudine and lamivudine to emtricitabine plus tenofovir disoproxil fumarate on peripheral fat loss with continued lamivudine and zidovudine-based treatment in HIV-1 infected adults also receiving a non-nucleoside reverse transcriptase inhibitor or (boosted) protease inhibitor. In the patients who discontinue the use of zidovudine and switch to emtricitabine and tenofovir disoproxil fumarate we expect to demonstrate a regaining or at least a lack of further loss of peripheral adipose tissue. Primary Objective: to compare the changes in limb fat between the 2 study arms.-2005-005672-33-UK - MHRA-lamivudine, zidovudine"
1,Combivir,"lamivudine, zidovudine","['infections', 'traitement infection', 'humaine']",Spain - AEMPS,2005-005672-33,"['Estudio randomizado, controlado, abierto, de 48 semanas sobre la continuación']",['PR-0095_01'],['Information not present in EudraCT'],['IATEC B.V.'],['Netherlands'],['Non-Commercial'],"['Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Glaxo Group Ltd', 'Gilead Sciences Intl Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Gilead Sciences Intl Ltd', 'Gilead Sciences Intl Ltd', 'Gilead Sciences Intl Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd']","['Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']",Combivir,"['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Film-coated tablet', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11']",['HIV-1 infection'],['No'],Antiretroviral regimens containing emtricitabine plus tenofovir disoproxil fumarate might be associated with a lower incidence and severity of lipoatrophy. In this study we compare the effect of proactively switching zidovudine and lamivudine to emtricitabine plus tenofovir disoproxil fumarate on peripheral fat loss with continued lamivudine and zidovudine-based treatment in HIV-1 infected adults also receiving a non-nucleoside reverse transcriptase inhibitor or (boosted) protease inhibitor. In the patients who discontinue the use of zidovudine and switch to emtricitabine and tenofovir disoproxil fumarate we expect to demonstrate a regaining or at least a lack of further loss of peripheral adipose tissue. Primary Objective: to compare the changes in limb fat between the 2 study arms.,"['- To compare the changes in other aspects of body fat distribution, i.e. fat loss, fat gain, as well as in markers of lipid and glucose metabolism, between the 2 study arms.']",['Information not present in EudraCT'],['- HIV-1 infected patients.'],['- Prior treatment with an NRTI other than zidovudine or lamivudine.'],['Difference between the continuation arm and the switch arm in changes in limb fat over 48 weeks as measured by whole body DEXA.'],['No'],['Information not present in EudraCT'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['15'],['Authorised'],['2006-09-08'],['2006-07-11'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Ongoing'],"Antiretroviral regimens containing emtricitabine plus tenofovir disoproxil fumarate might be associated with a lower incidence and severity of lipoatrophy. In this study we compare the effect of proactively switching zidovudine and lamivudine to emtricitabine plus tenofovir disoproxil fumarate on peripheral fat loss with continued lamivudine and zidovudine-based treatment in HIV-1 infected adults also receiving a non-nucleoside reverse transcriptase inhibitor or (boosted) protease inhibitor. In the patients who discontinue the use of zidovudine and switch to emtricitabine and tenofovir disoproxil fumarate we expect to demonstrate a regaining or at least a lack of further loss of peripheral adipose tissue. Primary Objective: to compare the changes in limb fat between the 2 study arms.-2005-005672-33-Spain - AEMPS-lamivudine, zidovudine"
1,Combivir,"lamivudine, zidovudine","['infections', 'traitement infection', 'humaine']",Finland - Fimea,2005-005672-33,"['A Randomized, Controlled, Open-Label, 48-Week Study of Continuing Successfully Suppressive Treatment in HIV-1 Infected Adults with First-Line Twice-Daily Zidovudine and Lamivudine-Based Regimens versus Proactively Replacing of Zidovudine and Lamivudine by Once-Daily Emtricitabine and Tenofovir Disoproxil Fumarate to Prevent Progression of or Reverse Peripheral Lipoatrophy.']",['PR-0095_01'],['Information not present in EudraCT'],['IATEC B.V.'],['Netherlands'],['Non-Commercial'],"['Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Glaxo Group Ltd', 'Gilead Sciences Intl Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Gilead Sciences Intl Ltd', 'Gilead Sciences Intl Ltd', 'Gilead Sciences Intl Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd', 'Glaxo Group Ltd']","['Finland', 'Finland', 'Finland', 'Finland', 'Finland', 'Finland', 'Finland', 'Finland', 'Finland', 'Finland', 'Finland']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']",Combivir,"['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Film-coated tablet', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet', 'Film-coated tablet', 'Oral solution']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11']",['HIV-1 infection'],['No'],Antiretroviral regimens containing emtricitabine plus tenofovir disoproxil fumarate might be associated with a lower incidence and severity of lipoatrophy. In this study we compare the effect of proactively switching zidovudine and lamivudine to emtricitabine plus tenofovir disoproxil fumarate on peripheral fat loss with continued lamivudine and zidovudine-based treatment in HIV-1 infected adults also receiving a non-nucleoside reverse transcriptase inhibitor or (boosted) protease inhibitor. In the patients who discontinue the use of zidovudine and switch to emtricitabine and tenofovir disoproxil fumarate we expect to demonstrate a regaining or at least a lack of further loss of peripheral adipose tissue. Primary Objective: to compare the changes in limb fat between the 2 study arms.,"['- To compare the changes in other aspects of body fat distribution, i.e. fat loss, fat gain, as well as in markers of lipid and glucose metabolism, between the 2 study arms.']",['Information not present in EudraCT'],['- HIV-1 infected patients.'],['- Prior treatment with an NRTI other than zidovudine or lamivudine.'],['Difference between the continuation arm and the switch arm in changes in limb fat over 48 weeks as measured by whole body DEXA.'],['No'],['Information not present in EudraCT'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['15'],['Authorised'],['2006-08-28'],['2006-08-01'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"Antiretroviral regimens containing emtricitabine plus tenofovir disoproxil fumarate might be associated with a lower incidence and severity of lipoatrophy. In this study we compare the effect of proactively switching zidovudine and lamivudine to emtricitabine plus tenofovir disoproxil fumarate on peripheral fat loss with continued lamivudine and zidovudine-based treatment in HIV-1 infected adults also receiving a non-nucleoside reverse transcriptase inhibitor or (boosted) protease inhibitor. In the patients who discontinue the use of zidovudine and switch to emtricitabine and tenofovir disoproxil fumarate we expect to demonstrate a regaining or at least a lack of further loss of peripheral adipose tissue. Primary Objective: to compare the changes in limb fat between the 2 study arms.-2005-005672-33-Finland - Fimea-lamivudine, zidovudine"
1,Aptivus,tipranavir,"['infections', 'combiné infection', 'initiation traitement doit tenir compte combinaisons mutations pouvant avoir']",Spain - AEMPS,2008-001611-38,['Estudio piloto prospectivo de la farmacocinética y farmacodinamia de la interaciión entre tipranavir/ritonavir y raltegravir en pacientes infectados por el VIH-1'],['PK12-RAL/TPV'],['Information not present in EudraCT'],['Jose M Gatell - Hospital Clinic de Barcelona'],['Spain'],['Non-Commercial'],"['Test', 'Test', 'Test']","['Yes', 'Yes', 'Yes']","['Merck Sharp & Dohme Ltd.', 'Boehringer Ingelheim International GmbH', 'Abbot Laboratories Ltd']","['Spain', 'Spain']","['No', 'No', 'No']",Aptivus,"['Yes', 'Yes', 'Yes']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Film-coated tablet', 'Capsule, soft', 'Capsule, soft']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3']",['Pacientes con infección crónica por VIH-1'],['No'],Evaluar la interacción farmacocinética entre raltegravir y la combinación de tipranavir/ritonavir en pacientes VIH que reciben ambos fármacos en una pauta de rescate.,['Evaluación de la respuesta virológica e inmunológica a las 24 semanas'],['No'],['Pacientes con infección por VIH'],"['Embarazo, lactancia o previsión de embarazo durante el periodo de estudio']","['Comparación de los niveles plasmáticos de raltegravir administrado sin TPV/r ( basal : día 5) y tras su administración conjunta con TPV/r (tras alcanzado el equilibrio estacionario (steady state) de éste a partir de las dos semanas de su coadministración, aproximadamente en el día 20)']",['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['Yes'],['Yes'],['No'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['10'],['Authorised'],['2008-06-27'],['2008-05-23'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Ongoing'],Evaluar la interacción farmacocinética entre raltegravir y la combinación de tipranavir/ritonavir en pacientes VIH que reciben ambos fármacos en una pauta de rescate.-2008-001611-38-Spain - AEMPS-tipranavir
3,Signifor,pasireotide,['lesquels'],Italy - Italian Medicines Agency,2013-000267-84,"['An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continued pasireotide treatment']",['CSOM230B2412'],['No'],['NOVARTIS FARMA'],['Italy'],['Commercial'],"['Test', 'Test', 'Test', 'Test', 'Test']","['Yes', 'No', 'Yes', 'Yes', 'No']","['Novartis Europharm Limited', 'Novartis Europharm Limited', 'Novartis Europharm Limited']","['European Union', 'European Union', 'European Union']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes']",Signifor,"['Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['Solution for injection', 'Powder and solvent for suspension for injection', 'Solution for injection', 'Solution for injection', 'Powder and solvent for suspension for injection']","['No', 'No', 'No', 'No', 'No']","['1', '2', '3', '4', '5']",['Cushing’s disease'],['Yes'],To provide continued supply of pasireotide to patients benefiting from treatment with pasireotide (s.c. and/or LAR) in a Novartis-sponsored study and have fulfilled all required assessments in the parent study,['To collect long term safety data'],['No'],['1. Patient is currently participating in a Novartis Oncology sponsored study receiving pasireotide (LAR and/or s.c.) and has fulfilled all required assessments in the parent study (unless the study is being terminated) and patients that are benefiting from the study drug have no other alternatives.'],"['1. Patient has been permanently discontinued from pasireotide study treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason.']",['Number of patients receiving pasireotide.'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['11'],['Authorised'],['2013-06-07'],['2013-04-18'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Ongoing'],To provide continued supply of pasireotide to patients benefiting from treatment with pasireotide (s.c. and/or LAR) in a Novartis-sponsored study and have fulfilled all required assessments in the parent study-2013-000267-84-Italy - Italian Medicines Agency-pasireotide
3,Signifor,pasireotide,['lesquels'],Belgium - FPS Health-DGM,2013-000267-84,"['An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continued pasireotide treatment']",['CSOM230B2412'],['No'],['Recordati AG'],['Switzerland'],['Commercial'],"['Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['Novartis Europharm Limited, United Kingdom', 'Novartis Europharm Limited', 'Novartis Europharm Limited', 'Novartis Europharm Limited', 'Novartis Europharm Limited', 'Novartis Europharm Limited, United Kingdom', 'Novartis Europharm Limited, United Kingdom']","['United Kingdom', 'European Union', 'European Union', 'European Union', 'European Union', 'United Kingdom', 'United Kingdom']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']",Signifor,"['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['Solution for injection', 'Powder and solvent for suspension for injection', 'Powder and solvent for suspension for injection', 'Powder and solvent for suspension for injection', 'Powder and solvent for suspension for injection', 'Solution for injection', 'Solution for injection']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['1', '2', '3', '4', '5', '6', '7']","[""Cushing's disease""]",['Yes'],To evaluate long term safety data,['To evaluate clinical benefit as assessed by the investigator at scheduled visits'],['No'],['1. Patient is currently participating in a Novartis Oncology sponsored study receiving pasireotide (LAR and/or s.c.) and has fulfilled all required assessments in the parent study (unless the study is being terminated) and patients that are benefiting from the study drug have no other alternatives.'],"['1. Patient has been permanently discontinued from pasireotide study treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason.']",['Frequency and severity of AEs/SAEs'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['22'],['Authorised'],['2013-05-17'],['2013-06-05'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Ongoing'],To evaluate long term safety data-2013-000267-84-Belgium - FPS Health-DGM-pasireotide
3,Signifor,pasireotide,['lesquels'],Spain - AEMPS,2013-000267-84,"['An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continued pasireotide treatment']",['CSOM230B2412'],['No'],"['Novartis Farmacéutica, S.A.']",['Spain'],['Commercial'],"['Test', 'Test', 'Test', 'Test', 'Test', 'Test']","['Yes', 'Yes', 'Yes', 'No', 'No', 'No']","['Novartis Europharm Limited', 'Novartis Europharm Limited', 'Novartis Europharm Limited']","['European Union', 'European Union', 'European Union']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']",Signifor,"['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['Solution for injection', 'Solution for injection', 'Solution for injection', 'Powder and solvent for suspension for injection', 'Powder and solvent for suspension for injection', 'Powder and solvent for suspension for injection']","['No', 'No', 'No', 'No', 'No', 'No']","['1', '2', '3', '4', '5', '6']","[""Cushing's disease Acromegaly Neuroendocrine tumors Pituitary tumors Ectopic""]",['Yes'],To provide continued supply of pasireotide to patients benefiting from treatment with pasireotide (s.c. and/or LAR) in a Novartis-sponsored study and have fulfilled all required assessments in the parent study,['To collect long term safety data'],['No'],['1. Patient is currently participating in a Novartis Oncology sponsored study receiving pasireotide (LAR and/or s.c.) and has fulfilled all required assessments in the parent study (unless the study is being terminated) and patients that are benefiting from the study drug have no other alternatives.'],"['1. Patient has been permanently discontinued from pasireotide study treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason.']",['Number of patients receiving pasireotide.'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['2'],['Authorised'],['2015-03-11'],['2015-01-14'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],To provide continued supply of pasireotide to patients benefiting from treatment with pasireotide (s.c. and/or LAR) in a Novartis-sponsored study and have fulfilled all required assessments in the parent study-2013-000267-84-Spain - AEMPS-pasireotide
3,Signifor,pasireotide,['lesquels'],Greece - EOF,2013-000267-84,"['An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continued pasireotide treatment']",['CSOM230B2412'],['No'],['Novartis Pharma Services AG'],['Switzerland'],['Commercial'],"['Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['Novartis Europharm Limited', 'Novartis Europharm Limited', 'Novartis Europharm Limited', 'Novartis Europharm Limited', 'Novartis Europharm Limited', 'Novartis Europharm Limited', 'Novartis Europharm Limited', 'Novartis Europharm Limited', 'Novartis Europharm Limited']","['European Union', 'European Union', 'European Union', 'European Union', 'European Union', 'European Union', 'European Union', 'European Union', 'European Union']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']",Signifor,"['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Solution for injection', 'Powder and solvent for suspension for injection', 'Solution for injection', 'Solution for injection', 'Powder and solvent for suspension for injection', 'Powder and solvent for suspension for injection', 'Powder and solvent for suspension for injection', 'Solution for injection', 'Solution for injection']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['1', '2', '3', '4', '5', '6', '7', '8', '9']",['Dumping Syndrome'],['Yes'],To provide continued supply of pasireotide to patients benefiting from treatment with pasireotide (s.c. and/or LAR) in a Novartis-sponsored study and have fulfilled all required assessments in the parent study,['To collect long term safety data'],['No'],['1. Patient is currently participating in a Novartis Oncology sponsored study receiving pasireotide (LAR and/or s.c.) and has fulfilled all required assessments in the parent study (unless the study is being terminated) and patients that are benefiting from the study drug have no other alternatives.'],"['1. Patient has been permanently discontinued from pasireotide study treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason.']",['Number of patients receiving pasireotide.'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['2'],['Authorised'],['2015-07-10'],['2015-07-29'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],To provide continued supply of pasireotide to patients benefiting from treatment with pasireotide (s.c. and/or LAR) in a Novartis-sponsored study and have fulfilled all required assessments in the parent study-2013-000267-84-Greece - EOF-pasireotide
3,Signifor,pasireotide,['lesquels'],France - ANSM,2013-000267-84,"['An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continued pasireotide treatment']",['CSOM230B2412'],['No'],['Novartis Pharma Services AG'],['Switzerland'],['Commercial'],"['Test', 'Test', 'Test', 'Test', 'Test', 'Test']","['Yes', 'Yes', 'Yes', 'No', 'No', 'No']","['Novartis Europharm Limited', 'Novartis Europharm Limited', 'Novartis Europharm Limited']","['European Union', 'European Union', 'European Union']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']",Signifor,"['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No']","['Solution for injection', 'Solution for injection', 'Solution for injection', 'Powder and solvent for suspension for injection', 'Powder and solvent for suspension for injection', 'Powder and solvent for suspension for injection']","['No', 'No', 'No', 'No', 'No', 'No']","['1', '2', '3', '4', '5', '6']",['Cushing’s disease'],['Yes'],To provide continued supply of pasireotide to patients benefiting from treatment with pasireotide (s.c. and/or LAR) in a Novartis-sponsored study and have fulfilled all required assessments in the parent study,['To collect long term safety data'],['No'],['1. Patient is currently participating in a Novartis Oncology sponsored study receiving pasireotide (LAR and/or s.c.) and has fulfilled all required assessments in the parent study (unless the study is being terminated) and patients that are benefiting from the study drug have no other alternatives.'],"['1. Patient has been permanently discontinued from pasireotide study treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason.']",['Number of patients receiving pasireotide.'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['9'],['Authorised'],['2013-06-19'],['2013-08-07'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],To provide continued supply of pasireotide to patients benefiting from treatment with pasireotide (s.c. and/or LAR) in a Novartis-sponsored study and have fulfilled all required assessments in the parent study-2013-000267-84-France - ANSM-pasireotide
3,Signifor,pasireotide,['lesquels'],Poland - Office for Medicinal Products,2013-000267-84,"['An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continued pasireotide treatment']",['CSOM230B2412'],['No'],['Novartis Pharma Services AG'],['Switzerland'],['Commercial'],"['Test', 'Test', 'Test', 'Test', 'Test', 'Test', 'Test']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['Novartis Europharm Limited', 'Novartis Europharm Limited', 'Novartis Europharm Limited', 'Novartis Europharm Limited', 'Novartis Europharm Limited', 'Novartis Europharm Limited', 'Novartis Europharm Limited']","['European Union', 'European Union', 'European Union', 'European Union', 'European Union', 'European Union', 'European Union']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']",Signifor,"['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['Solution for injection', 'Powder and solvent for suspension for injection', 'Solution for injection', 'Solution for injection', 'Powder and solvent for suspension for injection', 'Powder and solvent for suspension for injection', 'Powder and solvent for suspension for injection']","['No', 'No', 'No', 'No', 'No', 'No', 'No']","['1', '2', '3', '4', '5', '6', '7']","[""Cushing's disease""]",['Yes'],To evaluate long term safety data,['To evaluate clinical benefit as assessed by the investigator at scheduled visits'],['No'],['1. Patient is currently participating in a Novartis Oncology sponsored study receiving pasireotide (LAR and/or s.c.) and has fulfilled all required assessments in the parent study (unless the study is being terminated) and patients that are benefiting from the study drug have no other alternatives.'],['1. Patient has been permanently discontinued from pasireotide study'],['Frequency and severity of AEs/SAEs'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['25'],['Authorised'],['2016-02-05'],['2015-12-16'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],To evaluate long term safety data-2013-000267-84-Poland - Office for Medicinal Products-pasireotide
3,Signifor,pasireotide,['lesquels'],Portugal - INFARMED,2013-000267-84,"['An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continued pasireotide treatment']",['CSOM230B2412'],['No'],['Recordati AG'],['Switzerland'],['Commercial'],"['Test', 'Test', 'Test']","['Yes', 'Yes', 'Yes']","['Novartis Europharm Limited', 'Novartis Europharm Limited', 'Novartis Europharm Limited']","['European Union', 'European Union', 'European Union']","['No', 'No', 'No']",Signifor,"['Yes', 'Yes', 'Yes']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Powder and solvent for suspension for injection', 'Powder and solvent for suspension for injection', 'Powder and solvent for suspension for injection']","['No', 'No', 'No']","['1', '2', '3']","[""Cushing's disease""]",['Yes'],To evaluate long term safety data,['To evaluate clinical benefit as assessed by the investigator at scheduled visits'],['No'],['1. Patient is currently participating in a Novartis Oncology sponsored study receiving pasireotide (LAR and/or s.c.) and has fulfilled all required assessments in the parent study (unless the study is being terminated) and patients that are benefiting from the study drug have no other alternatives.'],"['1. Patient has been permanently discontinued from pasireotide study treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason.']",['Frequency and severity of AEs/SAEs'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['4'],['Authorised'],['2017-04-07'],['2017-04-24'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],To evaluate long term safety data-2013-000267-84-Portugal - INFARMED-pasireotide
3,Signifor,pasireotide,['lesquels'],Bulgarian Drug Agency,2013-000267-84,"['An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continued pasireotide treatment']",['CSOM230B2412'],['No'],['Recordati AG'],['Switzerland'],['Commercial'],"['Test', 'Test', 'Test']","['Yes', 'Yes', 'Yes']","['Novartis Europharm Limited', 'Novartis Europharm Limited', 'Novartis Europharm Limited']","['European Union', 'European Union', 'European Union']","['No', 'No', 'No']",Signifor,"['Yes', 'Yes', 'Yes']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Powder and solvent for suspension for injection', 'Powder and solvent for suspension for injection', 'Powder and solvent for suspension for injection']","['No', 'No', 'No']","['1', '2', '3']","[""Cushing's disease""]",['Yes'],To evaluate long term safety data,['To evaluate clinical benefit as assessed by the investigator at scheduled visits'],['No'],['1. Patient is currently participating in a Novartis Oncology sponsored study receiving pasireotide (LAR and/or s.c.) and has fulfilled all required assessments in the parent study (unless the study is being terminated) and patients that are benefiting from the study drug have no other alternatives.'],"['1. Patient has been permanently discontinued from pasireotide study treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason.']",['Frequency and severity of AEs/SAEs'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['4'],['Authorised'],['2017-11-29'],['2017-12-12'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],To evaluate long term safety data-2013-000267-84-Bulgarian Drug Agency-pasireotide
3,Zeffix,lamivudine,"['compensée signes réplication', 'inflammation', 'hépatique active fibrose instauration traitement']",Germany - BfArM,2005-005987-94,['Double-blind placebo-controlled randomised trial of lamivudine in the treatment of acute hepatitis B'],['GAHB-Study'],['Information not present in EudraCT'],['University of Leipzig'],['Germany'],['Non-Commercial'],['Test'],['Yes'],['GSK'],['Germany'],['No'],Zeffix,['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],"['Capsule, hard']",['Information not present in EudraCT'],['1'],['Acute Hepatitis B'],['No'],- Is time to bilirubin < 2mg/dl shortened by the treatment with lamivudine?,['- Is the time to clear HBV-DNA/HBeAg/HBsAg and/or development of anti-HBe/anti-'],['Yes'],['- Acute hepatitis'],"['- Known or obvious pre-existing liver disease (by e.g. spider naevis, ascites)']",['Time until Bilirubin < 2 mg/dl'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['140'],['Authorised'],['2006-07-17'],['2006-06-21'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],- Is time to bilirubin < 2mg/dl shortened by the treatment with lamivudine?-2005-005987-94-Germany - BfArM-lamivudine
0,Naglazyme,galsulfase,"['déficit n-acétylgalactosamine-4-sulfatase syndrome maroteaux-lamy voir rubrique 5 1 comme tous', 'irréversibles maladie', 'traiter']",France - ANSM,2005-003512-30,"['A Phase 4 Multi-center, Multi-national, Open-label, Randomized, Two Dose Level Study of Naglazyme (galsulfase) in Infants with Maroteaux-Lamy Syndrome (MPS VI)']",['ASB-008'],['Information not present in EudraCT'],['BioMarin Pharmaceutical Inc.'],['United States'],['Commercial'],['Test'],['Yes'],['BioMarin Europe Ltd.'],['European Union'],['Yes'],Naglazyme,['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Concentrate for solution for infusion'],['Information not present in EudraCT'],['1'],['Mucopolysaccharidosis Type VI (MPS VI; Maroteaux-Lamy Syndrome)'],['Yes'],"The primary objective of the study is to evaluate the efficacy of two dose levels of Naglazyme in preventing the progression of skeletal dysplasia in infants under the age of one year who have MPS VI by monitoring physical appearance, x-ray of the skeletal system and growth.","['The secondary objective of the study is to evaluate the efficacy of the two dose levels of Naglazyme in preventing several measures of disease progression in infants under the age of one year who have MPS VI by monitoring urinary GAGs, gross and fine motor function, cardiac function, vision, hearing, and use of health resources.']",['No'],"['· In the case of subjects under the age of 18, provide written assent (if required) and written informed consent by a parent or legal guardian after the nature of the study has been explained and prior to any research-related procedures;']","['· Perceived to be unreliable or unavailable for study participation or, if under the age of 18, have parents or legal guardians who are perceived to be unreliable or unavailable;']","['The primary efficacy endpoint will be assessed by changes in dysmorphic features as assessed by photographs, changes in skeletal dysplasia as assessed by skeletal survey, and growth as measured by height, weight and head circumference. Other potential benefits of treatment will be periodically assessed by evaluation of gross and fine motor skills as part of the Denver II Development Test, cardiac evaluation by echocardiography, complete eye and visual exam, hearing test by audiometry, Health Resource Utilization Questionnaire, and urinary GAGs.']",['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Information not present in EudraCT'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['Yes'],['No'],,['Authorised'],['2007-04-05'],['2007-03-22'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"The primary objective of the study is to evaluate the efficacy of two dose levels of Naglazyme in preventing the progression of skeletal dysplasia in infants under the age of one year who have MPS VI by monitoring physical appearance, x-ray of the skeletal system and growth.-2005-003512-30-France - ANSM-galsulfase"
0,Kiovig,human normal immunoglobulin (IVIg),"['purpura', 'idiopathique greffe moelle osseuse syndromes déficit immunologique syndrome guillain barre syndrome ganglions lymphatiques cutanéomuqueux thérapie', 'échoué hypogammaglobulinémie infections', 'après', 'infections', 'barré maladie', 'kawasaki neuropathie motrice multifocale']",Germany - PEI,2007-005548-25,"['Prospective, randomised (using minimisation), double-blind, placebo controlled study to evaluate the safety and efficacy of human normal immunoglobulin as a prophylactic agent against infections in patients with high grade gliomas']",['RNOP-12'],['Information not present in EudraCT'],"['Freistaat Bayern, vertreten durch Klinikum der Universität Regensburg']",['Germany'],['Non-Commercial'],['Test'],['Yes'],['Baxter AG'],['European Union'],['No'],Kiovig,['No'],['No'],['No'],['No'],['No'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['Yes'],['No'],['Information not present in EudraCT'],['Intravenous infusion'],['Information not present in EudraCT'],['1'],"['Patients with high-grade gliomas (world health organisation [WHO] grade III or IV) in the first relapse after first-line therapy including chemotherapy with or without nitrososurea, with a life expectancy of at least 6 months and undergoing active treatment with chemotherapy']",['No'],To determine the number of infective episodes in patients with high grade gliomas during treatment with 10% intravenous immunoglobulin (Kiovig) compared with placebo (normal saline).,['To determine the following during treatment with Kiovig compared with placebo:'],['No'],['1.\tMale and female patients ≥ 18 years old'],['1.\tParticipation in another clinical trial'],['The primary endpoint of the study will be the number of infective episodes in patients with high grade glioma during treatment with Kiovig compared with placebo.'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['80'],['Authorised'],['2008-04-30'],['2008-07-28'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Prematurely Ended'],To determine the number of infective episodes in patients with high grade gliomas during treatment with 10% intravenous immunoglobulin (Kiovig) compared with placebo (normal saline).-2007-005548-25-Germany - PEI-human normal immunoglobulin (IVIg)
0,Votubia,everolimus,"['risque complications fonction facteurs tels taille', 'atteints astrocytome sous-épendymaire cellules géantes sega associé', 'volume sega aucun bénéfice']",Netherlands - Competent Authority,2010-019519-39,['Efficacy of RAD001/everolimus in Autism and NeuroPsychological deficits in children with TSC (RAPIT-trial)'],['RAPIT'],['No'],['Erasmus MC - Department of Neurology'],['Netherlands'],['Non-Commercial'],['Test'],['Yes'],['Novartis Europharm Ltd'],['European Union'],['Yes'],Votubia,['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Tablet'],['No'],['1'],['Tuberous Sclerosis Complex'],['Yes'],"The primary objective is to determine the effect of Everolimus on the cognition of children with TSC, measured by","['We will also evaluate the effect on symptoms of autism spectrum disorder, other (neuro) psychological test parameters, seizure frequency, EEG-abnormalities and specific symptoms of learning disability. Furthermore, we will observe the tolerability of Everolimus in children with TSC.']",['Yes'],['• Children with a definite diagnosis of TSC between 3 and 18 years.'],['• Renal or liver dysfunction'],['Cognitive functioning: Mullen scales (IQ)'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['60'],['Authorised'],['2011-12-02'],['2012-03-14'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Ongoing'],"The primary objective is to determine the effect of Everolimus on the cognition of children with TSC, measured by-2010-019519-39-Netherlands - Competent Authority-everolimus"
3,Torisel,Temsirolimus,['risque pronostiques lymphome cellules manteau mcl réfractaire'],Sweden - MPA,2008-003328-45,['Klinisk utvecklingsarbete för utvärdering av molykulärt riktad behandling vid metastaserande njurcancer- PETTO'],,['Information not present in EudraCT'],['Sahlgrenska Universitetssjukhuset'],['Sweden'],['Non-Commercial'],['Test'],['Yes'],['Wyeth Europa Ltd'],['European Union'],['Yes'],Torisel,['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Intravenous infusion'],['Information not present in EudraCT'],['1'],['Metastaserande njurcancer'],['No'],To study if changes in FDG uptake measured by PET after one month of Temsirolimus treatment can predict a later clinical response.,['To study if the metabolic effect (measured FDG - PET) of temsirolimus in metastatic renalcell carcinoma is different in the different histologcical subtypes and in different metastacic sites.'],['No'],['Patients with metastatic renal cell carcinoma in progress after treatment with Sorafenib or Sunitinib.'],['Diabetes mellitus'],['Change in FDG uptake after one month treatment with Temsirolimus compared to baseline.'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Yes'],['No'],['No'],['No'],['No'],['No'],['20'],['Authorised'],['2008-10-03'],['2008-06-17'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Ongoing'],To study if changes in FDG uptake measured by PET after one month of Temsirolimus treatment can predict a later clinical response.-2008-003328-45-Sweden - MPA-Temsirolimus
0,Erbitux,cetuximab,"['cancer colorectal métastatique type sauvage ras exprimant récepteur facteur croissance', 'cancer', 'cancers']",UK - MHRA,2004-001926-26,['XERXES: Examining the role of early neoadjuvant and synchronous Erbitux in pre-operative chemo-radiotherapy using Xeloda followed by excisional surgery.'],['XERXES'],['Information not present in EudraCT'],['University College London'],['United Kingdom'],['Non-Commercial'],"['Test', 'Test']","['Yes', 'Information not present in EudraCT']",['Merck KGaA'],,"['No', 'No']",Erbitux,"['No', 'Yes']","['No', 'No']","['No', 'No']","['No', 'No']","['Yes', 'No']","['Yes', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No']","['No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT']","['Solution for infusion', 'Tablet']","['Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2']",['Locally advanced rectal cancer'],['No'],"To evaluate the safety and toxicity of the combination of erbitux, capecitabine and radiotherapy. This will be determined through an assessment of the patient’s toxicity",['To determine the efficacy of the treatment schedules.  This will be determined through an evaluation of disease-free survival.'],['Information not present in EudraCT'],['Biopsy proven adenocarcinoma of the rectum (tumour <15cm from anal verge); Indication for pre-operative chemoradiotherapy by virtue of partially fixed/unresectable disease and locally advanced disease (T3/T4) where the preoperative MRI confirms the surgeon is unlikely to perform a R0 resection; WHO performance status 0 or 1; Age ≥18 and fit for surgery.'],"['Uncontrolled cardiac, respiratory or other disease, or any serious medical or psychiatric disorder that would preclude trial therapy or informed consent; Previous radiotherapy to the pelvis; Previous chemotherapy or radiation for rectal cancer']",['Acute Toxicity (grade 3 or above in defined Dose Limiting Toxicities)'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['48'],['Authorised'],['2005-06-10'],['2005-04-05'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To evaluate the safety and toxicity of the combination of erbitux, capecitabine and radiotherapy. This will be determined through an assessment of the patient’s toxicity-2004-001926-26-UK - MHRA-cetuximab"
3,Alimta,pemetrexed,"['pleural malin', 'cancer poumon', 'pleural malin', '-cancer poumon petites cellules autre histologie', 'monothérapie traitement entretien cancer poumon', 'cancer poumon']",Germany - BfArM,2006-003816-23,['Multicenter phase II study with pemetrexed in patients with pre-treated metastatic soft tissue sarcomas'],['Alimta'],['Information not present in EudraCT'],['Universitätsklinikum Tübingen'],['Germany'],['Non-Commercial'],['Test'],['Yes'],['Lilly'],['Germany'],['No'],Alimta,['Yes'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Powder for infusion*'],['Information not present in EudraCT'],['1'],['patients with previously treated metastatic soft tissue sarcoma'],['No'],Rate of response,"['Determination of the rate of patients who are progression free at 3 and 6 months, changes in median period of survival and progression free survival, determination of toxicity']",['No'],['- Histologically confirmed metastasized or locally inoperable soft tissue sarcoma'],['- Previous or concurrent irradiation of the indicator lesion'],,['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['28'],['Authorised'],['2006-12-13'],['2006-11-29'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],Rate of response-2006-003816-23-Germany - BfArM-pemetrexed
3,Abilify,aripiprazole,['abilify'],Spain - AEMPS,2005-000472-40,"['A Comparative, Randomized, Open -Label, Multicenter Study on the Efficacy and Safety of Switch Treatment with Aripiprazole in Schizophrenic Out-patients who are']",['CN138-169'],['Information not present in EudraCT'],['Bristol-Myers Squibb International Corporation'],['Belgium'],['Commercial'],"['Test', 'Test', 'Test']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Otsuka Pharmaceutical Europe Ltd.', 'Otsuka Pharmacetical Europe Ltd.', 'Otsuka Pharmaceutical Europe Ltd.']","['Spain', 'Spain', 'Spain']","['No', 'No', 'No']",Abilify,"['Yes', 'Yes', 'Yes']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Tablet', 'Tablet', 'Tablet']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3']",['Schizophrenia'],['No'],To evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general psychiatric practice setting and who are currently experiencing,['To investigate whether out of two switching strategies one is best in term of:'],['Information not present in EudraCT'],['1) Patients with a diagnosis of schizophrenia as defined by DSM-IV-TR2 criteria'],['1) WOCBP who are unwilling or unable to use an acceptable method to avoid'],['Proportion of patients who discontinue due to AE’s.'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['42'],['Authorised'],['2005-08-10'],['2005-07-12'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],To evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general psychiatric practice setting and who are currently experiencing-2005-000472-40-Spain - AEMPS-aripiprazole
3,Abilify,aripiprazole,['abilify'],Hungary - National Institute of Pharmacy,2005-000472-40,"['A Comparative, Randomized, Open -Label, Multicenter Study on the Efficacy and Safety of Switch Treatment with Aripiprazole in Schizophrenic Out-patients who are']",['CN 138-169'],['Information not present in EudraCT'],['Bristol-Myers Squibb International Corporation'],['Belgium'],['Commercial'],"['Test', 'Test', 'Test']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Otsuka Pharmaceutical Europe Ltd.', 'Otsuka Pharmacetical Europe Ltd.', 'Otsuka Pharmaceutical Europe Ltd.']","['Hungary', 'Hungary', 'Hungary']","['No', 'No', 'No']",Abilify,"['Yes', 'Yes', 'Yes']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Tablet', 'Tablet', 'Tablet']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3']",['Schizophrenia'],['No'],To evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general psychiatric practice setting and who are currently experiencing,['To investigate whether out of two switching strategies one is best in term of:'],['Information not present in EudraCT'],['1) Patients with a diagnosis of schizophrenia as defined by DSM-IV-TR criteria'],['1) WOCBP who are unwilling or unable to use an acceptable method to avoid'],['Proportion of patients who discontinue due to AE’s.'],['No'],['Information not present in EudraCT'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['36'],['Authorised'],['2005-09-28'],['2005-09-07'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],To evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general psychiatric practice setting and who are currently experiencing-2005-000472-40-Hungary - National Institute of Pharmacy-aripiprazole
3,Abilify,aripiprazole,['abilify'],UK - MHRA,2005-000472-40,"['A Comparative, Randomized, Open -Label, Multicenter Study on the Efficacy and Safety of Switch Treatment with Aripiprazole in Schizophrenic Out-patients who are']",['CN 138-169'],['Information not present in EudraCT'],['Bristol-Myers Squibb International Corporation'],['Belgium'],['Commercial'],"['Test', 'Test', 'Test']","['Yes', 'Yes', 'Yes']","['Otsuka Pharmaceutical Europe Ltd', 'Otsuka Pharmaceutical Europe Ltd', 'Otsuka Pharmaceutical Europe Ltd']","['European Union', 'European Union', 'European Union']","['No', 'No', 'No']",Abilify,"['Yes', 'Yes', 'Yes']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Tablet', 'Tablet', 'Tablet']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3']",['Schizophrenia'],['No'],To evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general psychiatric practice setting and who are currently experiencing,['To investigate whether out of two switching strategies one is best in term of:'],['No'],['1) Patients with a diagnosis of schizophrenia as defined by DSM-IV-TR criteria'],['1) WOCBP who are unwilling or unable to use an acceptable method to avoid'],['Proportion of patients who discontinue due to AE’s.'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Yes'],['Yes'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['25'],['Authorised'],['2005-08-24'],['2005-10-05'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],To evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general psychiatric practice setting and who are currently experiencing-2005-000472-40-UK - MHRA-aripiprazole
3,Abilify,aripiprazole,['abilify'],Austria - BASG,2005-000472-40,"['A Comparative, Randomized, Open -Label, Multicenter Study on the Efficacy and Safety of Switch Treatment with Aripiprazole in Schizophrenic Out-patients who are']",['CN 138-169'],['Information not present in EudraCT'],['Bristol-Myers Squibb International Corporation'],['Belgium'],['Commercial'],"['Test', 'Test', 'Test']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Otsuka Pharmaceutical Europe Ltd.', 'Otsuka Pharmacetical Europe Ltd.', 'Otsuka Pharmaceutical Europe Ltd.']","['Austria', 'Austria', 'Austria']","['No', 'No', 'No']",Abilify,"['Yes', 'Yes', 'Yes']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Tablet', 'Tablet', 'Tablet']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3']",['Schizophrenia'],['No'],To evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general psychiatric practice setting and who are currently experiencing,['To investigate whether out of two switching strategies one is best in term of:'],['Information not present in EudraCT'],['1) Patients with a diagnosis of schizophrenia as defined by DSM-IV-TR criteria'],['1) WOCBP who are unwilling or unable to use an acceptable method to avoid'],['Proportion of patients who discontinue due to AE’s.'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['18'],['Authorised'],['2005-10-12'],['2005-10-12'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],To evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general psychiatric practice setting and who are currently experiencing-2005-000472-40-Austria - BASG-aripiprazole
3,Abilify,aripiprazole,['abilify'],Germany - BfArM,2005-000472-40,"['A Comparative, Randomized, Open -Label, Multicenter Study on the Efficacy and Safety of Switch Treatment with Aripiprazole in Schizophrenic Out-patients who are Experiencing Insufficient Efficacy with Risperidone and/or Safety and Tolerability Issues,While on Risperidone.']",['CN 138-169'],['Information not present in EudraCT'],['Bristol-Myers Squibb International Corporation'],['Belgium'],['Commercial'],"['Test', 'Test', 'Test']","['Yes', 'Yes', 'Yes']","['Otsuka Pharmaceutical Europe Ltd', 'Otsuka Pharmaceutical Europe Ltd', 'Otsuka Pharmaceutical Europe Ltd']","['European Union', 'European Union', 'European Union']","['No', 'No', 'No']",Abilify,"['Yes', 'Yes', 'Yes']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Tablet', 'Tablet', 'Tablet']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3']",['Schizophrenia'],['No'],To evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general psychiatric practice setting and who are currently experiencing,['To investigate whether out of two switching strategies one is best in term of:'],['No'],['1) Patients with a diagnosis of schizophrenia as defined by DSM-IV-TR criteria'],['1) WOCBP who are unwilling or unable to use an acceptable method to avoid'],['Proportion of patients who discontinue due to AE’s.'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Yes'],['Yes'],['No'],['Information not present in EudraCT'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['42'],['Authorised'],['2005-11-07'],['2005-12-07'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],To evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general psychiatric practice setting and who are currently experiencing-2005-000472-40-Germany - BfArM-aripiprazole
3,Abilify,aripiprazole,['abilify'],Czech Republic - SUKL,2005-000472-40,"['A Comparative, Randomized, Open -Label, Multicenter Study on the Efficacy and Safety of Switch Treatment with Aripiprazole in Schizophrenic Out-patients who are']",['CN 138-169'],['Information not present in EudraCT'],['Bristol-Myers Squibb International Corporation'],['Belgium'],['Commercial'],"['Test', 'Test', 'Test']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Otsuka Pharmaceutical Europe Ltd.', 'Otsuka Pharmacetical Europe Ltd.', 'Otsuka Pharmaceutical Europe Ltd.']","['Czech Republic', 'Czech Republic', 'Czech Republic']","['No', 'No', 'No']",Abilify,"['Yes', 'Yes', 'Yes']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Tablet', 'Tablet', 'Tablet']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3']",['Schizophrenia'],['No'],To evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general psychiatric practice setting and who are currently experiencing,['To investigate whether out of two switching strategies one is best in term of:'],['Information not present in EudraCT'],['1) Patients with a diagnosis of schizophrenia as defined by DSM-IV-TR criteria'],['1) WOCBP who are unwilling or unable to use an acceptable method to avoid'],['Proportion of patients who discontinue due to AE’s.'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['36'],['Authorised'],['2005-10-04'],['2005-10-12'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],To evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general psychiatric practice setting and who are currently experiencing-2005-000472-40-Czech Republic - SUKL-aripiprazole
3,Abilify,aripiprazole,['abilify'],Belgium - FPS Health-DGM,2005-000472-40,"['A Comparative, Randomized, Open-Label, Multicenter Study on the Efficacy and Safety of Switch Treatment with Aripiprazole in Schizophrenic Out-patients who are']",['CN 138-169'],['Information not present in EudraCT'],['Bristol-Myers Squibb International Corporation'],['Belgium'],['Commercial'],"['Test', 'Test', 'Test']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Otsuka Pharmaceutical Europe Ltd.', 'Otsuka Pharmacetical Europe Ltd.', 'Otsuka Pharmaceutical Europe Ltd.']","['Belgium', 'Belgium', 'Belgium']","['No', 'No', 'No']",Abilify,"['Yes', 'Yes', 'Yes']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Tablet', 'Tablet', 'Tablet']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3']",['Schizophrenia'],['No'],To evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general psychiatric practice setting and who are currently experiencing,['To investigate whether out of two switching strategies one is best in term of:'],['Information not present in EudraCT'],['1) Patients with a diagnosis of schizophrenia as defined by DSM-IV-TR criteria'],['1) WOCBP who are unwilling or unable to use an acceptable method to avoid'],['Proportion of patients who discontinue due to AE’s.'],['No'],['Information not present in EudraCT'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['36'],['Authorised'],['2005-11-09'],['2006-09-05'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],To evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general psychiatric practice setting and who are currently experiencing-2005-000472-40-Belgium - FPS Health-DGM-aripiprazole
0,Temomedac,temozolomide,['atteints gliome malin tel glioblastome multiforme astrocytome anaplasique montrant'],Germany - BfArM,2011-004062-15,"['Prospective, open label, randomized phase II trial to assess a multimodal molecular targeted therapy in children, adolescent and young adults with relapsed or refractory high risk neuroblastoma']",['RIST-rNB-2011'],['No'],['University Hospital of Regensburg'],['Germany'],['Non-Commercial'],"['Test', 'Comparator', 'Test', 'Comparator', 'Test', 'Test', 'Test', 'Comparator', 'Comparator', 'Comparator', 'Test', 'Test', 'Test', 'Test', 'Test']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['Bristol-Myers-Squibb', 'Medac', 'Pfizer Ltd', 'Medac', 'Pfizer Ltd.', 'Bristol-Myers-Squibb', 'Bristol-Myers-Squibb', 'Medac', 'Medac', 'Medac', 'Pfizer Ltd.', 'Pfizer Ltd.', 'Pfizer Ltd.', 'Bristol-Myers-Squibb', 'Bristol-Myers-Squibb']","['Germany', 'Germany', 'Germany', 'Germany', 'Germany', 'Germany', 'Germany', 'Germany', 'Germany', 'Germany', 'Germany', 'Germany', 'Germany', 'Germany', 'Germany']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']",Temomedac,"['Yes', 'Yes', 'No', 'Yes', 'No', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'No', 'No', 'No', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'Yes', 'No', 'Yes', 'No', 'No', 'No', 'No', 'No', 'Yes', 'Yes', 'Yes', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['No', 'No', 'Yes', 'No', 'Yes', 'No', 'No', 'No', 'No', 'No', 'Yes', 'Yes', 'Yes', 'No', 'No']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['Film-coated tablet', 'Capsule, hard', 'Oral solution', 'Concentrate for solution for infusion', 'Tablet', 'Film-coated tablet', 'Film-coated tablet', 'Capsule, hard', 'Capsule, hard', 'Capsule, hard', 'Tablet', 'Tablet', 'Tablet', 'Film-coated tablet', 'Film-coated tablet']","['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No']","['1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '14', '15']",['Relapsed or refractory high risk neuroblastoma'],['Yes'],"The primary objective of this trial is the evaluation of progression-free survival of rNB in children, adolescents and young adults, comparing a multimodal treatment regimen consisting of temozolomide (T), irinotecan (I), rapamycin (R) and dasatinib (S) against Irinotecan (I)/Temozolomide (T) alone.",['Secondary objectives are'],['No'],['Patients with relapsed high-risk neuroblastoma (stage IV and all MYCN pos. stages) or progressive disease during primary treatment (=rNB) / Patients with relapsed'],['Patients presenting with any of the following criteria will not be included in this clinical trial:'],"['The primary endpoint is progression-free survival (PFS), which is defined as the time interval between randomization and date of progression (first time at which progression can be declared) according to']",['Yes'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['114'],['Authorised'],['2012-08-06'],['2012-07-04'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"The primary objective of this trial is the evaluation of progression-free survival of rNB in children, adolescents and young adults, comparing a multimodal treatment regimen consisting of temozolomide (T), irinotecan (I), rapamycin (R) and dasatinib (S) against Irinotecan (I)/Temozolomide (T) alone.-2011-004062-15-Germany - BfArM-temozolomide"
3,Brinavess,Vernakalant hydrochloride,"['fibrillation', 'rapide fibrillation auriculaire', 'chirurgicaux fibrillation auriculaire']",Netherlands - Competent Authority,2012-001898-90,['Effects of vernakalant and flecainide on atrial contractility in patients with atrial fibrillation'],['Crijns01.12-02-026'],['No'],['Maastricht University Medical Center'],['Netherlands'],['Non-Commercial'],"['Comparator', 'Comparator']","['Yes', 'Yes']","['Merck Sharp & Dohme', 'Meda Health Sales']","['European Union', 'Netherlands']","['No', 'No']",Brinavess,"['Yes', 'Yes']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['No', 'No']","['Concentrate for solution for infusion', 'Solution for injection']","['No', 'No']","['1', '2']",['Patients with paroxysmal or persistent atrial fibrillation (AF) reporting at the first heart aid.'],['No'],To compare the atrial contractility by means of echocardiography between patients receiving flecainide and vernakalant i.v. after conversion to sinus rhythm.,['a. To compare the conversion rate of AF between patients receiving flecainide and vernakalant i.v.'],['No'],['- patients presenting with paroxysmal or persistent AF'],['- atrial flutter'],['Echocardiography to evaluate atrial contractility after conversion to sinus rhythm.'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['50'],['Authorised'],['2012-05-01'],['2012-06-25'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Ongoing'],To compare the atrial contractility by means of echocardiography between patients receiving flecainide and vernakalant i.v. after conversion to sinus rhythm.-2012-001898-90-Netherlands - Competent Authority-Vernakalant hydrochloride
3,Baraclude,Entecavir,"['compensée signes réplication', 'inflammation', 'infection']",UK - MHRA,2006-000977-31,"['PHASE IIIB, RANDOMIZED, OPEN LABEL STUDY OF PEGYLATED INTERFERON ALFA-2A IN COMBINATION WITH LAMIVUDINE OR ENTECAVIR COMPARED WITH UNTREATED CONTROL PATIENTS IN CHILDREN WITH HBEAG POSITIVE CHRONIC HEPATITIS B IN THE IMMUNE TOLERANT PHASE']",['NV25361'],['Yes'],['F. Hoffmann-La Roche Ltd'],['Switzerland'],['Commercial'],"['Test', 'Test', 'Test', 'Test', 'Test']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['Roche Registration Ltd', 'ViiV Healthcare UK Ltd.', 'TEVA Pharma B.V', 'BRISTOL-MYERS SQUIBB PHARMA EEIG', 'BRISTOL-MYERS SQUIBB PHARMA EEIG']","['European Union', 'European Union', 'European Union', 'European Union', 'European Union']","['No', 'No', 'No', 'No', 'No']",Baraclude,"['No', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['Yes', 'No', 'No', 'No', 'No']","['Yes', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['Yes', 'No', 'No', 'No', 'No']","['Injection', 'Oral solution', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet']","['No', 'No', 'No', 'No', 'No']","['1', '2', '3', '4', '5']",['Chronic Hepatitis B Virus infection'],['No'],"To evaluate the efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by loss of HBsAg 24 weeks post-end of treatment/end of untreated observation.","['•To evaluate efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by seroconversion to anti-HBs, seroconversion to anti-HBe, loss of HBeAg, and HBV DNA levels, at 24 weeks post-end of treatment/end of untreated observation.']",['No'],['• Male and female patients 3 to less than 18 years of age at baseline (12< 18 years of age at baseline in Russia and India)'],"['Patients who have had any previous anti-HBV treatment, or who are co-infected with hepatitis A virus (HAV), HCV, hepatitis D virus (HDV) or HIV, or who have decompensated liver disease will beexcluded.']",['Loss of HBsAg at 24 weeks post-end of treatment (follow-up Week 24)/end of untreated observation (Week 80).'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['10'],['Authorised'],['2006-04-27'],['2006-05-05'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To evaluate the efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by loss of HBsAg 24 weeks post-end of treatment/end of untreated observation.-2006-000977-31-UK - MHRA-Entecavir"
3,Baraclude,Entecavir,"['compensée signes réplication', 'inflammation', 'infection']",Belgium - FPS Health-DGM,2006-000977-31,"['PHASE IIIB, RANDOMIZED, OPEN LABEL STUDY OF PEGYLATED INTERFERON ALFA-2A IN COMBINATION WITH LAMIVUDINE OR ENTECAVIR COMPARED WITH UNTREATED CONTROL PATIENTS IN CHILDREN WITH HBEAG POSITIVE CHRONIC HEPATITIS B IN THE IMMUNE TOLERANT PHASE']",['NV25361'],['Yes'],['F. Hoffmann-La Roche Ltd'],['Switzerland'],['Commercial'],"['Test', 'Test', 'Test', 'Test', 'Test']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['Roche Registration Ltd', 'ViiV Healthcare UK Ltd.', 'TEVA Pharma B.V', 'BRISTOL-MYERS SQUIBB PHARMA EEIG', 'BRISTOL-MYERS SQUIBB PHARMA EEIG']","['European Union', 'European Union', 'European Union', 'European Union', 'European Union']","['No', 'No', 'No', 'No', 'No']",Baraclude,"['No', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['Yes', 'No', 'No', 'No', 'No']","['Yes', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['Yes', 'No', 'No', 'No', 'No']","['Injection', 'Oral solution', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet']","['No', 'No', 'No', 'No', 'No']","['1', '2', '3', '4', '5']",['Chronic Hepatitis B Virus infection'],['No'],"To evaluate the efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by loss of HBsAg 24 weeks post-end of treatment/end of untreated observation.","['•To evaluate efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by seroconversion to anti-HBs, seroconversion to anti-HBe, loss of HBeAg, and HBV DNA levels, at 24 weeks post-end of treatment/end of untreated observation.']",['No'],['• Male and female patients 3 to less than 18 years of age at baseline (12< 18 years of age at baseline in Russia and India)'],"['Patients who have had any previous anti-HBV treatment, or who are co-infected with hepatitis A virus (HAV), HCV, hepatitis D virus (HDV) or HIV, or who have decompensated liver disease will beexcluded.']",['Loss of HBsAg at 24 weeks post-end of treatment (follow-up Week 24)/end of untreated observation (Week 80).'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],,['Authorised'],['2015-10-29'],['2015-11-02'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To evaluate the efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by loss of HBsAg 24 weeks post-end of treatment/end of untreated observation.-2006-000977-31-Belgium - FPS Health-DGM-Entecavir"
3,Baraclude,Entecavir,"['compensée signes réplication', 'inflammation', 'infection']",Germany - BfArM,2006-000977-31,"['PHASE IIIB, RANDOMIZED, OPEN-LABEL STUDY OF PEGYLATED INTERFERON ALFA-2A IN COMBINATION WITH LAMIVUDINE OR ENTECAVIR COMPARED WITH UNTREATED CONTROL PATIENTS IN CHILDREN WITH HBEAG-POSITIVE CHRONIC HEPATITIS B IN THE IMMUNE-TOLERANT PHASE']",['NV25361'],['No'],['F. Hoffmann-La Roche Ltd'],['Switzerland'],['Commercial'],"['Test', 'Test', 'Test', 'Test', 'Test']","['Yes', 'Yes', 'Yes', 'Yes', 'Yes']","['Roche Registration GmbH', 'ViiV Healthcare UK Ltd.', 'TEVA Pharma B.V', 'BRISTOL-MYERS SQUIBB PHARMA EEIG', 'BRISTOL-MYERS SQUIBB PHARMA EEIG']","['European Union', 'European Union', 'European Union', 'European Union', 'European Union']","['No', 'No', 'No', 'No', 'No']",Baraclude,"['No', 'Yes', 'Yes', 'Yes', 'Yes']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['Yes', 'No', 'No', 'No', 'No']","['Yes', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['No', 'No', 'No', 'No', 'No']","['Yes', 'No', 'No', 'No', 'No']","['Injection', 'Oral solution', 'Film-coated tablet', 'Oral solution', 'Film-coated tablet']","['No', 'No', 'No', 'No', 'No']","['1', '2', '3', '4', '5']",['Chronic Hepatitis B Virus infection'],['No'],"To evaluate the efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by loss of HBsAg 24 weeks post-end of treatment/end of untreated observation.","['•To evaluate efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by seroconversion to anti-HBs, seroconversion to anti-HBe, loss of HBeAg, and HBV DNA levels, at 24 weeks post-end of']",['No'],['• Male and female patients 3 to less than 18 years of age at baseline (12 to < 18 years of age at baseline in Russia and India)'],"['Patients who have had any previous anti-HBV treatment, or']",['Loss of HBsAg at 24 weeks post-end of treatment (follow-up Week 24)/end of untreated observation (Week 80).'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['10'],['Authorised'],['2014-10-06'],['2015-01-19'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To evaluate the efficacy of Pegasys® + lamivudine or entecavir compared with an untreated control in children with CHB, as measured by loss of HBsAg 24 weeks post-end of treatment/end of untreated observation.-2006-000977-31-Germany - BfArM-Entecavir"
1,Twinrix Paediatric,"hepatitis A virus (inactivated), hepatitis B surface antigen",['infection'],Sweden - MPA,2006-005999-41,"['A phase III, randomized, open, controlled, multicenter primary vaccination study to demonstrate the non inferiority of the immunogenicity of GSK Biologicals’ meningococcal serogroup ACWY conjugate vaccine when given as one dose with Twinrix™ versus GSK Biologicals’ meningococcal serogroup ACWY conjugate vaccine alone and versus Twinrix™ alone in healthy subjects aged 11 through 17 years']",['109063'],['Information not present in EudraCT'],['GlaxoSmithKline Biologicals'],['Belgium'],['Commercial'],"['Test', 'Test', 'Test']","['No', 'Yes', 'Yes']","['GlaxoSmithKline Biologicals', 'GlaxoSmithKline Biologicals']","['European Union', 'European Union']","['No', 'No', 'No']",Twinrix Paediatric,"['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Yes', 'Yes', 'Yes']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['Yes', 'Yes', 'Yes']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Powder and solvent for solution for injection', 'Suspension for injection', 'Suspension for injection']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3']","['Primary immunization of healthy subjects aged 11 through 17 years against meningococcal serogroups A, C, W 135 and Y and/or hepatitis A and hepatitis B diseases']",['No'],"To demonstrate the non-inferiority of the MenACWY-TT conjugate vaccine co-administered with Twinrix as compared to the MenACWY-TT conjugate vaccine administered alone with respect to the serum bactericidal antibody geometric mean titres as measured using baby rabbit complement (rSBA GMTs) for N. meningitidis serogroups A, C, W-135 and Y.",['To compare the immunogenicity of the MenACWY TT conjugate vaccine co-administered with Twinrix compared to that of the MenACWY-TT vaccine alone; To evaluate the safety and reactogenicity of the MenACWY-TT conjugate vaccine co-administered with Twinrix to that of the MenACWY-TT vaccine alone; To compare the immunogenicity of the 3th dose of Twinrix in the MenACWY-TT+ Twinrix group to that of the Twinrix group; To evaluate the safety and reactogenicity of Twinrix in the MenACWY-TT+Twinrix group to that of the Twinrix group after each Twinrix dose.'],['No'],"['healthy males and females aged 11 through 17 years who have previously completed routine childhood vaccinations to the best of his/her/the parents’/guardians’ knowledge. If a subject is female of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for two months after completion of the vaccination series']","['The following criteria should be checked at the time of study entry. If any apply, the subject must not be included in the study:']","['At one month after vaccination with MenACWY-TT and the first dose of Twinrix (Post vacc I Study Month 1), in subjects in the MenACWY-TT + Twinrix group and the MenACWY-TT group:']",['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['Information not present in EudraCT'],['No'],['Yes'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],['500'],['Authorised'],['2007-01-23'],['2007-01-10'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To demonstrate the non-inferiority of the MenACWY-TT conjugate vaccine co-administered with Twinrix as compared to the MenACWY-TT conjugate vaccine administered alone with respect to the serum bactericidal antibody geometric mean titres as measured using baby rabbit complement (rSBA GMTs) for N. meningitidis serogroups A, C, W-135 and Y.-2006-005999-41-Sweden - MPA-hepatitis A virus (inactivated), hepatitis B surface antigen"
1,Twinrix Paediatric,"hepatitis A virus (inactivated), hepatitis B surface antigen",['infection'],Denmark - DHMA,2006-005999-41,"['A phase III, randomized, open, controlled, multicenter primary vaccination study to demonstrate the non inferiority of the immunogenicity of GSK Biologicals’ meningococcal serogroup ACWY conjugate vaccine when given as one dose with Twinrix™ versus GSK Biologicals’ meningococcal serogroup ACWY conjugate vaccine alone and versus Twinrix™ alone in healthy subjects aged 11 through 17 years']",['109063'],['Information not present in EudraCT'],['GlaxoSmithKline Biologicals'],['Belgium'],['Commercial'],"['Test', 'Test', 'Test']","['No', 'Yes', 'Yes']","['GlaxoSmithKline Biologicals', 'GlaxoSmithKline Biologicals']",,"['No', 'No', 'No']",Twinrix Paediatric,"['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Yes', 'Yes', 'Yes']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['Yes', 'Yes', 'Yes']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Powder and solvent for solution for injection', 'Suspension for injection', 'Suspension for injection']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3']","['Primary immunization of healthy subjects aged 11 through 17 years against meningococcal serogroups A, C, W 135 and Y and/or hepatitis A and hepatitis B diseases']",['No'],"To demonstrate the non-inferiority of the MenACWY-TT conjugate vaccine co-administered with Twinrix as compared to the MenACWY-TT conjugate vaccine administered alone with respect to the serum bactericidal antibody geometric mean titres as measured using baby rabbit complement (rSBA GMTs) for N. meningitidis serogroups A, C, W-135 and Y.",['To compare the immunogenicity of the MenACWY TT conjugate vaccine co-administered with Twinrix compared to that of the MenACWY-TT vaccine alone; To evaluate the safety and reactogenicity of the MenACWY-TT conjugate vaccine co-administered with Twinrix to that of the MenACWY-TT vaccine alone; To compare the immunogenicity of the 3th dose of Twinrix in the MenACWY-TT+ Twinrix group to that of the Twinrix group; To evaluate the safety and reactogenicity of Twinrix in the MenACWY-TT+Twinrix group to that of the Twinrix group after each Twinrix dose.'],['No'],"['healthy males and females aged 11 through 17 years who have previously completed routine childhood vaccinations to the best of his/her/the parents’/guardians’ knowledge. If a subject is female of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for two months after completion of the vaccination series']","['The following criteria should be checked at the time of study entry. If any apply, the subject must not be included in the study:']","['At one month after vaccination with MenACWY-TT and the first dose of Twinrix (Post vacc I Study Month 1), in subjects in the MenACWY-TT + Twinrix group and the MenACWY-TT group:']",['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['Information not present in EudraCT'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['No'],['No'],['No'],['Yes'],['No'],,['Authorised'],['2007-03-20'],['2007-03-29'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To demonstrate the non-inferiority of the MenACWY-TT conjugate vaccine co-administered with Twinrix as compared to the MenACWY-TT conjugate vaccine administered alone with respect to the serum bactericidal antibody geometric mean titres as measured using baby rabbit complement (rSBA GMTs) for N. meningitidis serogroups A, C, W-135 and Y.-2006-005999-41-Denmark - DHMA-hepatitis A virus (inactivated), hepatitis B surface antigen"
3,Humalog,insulin lispro,['traitement adultes enfants atteints diabète sucré besoin insuline maintenir homéostasie normale'],Czech Republic - SUKL,2007-004864-29,['A Prospective Randomized Trial to Compare Basal Bolus therapies that use either Insulin Lispro Protamine Suspension or Insulin Glargine together with Lispro Insulin in Patients with Type 2 Diabetes'],['F3Z-EW-IOPJ'],['Information not present in EudraCT'],['Eli Lilly and Company'],['United States'],['Commercial'],"['Test', 'Comparator', 'Comparator']","['Yes', 'Yes', 'Yes']","['Eli Lilly Nederland B.V.', 'Eli Lilly Nederland B.V.', 'Sanofi-Aventis Deutschland GmbH']","['European Union', 'European Union', 'European Union']","['No', 'No', 'No']",Humalog,"['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Yes', 'Yes', 'Yes']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Suspension for injection', 'Solution for injection', 'Solution for injection']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3']",['Type II diabetes mellitus'],['No'],"To test the hypothesis that, in T2DM, a basal bolus regimen containing analog insulin lispro protamine suspension provides noninferior glycemic control to a basal bolus regimen containing analog insulin glargine, when these basal insulins are injected once daily together with insulin lispro injected 2-3 times daily.","['To compare the efficacy, safety of insulin lispro protamine suspension and glargine when used in a basal bolus regimen together with insulin Lispro in relation to:']",['No'],['Patients are eligible to be included in the study only if they meet all of the following criteria:'],['Patients will be excluded from the study if they meet any of the following criteria:'],,['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['40'],['Authorised'],['2008-02-13'],['2008-02-13'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To test the hypothesis that, in T2DM, a basal bolus regimen containing analog insulin lispro protamine suspension provides noninferior glycemic control to a basal bolus regimen containing analog insulin glargine, when these basal insulins are injected once daily together with insulin lispro injected 2-3 times daily.-2007-004864-29-Czech Republic - SUKL-insulin lispro"
3,Humalog,insulin lispro,['traitement adultes enfants atteints diabète sucré besoin insuline maintenir homéostasie normale'],UK - MHRA,2007-004864-29,['A Prospective Randomized Trial to Compare Basal Bolus therapies that use either Insulin Lispro Protamine Suspension or Insulin Glargine together with Lispro Insulin in Patients with Type 2 Diabetes'],['F3Z-EW-IOPJ'],['Information not present in EudraCT'],['Eli Lilly and Company Limited'],['United Kingdom'],['Commercial'],"['Test', 'Comparator', 'Comparator']","['Yes', 'Yes', 'Yes']","['Eli Lilly Nederland B.V.', 'Eli Lilly Nederland B.V.', 'Sanofi-Aventis Deutschland GmbH']","['European Union', 'European Union', 'European Union']","['No', 'No', 'No']",Humalog,"['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Yes', 'Yes', 'Yes']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Suspension for injection', 'Solution for injection', 'Solution for injection']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3']",['Type II diabetes mellitus'],['No'],"To test the hypothesis that, in T2DM, a basal bolus regimen containing analog insulin lispro protamine suspension provides noninferior glycemic control to a basal bolus regimen containing analog insulin glargine, when these basal insulins are injected once daily together with insulin lispro injected 2-3 times daily.","['To compare the efficacy, safety of insulin lispro protamine suspension and glargine when used in a basal bolus regimen together with insulin Lispro in relation to:']",['No'],['Patients are eligible to be included in the study only if they meet all of the following criteria:'],['Patients will be excluded from the study if they meet any of the following criteria:'],,['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['40'],['Authorised'],['2008-03-13'],['2008-10-21'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To test the hypothesis that, in T2DM, a basal bolus regimen containing analog insulin lispro protamine suspension provides noninferior glycemic control to a basal bolus regimen containing analog insulin glargine, when these basal insulins are injected once daily together with insulin lispro injected 2-3 times daily.-2007-004864-29-UK - MHRA-insulin lispro"
3,Humalog,insulin lispro,['traitement adultes enfants atteints diabète sucré besoin insuline maintenir homéostasie normale'],Belgium - FPS Health-DGM,2007-004864-29,['A Prospective Randomized Trial to Compare Basal Bolus therapies that use either Insulin Lispro Protamine Suspension or Insulin Glargine together with Lispro Insulin in Patients with Type 2 Diabetes'],['F3Z-EW-IOPJ'],['Information not present in EudraCT'],['Eli Lilly and Company Limited'],['United Kingdom'],['Commercial'],"['Test', 'Comparator', 'Comparator']","['Yes', 'Yes', 'Yes']","['Eli Lilly Nederland B.V.', 'Eli Lilly Nederland B.V.', 'Sanofi-Aventis Deutschland GmbH']","['European Union', 'European Union', 'European Union']","['No', 'No', 'No']",Humalog,"['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Yes', 'Yes', 'Yes']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Suspension for injection', 'Solution for injection', 'Solution for injection']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3']",['Type II diabetes mellitus'],['No'],"To test the hypothesis that, in T2DM, a basal bolus regimen containing analog insulin lispro protamine suspension provides noninferior glycemic control to a basal bolus regimen containing analog insulin glargine, when these basal insulins are injected once daily together with insulin lispro injected 2-3 times daily.","['To compare the efficacy, safety of insulin lispro protamine suspension and glargine when used in a basal bolus regimen together with insulin Lispro in relation to:']",['No'],['Patients are eligible to be included in the study only if they meet all of the following criteria:'],"['7. Have taken any glucose-lowering medications not included in Inclusion Criterion [3] (for example, acarbose, miglitol, pramlintide, exenatide) in the past 3 months before Visit 1.']",,['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],,['Authorised'],['2008-04-25'],['2008-08-14'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To test the hypothesis that, in T2DM, a basal bolus regimen containing analog insulin lispro protamine suspension provides noninferior glycemic control to a basal bolus regimen containing analog insulin glargine, when these basal insulins are injected once daily together with insulin lispro injected 2-3 times daily.-2007-004864-29-Belgium - FPS Health-DGM-insulin lispro"
3,Humalog,insulin lispro,['traitement adultes enfants atteints diabète sucré besoin insuline maintenir homéostasie normale'],Slovakia - SIDC (Slovak),2007-004864-29,['A Prospective Randomized Trial to Compare Basal Bolus therapies that use either Insulin Lispro Protamine Suspension or Insulin Glargine together with Lispro Insulin in Patients with Type 2 Diabetes'],['F3Z-EW-IOPJ'],['Information not present in EudraCT'],['Eli Lilly and Company'],['United States'],['Commercial'],"['Test', 'Comparator', 'Comparator']","['Yes', 'Yes', 'Yes']","['Eli Lilly Nederland B.V.', 'Eli Lilly Nederland B.V.', 'Sanofi-Aventis Deutschland GmbH']","['European Union', 'European Union', 'European Union']","['No', 'No', 'No']",Humalog,"['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Yes', 'Yes', 'Yes']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Suspension for injection', 'Solution for injection', 'Solution for injection']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3']",['Type II diabetes mellitus'],['No'],"To test the hypothesis that, in T2DM, a basal bolus regimen containing analog insulin lispro protamine suspension provides noninferior glycemic control to a basal bolus regimen containing analog insulin glargine, when these basal insulins are injected once daily together with insulin lispro injected 2-3 times daily.","['To compare the efficacy, safety of insulin lispro protamine suspension and glargine when used in a basal bolus regimen together with insulin Lispro in relation to:']",['No'],['Patients are eligible to be included in the study only if they meet all of the following criteria:'],['Patients will be excluded from the study if they meet any of the following criteria:'],,['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['40'],['Authorised'],['2008-11-11'],['2008-12-19'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To test the hypothesis that, in T2DM, a basal bolus regimen containing analog insulin lispro protamine suspension provides noninferior glycemic control to a basal bolus regimen containing analog insulin glargine, when these basal insulins are injected once daily together with insulin lispro injected 2-3 times daily.-2007-004864-29-Slovakia - SIDC (Slovak)-insulin lispro"
3,Humalog,insulin lispro,['traitement adultes enfants atteints diabète sucré besoin insuline maintenir homéostasie normale'],Italy - Italian Medicines Agency,2007-004864-29,['A Prospective Randomized Trial to Compare Bsal Bolus therapies that use either Insuline Lispro Protamine Suspension or Insulin Glargine together with Lispro Insulin in patients with type 2 Diabetes'],['F3Z-EW-IOPJ'],['Information not present in EudraCT'],['ELI LILLY'],['Italy'],['Commercial'],"['Test', 'Comparator', 'Comparator']","['Yes', 'Yes', 'Yes']","['Eli Lily Nederlands B.V.', 'Eli Lilly Nederlands B.V.', 'Sanofi-Aventis Deutschland GmbH']","['Netherlands', 'Netherlands', 'Germany']","['No', 'No', 'No']",Humalog,"['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Yes', 'Yes', 'Yes']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Suspension for injection', 'Suspension for injection', 'Solution for injection']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3']",['Type 2 Diabetes Mellitus'],['No'],"To test the hypothesis that, in T2DM, a basal bolus regimen containing analog insulin lispro protamine suspension provides noninferior glycemic control to a basal bolus regimen containing analog insulin glargine, when these basal insulins are injected once daily together with insulin lispro injected 2-3 times daily.  Glycemic control will be assessed by the change of HbA1c from baseline to 24 weeks","['To compare the efficacy, safety of insulin lispro protamine suspension and glargine when used in a basal bolus regimen together with insulin Lispro in relation to:   Change in HbA1c at 12 weeks and at 24 weeks;    percentage of patients with HbA1c <7.0% and HbA1c &amp;#8804;6.5% at 24 weeks;    7-point self-monitored blood glucose (SMBG) profile at 24 weeks;    glycemic variability at 24 weeks;    to compare the safety of insulin Lispro suspension and glargine when used in a basal bolus regimen together with insulin Lispro in relation to:   the incidence of self-reported hypoglycemic episodes    absolute body weight (kg) and incremental weight change from baseline to 24 weeks    treatment-emergent adverse events (TEAEs);    to compare total daily insulin dose and number of injections at 24 weeks.']",['No'],"['Patients are eligible to be included in the study only if they meet all of the following criteria:   Have type 2 diabetes mellitus (T2DM; World Health Organization [WHO] classification, Protocol Attachment 2) for at least 1 year.   Are &amp;#8805;18 years old.   Have been receiving oral antihyperglycemic medications (OAMs), with insulin, for at least 3 months immediately prior to the study and have been on stable doses of at least 2 of the following OAMs for the 6 weeks prior to Visit 1, at or above the doses defined in the following table:    Oral Antihyperglycemic Medication (OAM)     Minimum Dose   Metformin  1500 mg/day   Sulfonylureas;   Dipeptidyl peptidase-IV (DPP-IV) inhibitors  1/2 the maximum daily dose, according to the local package insert.    Thiazolidinediones (TZDs)  30 mg/day pioglitazone or 4 mg/day rosiglitazone     The OAMs also must have been used in accordance with the product label.  (Note: Combination treatments of the OAMs listed above are acceptable if they meet the above criteria.  For example, Avandamet [rosiglitazone maleate and metformin hydrochloride] would cover the categories of a thiazolidinedione (TZD) and metformin.)     Have a hemoglobin A1c (HbA1c) &amp;#8805;7.5% and &amp;#8804;11.0%, as measured by a central laboratory before Visit 2.    Body mass index (BMI) &amp;#8805;25 and &amp;#8804;45 kg/m2.    As determined by the investigator, are capable and willing to do the following:  o use the insulin injection device according to the instructions provided;  o perform self monitoring of blood glucose (SMBG);   o complete the study diary as required for this protocol;   o are receptive to diabetes education, including continuing their prestudy diet and activity levels, or following dietary advice recording as requested in the protocol;   o comply with the required study visits and willing to receive regular telephone calls between visits.   o Have given written informed consent to participate in this study in accordance with local regulations.']","['Patients will be excluded from the study if they meet any of the following criteria:    Have taken any glucose-lowering medications not included in Inclusion Criterion [3] (for example, acarbose, miglitol, pramlintide, exenatide, repaglinide, or nateglinide) in the past 3 months before Visit 1.      Have had more than 1 episode of severe hypoglycemia, as defined in the Abbreviations and Definitions section of the protocol, within 6 months prior to entry into the study, or is currently diagnosed as having hypoglycemia unawareness.      Have had 2 or more emergency room visits or hospitalizations due to poor glucose control in the past 6 months.    Are pregnant or intend to become pregnant during the course of the study or are sexually active women of childbearing potential not actively practicing birth control by a method determined by the investigator to be medically acceptable.      Women who are breastfeeding.      Have cardiac disease with functional status that is Class III or IV (see Protocol Attachment.3);       Have a history of renal transplantation or are currently receiving renal dialysis or creatinine >2.0 mg/dL (177 µmol/L).      Have obvious clinical signs or symptoms, or laboratory evidence, of liver disease (alanine transaminase [ALT], or aspartate transaminase [AST] greater than 2 times the upper limit of the reference range, as defined by the local laboratory) or have albumin value above or below the normal reference range, as defined by the local laboratory.      Patients with a malignancy other than basal cell or squamous cell skin cancer who have not yet been treated, are currently being treated, or who were diagnosed less than 5 years ago.      Have 1 of the following concomitant diseases:  presence of clinically significant hematologic, oncologic, renal, cardiac, hepatic, or gastrointestinal disease or any other serious disease considered by the investigator to be exclusionary.      Have known hypersensitivity or allergy to any of the study insulins or their excipients.      Have had a blood transfusion or severe blood loss within 3 months prior to Visit 1 or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia, or any other traits of hemoglobin abnormalities known to interfere with the HbA1c methodology.    Are receiving chronic (lasting longer than 14 consecutive days) systemic glucocorticoid therapy (excluding topical, intra-articular, intraocular, and inhaled preparations) or have received such therapy within the 4 weeks immediately preceding Visit 1.      Have an irregular sleep/wake cycle (for example, patients who sleep during the day and work during the night), in the investigator\x92s opinion.      Have any other condition (including known drug or alcohol abuse or psychiatric disorder) that precludes the patient from following and completing the protocol, according to the investigator\x92s judgment.     Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.    Are investigator site personnel directly affiliated with this study and/or their immediate families.  Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.      Are Lilly employees.      Have previously completed or withdrawn from this study after having signed the informed consent document (ICD).']","['To test the hypothesis that, in T2DM, a basal bolus regimen containing analog insulin lispro protamine suspension provides noninferior glycemic control to a basal bolus regimen containing analog insulin glargine, when these basal insulins are injected once daily together with insulin lispro injected 2-3 times daily.  Glycemic control will be assessed by the change of HbA1c from baseline to 24 weeks']",['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Yes'],['Yes'],['No'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['84'],['Authorised'],['2008-06-11'],['2008-04-23'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To test the hypothesis that, in T2DM, a basal bolus regimen containing analog insulin lispro protamine suspension provides noninferior glycemic control to a basal bolus regimen containing analog insulin glargine, when these basal insulins are injected once daily together with insulin lispro injected 2-3 times daily.  Glycemic control will be assessed by the change of HbA1c from baseline to 24 weeks-2007-004864-29-Italy - Italian Medicines Agency-insulin lispro"
3,Humalog,insulin lispro,['traitement adultes enfants atteints diabète sucré besoin insuline maintenir homéostasie normale'],Germany - BfArM,2007-004864-29,['A Prospective Randomized Trial to Compare Basal Bolus therapies that use either Insulin Lispro Protamine Suspension or Insulin Glargine together with Lispro Insulin in Patients with Type 2 Diabetes'],['F3Z-EW-IOPJ(a)'],['Information not present in EudraCT'],['Eli Lilly and Company Limited'],['United Kingdom'],['Commercial'],"['Test', 'Comparator', 'Comparator']","['Yes', 'Yes', 'Yes']","['Eli Lilly Nederland B.V.', 'Eli Lilly Nederland B.V.', 'Sanofi-Aventis Deutschland GmbH']","['European Union', 'European Union', 'European Union']","['No', 'No', 'No']",Humalog,"['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Yes', 'Yes', 'Yes']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Suspension for injection', 'Solution for injection', 'Solution for injection']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3']",['Type II diabetes mellitus'],['No'],"To test the hypothesis that, in T2DM, a basal bolus regimen containing analog insulin lispro protamine suspension provides noninferior glycemic control to a basal bolus regimen containing analog insulin glargine, when these basal insulins are injected once daily together with insulin lispro injected 2-3 times daily.","['To compare the efficacy, safety of insulin lispro protamine suspension and glargine when used in a basal bolus regimen together with insulin Lispro in relation to:']",['No'],['Patients are eligible to be included in the study only if they meet all of the following criteria:'],"['7. Have taken any glucose-lowering medications not included in Inclusion Criterion [3] (for example, acarbose, miglitol, pramlintide, exenatide) in the past 3 months before Visit 1.']",,['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Information not present in EudraCT'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['Yes'],['Yes'],['No'],['No'],['No'],['No'],['No'],['84'],['Authorised'],['2008-06-06'],['2008-05-20'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"To test the hypothesis that, in T2DM, a basal bolus regimen containing analog insulin lispro protamine suspension provides noninferior glycemic control to a basal bolus regimen containing analog insulin glargine, when these basal insulins are injected once daily together with insulin lispro injected 2-3 times daily.-2007-004864-29-Germany - BfArM-insulin lispro"
0,Sutent,sunitinib,['mrcc chez adulte tumeurs neuroendocrines'],Austria - BASG,2008-008852-18,['Profile of soluble and cellular biomarkers and of functional imaging during antiangiogenic therapies in cancer patients'],['PRAEMARKERAAT08'],['Information not present in EudraCT'],['Medizinische Universität Innsbruck Innere Medizin V'],['Austria'],['Non-Commercial'],,"['Yes', 'Yes', 'Yes']","['Pfizer Ltd', 'Bayer Health Care AG', 'Roche']","['United Kingdom', 'Germany']","['No', 'No', 'No']",Sutent,"['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['No', 'No', 'No']","['Yes', 'Yes', 'Yes']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['No', 'No', 'No']","['No', 'No', 'Yes']","['No', 'No', 'No']","['No', 'No', 'No']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['Tablet', 'Tablet', 'Concentrate and solvent for solution for injection']","['Information not present in EudraCT', 'Information not present in EudraCT', 'Information not present in EudraCT']","['1', '2', '3']","['The present project is an academic clinical trial in which patient suffering from hepatocellular carcinoma, non-small cell lung cancer, renal cell cancer and colorectal cancer treated routinely with antiangiogenic agents. The study protocol intends to include ten patients per tumour entitity (n=40), treated either with Sorafenib (Nexavar), Bevacizumab (Avastin) or Sunitinib (Sutent), which are all approved antiangiogenic drugs in Austria in one of the cancer types defined above.']",['No'],"Biomarker evaluation under antiannagiogenic therapy with Nexavar, Sutent and Avastin. Eligible patients are suffering from hepatocellular carcinoma, non small cell lung cancer, renal cell cancer and colorectal cancer routinely treated with the abov mentioned antiangiogenic agents.",,['No'],"['Histological confirmed Tumor specimen RCC, HCC, CRC or NSCLC']",['Prior or concurrent antitumor therapy (<3 weeks)'],['Evaluation of biomarker analyses'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['No'],['Yes'],['No'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['No'],['No'],['Yes'],['No'],['No'],['No'],['Information not present in EudraCT'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Yes'],['Yes'],['Yes'],['Yes'],['No'],['Yes'],['No'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['Information not present in EudraCT'],['No'],['40'],['Authorised'],['2009-06-10'],['2009-06-10'],['Reason(s) for unfavourable opinion:'],['Favourable'],['Completed'],"Biomarker evaluation under antiannagiogenic therapy with Nexavar, Sutent and Avastin. Eligible patients are suffering from hepatocellular carcinoma, non small cell lung cancer, renal cell cancer and colorectal cancer routinely treated with the abov mentioned antiangiogenic agents.-2008-008852-18-Austria - BASG-sunitinib"
